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Abstract 
A New Zealand White (NZW) rabbit model was used to investigate the effect of 
cyclical cytotoxic chemotherapy on the structural and material properties of 
regenerate bone. This attempted to reproduce the biological situation encountered 
in a human adolescent with a primary malignant bone tumour, treated by surgical 
resection and either adjuvant or neo-adjuvant cyclical chemotherapy with bone 
transport to reconstruct the skeletal defect.  
 
General Hypothesis  
It is possible to produce normal bone by distraction osteogenesis in the presence 
of cyclical cytotoxic therapy. 
 
Materials and Methods 
Forty immature male rabbits were divided equally into 2 groups. Each received 2 
cycles of either cis-platinum / adriamycin or normal saline, with a tibial osteotomy 
and lengthening at 12-weeks of age. The timing of the cytotoxic drugs differed 
between groups in an attempt to simulate an adjuvant and neo-adjuvant dose 
schedule. 
 
Results  
A reproducible animal model was developed, appropriate doses of cis-platinum 
and adriamycin were determined and it was demonstrated that surgical 
lengthening was possible in animals receiving chemotherapy. 
There were no differences in the physical characteristics of the regenerate or 
lengthened bone in either arm of the study. 
In the group that received 2-cycles of chemotherapy before lengthening (neo-
adjuvant group), there was a significant reduction in bone mineral concentration 
(BMC), bone mineral density (BMD) and volumetric bone mineral density (vBMD), 
assessed by dual X- ray absorptiometry (DXA). There was no effect on the 
structural properties assessed by compression testing  
In the group that received chemotherapy before and during lengthening (adjuvant 
group), there was no effect on mineralisation but a reduction in energy to yield and 
yield strain was demonstrated. 
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Conclusion 
These findings should be interpreted with caution, as the animals did not have 
malignant bone tumours and were given a limited drug regimen. The study did not 
demonstrate any consistent effect on the properties of regenerate bone but the 
assessment did not include histological analysis. Further work is needed to 
investigate the mechanism in which these agents affect distraction osteogenesis 
and this will require a dynamic assessment of bone formation and more 
sophisticated analysis of regenerate structure.   
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Section 1 Osteogenic Sarcoma; Historical Perspectives, Current Concepts 
and the Aim of This Work 
 
1.1 Introduction 
My clinical interest in this subject is based on fifteen-years experience using 
distraction osteogenesis in the context of paediatric limb reconstruction. The 
motivation for this work is an ambition to investigate the use of this technique in 
the treatment of patients with osteogenic sarcoma. 
 
This section presents an overview of the management of malignant tumours of the 
immature skeleton, concentrating on the development of pharmacological and 
surgical strategies that are in current use. An appreciation of the potential 
deficiencies in contemporary management is necessary to understand the process 
that led to the general hypothesis and experimental component of this thesis. 
 
The description concentrates on osteogenic sarcoma as the index disease and 
defines the demographics and clinical features relevant to a Northern European 
population.  Advances in the management over the last 4-decades are described, 
to highlight the very significant improvements in outcome that have occurred as a 
result of parallel contributions from disciplines including surgery, medical oncology 
and bioengineering. 
 
Advances in cytotoxic chemotherapy are discussed with reference to complex 
drug combinations, which became prevalent in the 1980’s and more recent 2-drug 
prescriptions, which form the basis of the experimental pillar of this work. 
Adriamycin and cis-platinum are considered in detail, as it is necessary to 
understand how the pharmacology of these drugs in general and side effects in 
particular, influenced the development of the experimental model.   
 
Contemporary surgical approaches are evaluated to highlight the advantages and 
potential limitations of each technique.  A systematic review of the literature 
available at the time of writing considers the use of distraction osteogenesis in 
treatment of benign and malignant tumours. 
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The purpose of this review is to identify areas of technical difficulty and explore 
potential advantages of distraction osteogenesis in the management of osteogenic 
sarcoma. 
 
1.2 Osteogenic sarcoma 
Osteogenic sarcoma is the most common primary malignant tumour involving 
bone with approximately 1200 new cases diagnosed in European children each 
year. (Stiller et al., 2006) The age standardised rate for European patients up to 
15-years is 2.8 cases per million and 6.8 cases per million between the age of 10 
and 14-years. (Stiller et al., 2006) 
 
Osteogenic sarcoma is a mesenchymal malignancy in which the malignant cell 
population produces a variable amount of osteoid, leading to a spectrum of clinical 
subtypes. Approximately 80% are high-grade central tumours, which are classified 
as osteoblastic, chondroblastic or fibroblastic. The typical presentation involves 
pain and swelling of the affected limb, most commonly the metaphyseal regions of 
the femur, tibia and proximal humerus.  
Telangectatic, high-grade surface and small cell osteogenic sarcomas have a 
similar clinical course and treatment involves multi-modal chemotherapy.  
 
There have been important advances in the management of malignant bone 
tumours in children over the last 4-decades. Improvements have occurred 
because of progress in many disciplines, but the development of potent cytotoxic 
drugs has been of fundamental importance. (Eilber et al., 1987, Jaffe et al., 1974, 
Link et al., 1986, Rosen et al., 1983, Rosen et al., 1976)  
 
Local control is also essential and failure to remove the primary tumour completely 
is associated with a high risk of local and metastatic recurrence even with adjuvant 
chemotherapy. (Bacci et al., 1998a, Bacci et al., 1998b) 
 
In 1966, McKenna et al (McKenna et al., 1966) reported the 5-year survival of a 
group of 552 patients with osteogenic sarcoma. Irrespective of whether they were 
treated or not treated and disregarding the mode of treatment, the 5-year survival 
rate was 22.7% and long-term survival rate was 24.5% after amputation and 
20.5% after resection. 
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In 1967, Dahlin et al (Dahlin and Coventry, 1967) reported the outcome of 410 
patients with osteogenic sarcoma and noted an overall 5-year survival of 20.3% 
and  25.4% for patients with humeral and femoral tumours. 
 
In 1973, Sweetnam (Sweetnam, 1973) reported a 5-year survival of 26% for 
patients with distal femoral osteogenic sarcoma, treated by high thigh amputation 
or hip disarticulation. Pulmonary metastases developed in a large proportion of 
these patients, indicating that control of metastatic disease was a major factor in 
determining survival.  
 
1.3 Multi-agent Chemotherapy in the Management of Osteogenic Sarcoma 
The introduction of multi-modal chemotherapy in the early 1970’s produced 
significant improvements in the treatment of patients with metastatic osteogenic 
sarcomas. Complex treatment protocols evolved which are broadly defined as 
adjuvant or neo-adjuvant. Adjuvant chemotherapy involves the administration of 
chemotherapeutic agents following surgery. Neo-adjuvant chemotherapy refers to 
chemotherapy that is employed prior to surgical treatment. 
 
The use of multi-agent chemotherapy was first reported in the 1980’s. (Eilber et 
al., 1987, Link et al., 1986, Rosen, 1985, Rosen et al., 1983) Rosen (Rosen, 1985) 
reported the 10-year results of 208 patients with primary osteogenic sarcomas of 
the extremity, treated with pre-operative chemotherapy using one of 4 treatment 
protocols.  
 
At a minimum follow-up interval of 36-months, 77% of 87 patients treated on the 
Memorial Sloan-Kettering Cancer Centre T10 regimen remained alive and 
continuously disease free and 81.6% were free of disease at most recent 
assessment. This protocol involved pre-operative high dose methotrexate and 
leucovorin with surgery on day-28. High dose methotrexate, leucovorin, bleomycin, 
cyclophosphamide, actinomycin and adriamycin were administered in combination 
following surgery. 
 
The Multi Institutional Osteosarcoma Study (MIOS) was initiated in June 1982 and 
used high dose methotrexate, adriamycin, cis-platinum, bleomycin, 
cyclophosphamide and actinomycin D. Patients were randomly assigned to 
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immediate adjuvant chemotherapy or to observation without adjuvant treatment 
after definitive surgical management of the primary tumour. The study consisted of 
113 eligible patients of whom 36 accepted the randomisation and 18 were 
assigned to immediate adjuvant chemotherapy and 18 to observation.  
 
The initial results were reported in 1986 (Link et al., 1986) and midterm results in 
1991 (Link et al., 1991). The 6-year disease free survival rate for the control group 
was 11% compared to 61% for patients receiving chemotherapy. Patients who 
declined randomisation but were treated according to protocol also demonstrated 
a significant survival advantage. 
 
Eilber et al (Eilber et al., 1987) reported a study involving 59 patients with non-
metastatic, classic intra-medullary osteogenic sarcoma. Thirty-two were 
randomised to receive high dose methotrexate, adriamycin, bleomycin, cytoxan, 
and actinomycin D, 27 did not receive adjuvant chemotherapy. At a mean follow-
up of 2-years, there was a statistically significant improvement in disease-free and 
overall survival in those who received adjuvant chemotherapy. 
 
1.3.1 cis-Platinum and Adriamycin in the Treatment of Osteogenic Sarcoma  
In 1981, Ettinger et al (Ettinger et al., 1981) reported the use of cis-platinum and 
adriamycin following definitive surgery in 12 patients with non-metastatic primary 
osteogenic sarcoma. All patients were alive and 10 remained continually disease 
free at a median time of 23-months. 
 
In 1991, Malawer et al (Malawer et al., 1991) used 2 cycles of pre-operative, intra-
arterial cis-platinum and intravenous adriamycin for high-grade sarcomas of the 
extremity. This group of patients presented with osteogenic sarcoma, malignant 
fibrous histiocytoma, leiomyosarcoma and malignant schwannoma. All patients 
received post-operative cycles of cis-platinum and adriamycin and at median 
follow-up of 30-months, 95% of patients (21/22) had evidence of local control. Six 
(27.3%) however, developed metastatic disease at a median interval of 16.6-
months. 
 
The European Osteosarcoma Intergroup (EOI) recruited 198 eligible patients 
between July 1983 and December 1986. These patients had classic, high-grade 
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extremity osteogenic sarcomas and were randomised to receive cis-platinum and 
adriamycin prior to and following definitive surgery or the same combination with 
high dose methotrexate.  
 
Bramwell (Bramwell et al., 1992) reported the initial results at a mean time of 53-
months and the disease free survival was superior in the cis-platinum and 
adriamycin group, although this was not statistically significant. The conclusion of 
this paper was that a brief, intensive regimen of cis-platinum and adriamycin 
produced excellent long-term results, which were equivalent to those using longer, 
more complex multi-agent combinations. 
 
In 1997, Souhami et al (Souhami et al., 1997) reported the results of an EOI study 
that compared a short intensive treatment using cis-platinum and adriamycin with 
a multi-drug regimen, based on the T10 protocol. This involved pre-operative 
vincristine, high dose methotrexate and adriamycin and post-operative bleomycin, 
cyclophosamide, dactinomycin, vincristine, methotrexate, adriamycin and cis-
platinum.  
 
Four hundred and seven patients were randomised, 390 were eligible and were 
followed up for at least 4-years. Surgery involved amputation or limb sparing 
surgery and this was determined on the basis of clinical preference and not trial 
randomisation. The overall survival was 65% at 3-years and 55% at 5-years in 
both groups. The authors observed that the 5-year survival was unsatisfactory and 
that new approaches including dose intensification were required. 
 
1.3.2 cis-Platinum Pharmacology  
cis-Platinum was first described in 1845 as Peyrone’s salt. (Peyrone, 1845) 
Werner elucidated the molecular structure in 1893 and this formed part of the work 
that was recognised with the Nobel Prize for Chemistry in 1913. (Figure i) 
 
 
Figure i The Molecular Structure of cis-Platinum 
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The cytotoxic properties of cis-platinum were discovered by Rosenburg, 
(Rosenberg et al., 1965) who observed that electrolysis products from a platinum 
electrode inhibited mitosis in Escherichia coli. 
 
Initial animal studies were conducted in 1971, (Kociba and Sleight, 1971) leading 
to a clinical trial involving 26 patients with a variety of malignancies in 1973 
(Lippman et al., 1973) and approval for clinical use by the American Food and 
Drug Administration (FDA) in 1978. 
 
cis-Platinum has been demonstrated to have an anti-neoplastic activity with a 
clinically useful anti-cancer effect on ovarian and testicular tumours, malignant 
melanoma and osteogenic sarcomas. Efficacy is limited by undesirable dose 
limiting side effects, which include severe nephrotoxicity, nausea, vomiting, 
neurotoxicity, ototoxicity and myelosuppression. 
 
Cytotoxicity is mediated by inhibition of Deoxyribonucleic Acid (DNA) synthesis 
and this occurs at significantly lower doses than are required to inhibit Ribonucleic 
Acid (RNA) and protein synthesis. (Harder and Rosenberg, 1970) The mechanism 
of cis-platinum damage to DNA is similar to alkylating agents and X-irradiation 
(Weiss and Poster, 1982), binding to 2 specific sites on the DNA molecule. 
(Munchausen and Rahn, 1975) This causes inter-and intra-strand DNA binding in 
addition to DNA/protein cross linkage. (Javadpour, 1985) cis-Platinum appears to 
have a preferential toxicity to the DNA of cancer cells compared to normal cells, 
although this phenomenon is not completely understood. (Javadpour, 1985) The 
cross-linked DNA prevents rapidly dividing cells from duplicating DNA for mitosis. 
The damaged DNA triggers repair mechanisms, which lead to cell death by 
apoptosis when repair proves impossible. 
 
1.3.3 Side Effects of cis-Platinum 
Nephrotoxicity is common due to the fact that the kidney accumulates and retains 
platinum and is the primary method of excretion of platinum compounds. Toxicity 
results in renal tubular damage that may be reduced by vigorous hydration and 
mannitol induced diuresis. (Hayes et al., 1977)  
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The mechanism of nephrotoxicity induced by platinum complexes is not 
completely understood. Reports implicate site specific injury to the S3 segment 
(pars recta) of the proximal convoluted tubules (PCT) (Dobyan et al., 1980) and 
reaction of platinum complexes with protein bound sulphydryl groups present in 
the proximal tubules. (Appleton T et al., 1989) Other authors have reported the 
distal tubules (Gonzales-Vitale et al., 1977) and proximal and distal tubules (Jones 
et al., 1980) as the site of maximum damage. 
 
1.3.4 Adriamycin Pharmacology  
Adriamycin is an anthracycline antibiotic, produced by solvent extraction of the 
products of aerobic fermentation of Streptomyces peucetius. The molecular 
structure was described by Arcamone in 1969 (Arcamone et al., 1969) (Figure ii) 
and clinical trials began in 1970. (Middleman et al., 1971, Wiernik and Serpick, 
1972) Adriamycin has subsequently been used as an anti-cancer agent to treat a 
spectrum of solid tumors and leukaemias. (Chabner et al., 1975)  
 
Adriamycin acts by binding to DNA where it inhibits the enzyme topoisomerase II.  
Adriamycin stabilises the topoisomerase II complex after it has broken the DNA 
chain for replication, preventing the DNA double helix from being resealed and 
thereby stopping the process of replication. (Tewey et al., 1984)  
 
Topoisomerase II is now known to be a common target for many families of DNA 
intercalating anti-cancer drugs. Other potential mechanisms of action include 
enzyme catalysed and ion mediated free radical formation (Handa and Sato, 1975) 
covalent binding to DNA, (Sinha et al., 1987) and direct interaction with the cell 
membrane. (Tritton, 1991) 
 
 
Figure ii  The Molecular Structure of Adriamycin 
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1.3.5 Side Effects of Adriamycin  
Clinical use is limited because of acute bone marrow toxicity, which has been 
partially improved with the use of bone marrow stem cell colony stimulating factors. 
The frequency of administration is limited because of drug resistance and side 
effects which include stomatitis, alopecia (Wang et al., 1971) and a delayed dose 
dependant cardiotoxicity, eventually resulting in congestive cardiac failure. 
(Billingham et al., 1978, Lenaz and Page, 1976, Minow et al., 1977, Von Hoff et al., 
1979, Wang et al., 1971) 
 
The exact mechanism that leads to cardiomyopathy is unknown, but oxygen free 
radical generation with subsequent lipid peroxidation, local release of vasoactive 
substances, calcium overload, mitochondrial dysfunction, and intercalation of 
adriamycin into DNA base pairs, leading to faulty cellular repair have all been 
implicated. (Bristow et al., 1981, Keizer et al., 1990, Lazarus et al., 1980, Miwa et 
al., 1986, Singal and Pierce, 1986, Zahringer, 1981) 
 
Sakski et al (Sasaki et al., 1987) investigated the effect of adriamycin on collagen 
production and fibroblast proliferation in normal human skin fibroblast culture using  
[3H]  hydroxyproline as a marker of collagen turnover. There was inhibition of 
fibroblast proliferation, generalised inhibition of protein synthesis and specific 
inhibition of prolyl hydroxylation leading to loss of stability of procollagen in the 
triple helix which may explain impairment of wound healing in patients treated with 
adriamycin 
 
1.3.6 Overview of the Role of Chemotherapy in the Management of 
Osteogenic Sarcoma 
Since the introduction of multi-modal chemotherapy in the 1980’s, cis-platinum and 
adriamycin have been used successfully in the management of osteogenic 
sarcoma and Ewing’s sarcoma.  
 
Initial studies used complex drug prescriptions and produced a significant 
improvement in disease free survival. More recent studies demonstrated that an 
equivalent therapeutic effect could be achieved using a combination of cis-
platinum and adriamycin.   
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The therapeutic use of these agents is limited due to significant side effects.  Cis-
platinum is a potent nephrotoxic agent and adriamycin produces cardiac and bone 
marrow toxicity, which also limits the use in a clinical context.   
 
1.4 Surgical Management of Osteogenic Sarcoma in Childhood 
Significant improvements in survivorship, independent of the primary method of 
treatment, led to advances in surgical reconstruction following osteogenic sarcoma 
excision. This section evaluates the development of these techniques and 
describes bone transport by distraction osteogenesis and its potential use in this 
context.   
 
1.4.1 Historical Perspective  
In 1986, Simon et al (Simon et al., 1986) conducted a retrospective, multi-
institutional study of patients with osteogenic sarcoma of the distal femur. Three 
patient groups were identified who had either a limb sparing procedure, above 
knee amputation or disarticulation of the hip. There was no demonstrable 
difference in disease free interval or long-term survival between these groups.  
 
The improvement in disease control associated with cytotoxic chemotherapy has 
resulted in patients presenting with conventional intra-medullary osteogenic 
sarcoma, without metastatic disease, expecting a cure rate of the order of 70%.  
Improved survival following chemotherapy, with equivalent results for amputation 
and limb salvage, (Eilber et al., 1987, Marcove, 1978, Springfield et al., 1988) led 
to advances in limb sparing surgery using biological and bioengineering 
techniques. Local control is a prerequisite for limb salvage and is achieved by 
surgical excision of the tumour with adjuvant or neo-adjuvant chemotherapy to 
control micro-metastatic disease.  
 
Limb sparing procedures are possible when pre-operative staging demonstrates 
adequate surgical margins. This is based on the pathological examination of the 
surgical specimen and the presence of an inadequate surgical margin should lead 
to amputation, particularly if there had been a poor response to pre-operative 
chemotherapy. (Bacci et al., 1998a, Bacci et al., 1998b) 
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The aim of limb sparing surgery is to achieve complete excision of the tumour, 
followed by reconstruction of the defect with minimal morbidity and optimum 
function. The ideal operation involves complete excision of isolated, non-functional 
bones and this is appropriate for tumours affecting the ribs, fibula and lower 
scapula. 
 
The options for biological reconstruction of long bones include allograft, 
vascularised free fibular graft and bone transport. The alternative is to use an 
implantable prosthetic device with or without the potential for longitudinal 
extension to accommodate for remaining growth. 
 
Grimer et al (Grimer et al., 1997) investigated the cost implications of limb salvage 
and compared this to the estimated cost of an amputation including lifelong 
prosthetic requirements. This demonstrated financial advantages associated with 
endoprosthetic replacement compared with amputation either in the public or 
private sector. 
 
1.4.2 Allograft Reconstruction  
An allograft or allogeneic transplant uses tissue derived from a genetically non-
identical member of the same species. The use of allograft in the treatment of 
patients with segmental bone loss that has occurred because of tumour or trauma 
has its roots in antiquity. The earliest contemporary study involved transplantation 
of the knee and was reported in 1925 (Lexer, 1925) with approximately 50% of the 
grafts demonstrating acceptable long term function. 
 
Mankin et al (Mankin et al., 1987) reported the experience with 314 patients at the 
Massachusetts General Hospital between 1971 and 1986. Patients with follow-up 
of greater than 2-years were considered separately and accounted for 74% of the 
total. In this group, 77% were regarded as satisfactory but the rate of significant 
complications was high. The complications included death (7%), metastases (9%), 
local recurrence (7%), infection (14%), fracture (19%) and non-union (13%). 
 
Gebhardt et al (Gebhardt et al., 1991) reported the results of 53 patients aged 30-
years or younger in whom fresh frozen allografts were used as osteoarticular 
grafts, allografts, arthrodeses, allograft prosthesis or inter-calary grafts. Function 
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was satisfactory in 70% of 38 patients with more than 2-years follow-up with no 
evidence of local recurrence. Complications were also common and included 
infection (30%), fracture (11%), non-union (23%) and joint instability (11%).  
 
The authors concluded that this was appropriate management for patients with 
high-grade osteogenic sarcoma who received aggressive adjuvant chemotherapy. 
The results were considered to be comparable to other methods of reconstruction 
and compared to metallic prostheses, offered the advantage of potential 
integration with added longevity. 
 
Enneking et al (Enneking and Mindell, 1991) reported the radiographic and 
histological details of 16 retrieved massive allografts that had been implanted for 
between 4 to 65-months. Union between allograft and host occurred slowly, with 
formation of an external callus derived from the host cortex. Internal repair also 
occurred slowly and was confined to the superficial ends of the graft and only 
involved 20% of the graft at 5-years. There was no histological evidence of 
chondrocyte survival, even when the graft had been cryoprotected before freezing. 
Necrotic cartilage appeared to function well for as long as 5-years and was 
replaced by a pannus of fibro-vascular tissue. 
 
Alman et al (Alman et al., 1995) reported a retrospective analysis of allograft 
reconstruction in 26 skeletally immature patients. The results were considered to 
be good in 70% of patients but there was a high rate of complications with fracture 
occurring in 54%. Significant limb length discrepancies were identified and 5 of this 
group were managed with contra-lateral epiphysiodesis and one with an 
unsuccessful attempt at limb lengthening. The authors considered that this was a 
useful option for the management of skeletally immature individuals, accepting that 
its use in the lower extremity should be easier for patients in whom leg length 
inequality could be treated with epiphysiodesis.  
 
Donati et al (Donati et al., 2000) reported the results of 112 allografts to treat high-
grade osteogenic sarcomas following neo-adjuvant chemotherapy. The allografts 
were used as an arthrodesis in 44 cases and inter-calary graft in 39. The 
functional results were excellent/good in 74% of patients after primary surgery and 
83% after secondary surgery. There was a high complication rate with delayed 
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union in 49% and fracture in 27% but deep infection was not reported. It was felt 
that the delay in union was increased by the use of chemotherapy.   
 
1.4.3 Vascularised Fibular Graft Reconstruction  
In 1975, Taylor et al (Taylor et al., 1975) reported the first successful use of a 
vascularised fibular graft to reconstruct a tibial defect. The first description of use 
after bone tumour resection was by Weiland in 1981. (Weiland, 1981) 
 
In 1997, Hsu et al (Hsu et al., 1997) reported 30 patients following free 
vascularised fibular transfer to reconstruct massive defects after resection of 
primary bone tumours. The graft was fixed with a plate in 18 patients, an 
intramedullary nail in 5 and an external fixator in 7 patients. All patients had 
supplementary iliac crest bone grafting with a union rate of 90% at an average of 
7.6-months. The conclusion was that this was an effective method of 
reconstruction, although there was a high rate of complications (50%), which 
included infection and non-union and often required further surgery. 
 
Shea et al (Shea et al., 1997) reported 13 consecutive patients with an average 
follow-up of 53-months. The average time to union was 6.5-months, significant 
graft hypertrophy occurred in 61% and the complication rate was 54% with graft 
removal in 15%. The average Musculoskeletal Tumour Society Score (MTSS) was 
90, with 11 of the 13 patients rated good or excellent. The authors considered that 
this technique represented a potential option for reconstruction of skeletal defects 
after tumour resection. 
 
Shalaby et al (Shalaby et al., 2006) reported 6 patients with primary osteogenic 
sarcoma of the distal tibia treated with en bloc resection and tibio-talar arthrodesis. 
The defect was reconstructed with a non-vascularised fibular graft (3) and a 
vascularised pedicle fibular graft (3). This was supplemented with iliac crest bone 
graft and an Ilizarov fixator was used to bridge the defect in all cases.  All tumours 
were graded as Enneking stage II B and underwent 3 cycles of cis-platinum and 
adriamycin. The mean age of the patients was 18.8-years (16-23) and the mean 
follow- up time was 35-months (28-42). Two patients required secondary iliac crest 
bone grafting to achieve union with a mean time to graft union of 10-months (8-12) 
in patients with a vascularised graft and 18-months (16-22) in non-vascularised 
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grafts. All patients demonstrated evidence of graft hypertrophy at the time of 
follow-up apart from one patient with local recurrence, who required an above 
knee amputation.   
 
1.4.4 Rotationplasty 
Van Nes initially described rotationplasty in 3 patients with congenital femoral 
deficiency (van Nes, 1950) and reported excellent results in all patients after 8 to 
10-years. 
 
Kotz et al (Kotz and Salzer, 1982) reported rotationplasty for childhood osteogenic 
sarcoma in 4 patients, combined with an en-bloc excision of the proximal tibia, 
distal femur and knee. There was no clinical or radiological evidence of local 
recurrence at follow-up between 27 and 58-months following rotationplasty but one 
of this group had died of widespread metastatic disease. 
 
Jacobs (Jacobs, 1984) described the results of the van Nes rotationplasty in 2 
patients with osteogenic sarcoma. Both patients adapted well and enjoyed good 
postoperative function. The procedure was therefore considered a potential 
alternative to a high above knee amputation in a young patient with significant 
growth remaining. 
 
Hillmann et al (Hillmann et al., 1999) compared the results of rotationplasty in 33 
patients with endoprosthetic replacement in 34 patients, followed up for an 
average of 6-years. The groups were evaluated by questionnaire with functional 
results assessed by the MTSS. This study suggested that rotationplasty was not 
associated with any disadvantage in respect of function or quality of life. 
Restriction in daily activity due to pain was significantly less common in the 
rotationplasty group but there were significant cosmetic issues. 
 
Hanlon et al (Hanlon and Krajbich, 1999) reported the results of 21 patients who 
underwent a modified van Nes rotationplasty for osteogenic sarcoma. Of this 
group, 14 were followed-up at a mean of 8-years and all had good or excellent 
results with no long-term effect on recreational, sporting or occupational goals. 
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1.4.5 Endoprosthetic Reconstruction 
This approach was pioneered in the United Kingdom at the Royal National 
Orthopaedic Hospital (RNOH) in 1949 (Seddon and Scales, 1949) and the long-
term follow-up was reported in 1975. (Burrows et al., 1975) 
 
Roberts et al (Roberts et al., 1991) reported the experience from the Royal 
Orthopaedic Hospital in Birmingham with 135 custom made distal femoral 
prostheses. Survivorship analysis demonstrated a success rate of 72% at 5-years, 
64% at 7-years and 91% of surviving patients reported good or excellent function. 
The conclusion was the prosthetic replacement of the distal femur could 
predictably provide good functional results with no more risk to life than would be 
expected following amputation. 
 
Kabukcuoglu et al (Kabukcuoglu et al., 1999) reported endoprosthetic replacement 
of the proximal femur in 54 patients with a mean follow-up of 9-years. The 
survivorship of the prosthesis without revision was 77% at 10-years, and 57% at 
20-years.  
 
Torbet et al (Torbert et al., 2005) reported the results of a retrospective study of 
139 endoprosthetic procedures of which, 110 were used to reconstruct the femur 
or tibia. The overall event free endoprosthetic survival was 86% at 3-years, 80% at 
5-years and 69% at 10-year follow-up. Survival was not affected by patient age or 
whether the prosthesis was a primary or revision procedure. The rate of local 
recurrence was 6.8%, which was similar to previous limb salvage and amputation 
studies. 
 
1.4.6 Expandable Endoprosthetic Reconstruction  
Modular, extendable endoprosthetic replacements have been developed to 
accommodate future growth in younger patients. Most series involve small 
numbers with high rates of aseptic loosening, infection and prosthetic failure. 
 
Eckardt et al (Eckardt et al., 1993) reported the outcome of 12 skeletally immature 
patients with cemented, customised expandable endoprosthesis with mean follow-
up of 3.5-years for surviving patients. Eight patients had a total of 10 major 
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complications of which 7 were related to the prosthesis. The MTSS rating was 
good to excellent in 7 patients (58%), fair in 3 (25%) and poor in 2 (17%). 
 
Schiller et al (Schiller et al., 1995) reported the results of 6 skeletally immature 
patients who had been managed with an expandable tumour endoprosthesis at a 
mean age of 11-years with an average follow-up of 6-years. The mean length gain 
was 13.1 cm but this required a total of 53 procedures including 7 revisions. All 
cases demonstrated a good or excellent functional result with no local recurrences 
or evidence of metastatic disease at follow-up.  Three of these patients developed 
deep infection, which required debridement, immediate re-implantation of the 
endoprosthesis and long-term antibiotics.   
 
Schindler et al (Schindler et al., 1997) reported the experience from the RNOH 
between 1983 and 1990. Eighteen children were treated with an extendable distal 
femoral prosthesis, 4 had died from metastatic disease, 2 required amputation and 
12 were followed for a mean time of 8.7-years. In the follow-up group, a mean total 
lengthening of 5.2 cm was achieved after an average of 4 operations. Six patients 
required revision at a mean of 6.2-years after the initial procedure and at final 
review, the average function assessed by the MTSS score was 77% of the 
expected normal function. 
 
Gupta et al (Gupta et al., 2006) reported the early experience of the use of a non-
invasive distal femoral expandable endoprosthesis in 7 patients with osteogenic 
sarcoma of the distal femur at a mean age of 12.1-years. The prostheses were 
lengthened by a mean of 25 mm (4.25-55) and the MTSS was 68 at mean follow-
up of 20.2-months. Reported complications included a knee flexion deformity of 
25° in one patient and death from disseminated disease in one patient.  
 
1.4.7 Overview of the Surgical Management of Osteogenic Sarcoma 
Surgical treatment of osteogenic sarcoma has evolved from amputation 4-decades 
ago to contemporary methods of biological and prosthetic reconstruction. There 
are advocates for each approach, but the literature suggests that there are major 
complications associated with all currently available methods of reconstruction.  
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Allograft reconstruction is associated with a significant rate of infection and 
fracture at the allograft-bone interface and the use of alternatives including 
vascularised fibular grafts and rotationpasty has not been extensive. 
Recent advances in biomaterials and engineering have led to fixed and 
expandable endoprosthetic reconstruction. This is relevant to reconstruction in a 
child before skeletal maturity, which is the clinical scenario considered by this 
thesis. The literature reporting the short to mid-term use of these devices, 
suggests that there is also a high rate of infection and implant failure and there is 
no data relating to long-term use.   
 
1.5 Distraction Osteogenesis 
This section describes the origins of the technique of distraction osteogenesis and 
evaluates its use in the management of bone loss and deformity correction. 
Recent refinements of technique have broadened the indications to include 
reconstruction following excision of benign and malignant tumours and these are 
also discussed. 
 
1.5.1 Historical Perspective 
Ilizarov used the term “regenerate” to describe the bone formed by distraction 
osteogenesis and investigated the biological and mechanical factors that 
influenced bone formation. (Ilizarov, 1989a, Ilizarov, 1989b, Ilizarov, 1990, Ilizarov 
and Ledyaev, 1992) The conclusion of these experiments, in addition to 40-years 
clinical experience, was that osteogenic activity depended on the degree of 
stability of the external fixator and the amount of damage to the bone marrow, 
periosteum and intramedullary nutrient vessels occurring at the time of surgery.  
 
Ilizarov also published experimental evidence outlining the effect of the rate and 
frequency of distraction (Ilizarov, 1989a, Ilizarov, 1989b) and demonstrated that 
1mm/day in 60 increments was superior to 4 or one increments. This study also 
demonstrated that the soft tissues (fascia, nerves and vessels) lengthened at this 
rate and rhythm, replicated and took on the characteristics of foetal tissue. 
 
De Bastaini et al popularised distraction osteogenesis in Europe with the Orthofix 
mono-lateral external fixator and introduced the term ‘callotasis’. (De Bastiani et 
al., 1987) The technique involved a tissue preserving osteotomy and after a delay, 
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distraction at 1mm/day. When the target length was achieved, the fixator was 
dynamised, allowing load sharing between fixator and bone. The results of 100 
lengthening procedures were reported with an average increase in length of 6 cm 
with a mean increase of 22% of bone length. Complications occurred in 14% of 
which 5% involved refracture. 
 
1.5.2 The Biology of Distraction Osteogenesis  
Aronson et al (Aronson et al., 1989) investigated the biology of distraction 
osteogenesis and used the Ilizarov and Wagner external fixators to lengthen the 
tibia by 2.6 mm in 2 groups of adult dogs with the contralateral tibia acting as a 
control. Eight were lengthened with a basic Ilizarov device, with 2 rings and 4 
tensioned 1.6 mm pins and 8 with the small Wagner external fixator.  
 
The tibiae were analysed with standard radiographs at intervals during the 
osteogenic process and it was observed that bridging occurred, with parallel 
regenerate columns projecting from each osteotomy surface towards the centre of 
the regenerate organ. The columns were separated by radiolucent areas with a 
transverse radiolucent interface at the centre.  
 
The radiolucent band corresponded histologically to parallel bundles of collagen 
staining fibres, with short strands of spindle cells, all orientated in the direction of 
distraction. Large peripheral vascular channels were identified, with a similar 
longitudinal orientation interposed between collagen bundles. Near the vessels, 
the fibrous matrix condensed around the cells, which stained strongly for calcium. 
Bone formed parallel to the vascular channels with an alternating pattern of 
microcolumns extending from the fibrous interzone to each corticotomy surface in 
the longitudinal section.  
The authors observed that both fixators induced a similar degree of osteogenesis 
when distracted at a similar rate. Stable distraction with either fixator produced 
intramembranous ossification and the histology of the new bone reflected the 
different local strains that were predicted for each fixator.  
 
Yasui et al (Yasui et al., 1997) investigated the mechanism of bone formation in a 
Sprague-Dawley rat model using a Hoffman mini-lengthening system. Distraction 
at 0.25 mm every 12-hours was started 7-days after femoral osteotomy and was 
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stopped after 21-days distraction. Radiographs were taken each week and 
animals were killed at intervals.  
 
In-situ hybridisation was performed on de-calcified sections using a digoxigenin 
labelled cRNA probe for mouse α 1, type I and II collagen. Histological 
examination demonstrated that typical endochondral bone formation was 
prominent in the early stages of distraction. Intra-membranous bone formation was 
predominant in the later stages and a third method, which was termed 
transchondroid bone formation, also occurred. In-situ hybridisation demonstrated 
that the chondroid cells temporarily expressed type II collagen mRNA but did not 
show classical morphological characteristics of chondrocytes. It was assumed that 
these were young chondrocytes undergoing further differentiation into bone 
forming cells.  
 
Sato et al (Sato et al., 1998) used an identical model to investigate the histological 
and molecular events associated with distraction osteogenesis and demonstrated 
that the osteotomy site was initially surrounded by hyaline cartilage external callus.  
During distraction, chondrocytes were stretched along the axis of tension and 
differentiated into fibroblast like cells. These cells expressed osteopontin, 
osteocalcin and alkaline phosphatase mRNA’s. During the late distraction phase, 
the cartilaginous callus initially underwent endochondral ossification to form bony 
callus with later new bone formed by intramembranous ossification. Levels of 
osteopontin, osteonectin, matrix Gla protein and osteocalcin mRNA expression 
increased during distraction, suggesting that mechanical environment stress 
modulated cell shape and phenotype and stimulated the expression of mRNA for 
bone matrix proteins. 
 
Rowe et al (Rowe et al., 1999) investigated the mechanism of angiogenesis in a 
rabbit mandible model of distraction osteogenesis. The right hemi-mandible was 
osteotomised and distracted using a customised device at a rate of 0.25 mm every 
12 hours for 6-days. Animals were sacrificed at intervals and regenerate histology 
and intensity of angiogenesis were assessed. There was an intense early vascular 
response, with abundant new vessel formation during the first 2-days of 
distraction. This decreased significantly in later stages of distraction and during 
consolidation.  
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1.6 Bone Transport  
Bone transport describes a technique that uses distraction osteogenesis to 
reconstruct segmental defects, usually in long bones. Transport is mediated by 
monolateral or circular external fixators, restoring limb length without requiring 
massive bone grafting. The transporting segment gradually crosses the defect and 
regenerate bone is formed according to the principles of Ilizarov. Docking is 
eventually achieved and the integrity of the bone is restored by a combination of 
direct bone healing at the docking site and regenerate bone formation in the 
defect. 
 
1.6.1 Bone Transport for Traumatic Defects  
Paley et al (Paley et al., 1989) reported 25 patients with tibial non-union 
associated with a mean bone loss of 6.2 cm. Thirteen of this group had chronic 
osteomyelitis, 19 had limb length discrepancies, 12 had a bony defect and 13 had 
deformity. 
 
Management involved internal bone transport with limb length correction by 
distraction of a percutaneous corticotomy or compression and subsequent 
distraction of a pseudarthrosis. Infection was treated by radical resection of 
necrotic bone followed by internal lengthening to reconstruct the defects. Union 
was achieved in all cases at the mean time of 13.6-months. The results were 
graded as excellent in 18 cases but there was persistent infection in 3, deformity in 
4 and limb shortening in one. 
 
Cattaneo et al (Cattaneo et al., 1992) reported internal bone transport in 28 
patients with infected non-union or inter-calary tibial bone loss. Six of this group 
had infected non-union, with hemi-circumferential bone loss; the remainder had an 
average 4 cm segmental bone loss. The non-unions were treated by en-block 
resection and internal transport using olive drag wires. Equal limb length and  
good to excellent function was achieved in 75% of cases. 
 
Green et al (Green et al., 1992) reported 17 patients with inter-calary defects 
managed with an Ilizarov fixator. The mean length of regenerate was 5.14 cm (1.5-
14.5) in tibial cases. The mean external fixator time for all patients was 9.6-months 
(5.5-17.7). The mean time for transport of the moving segments was 4.8-months 
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(2.3-6.0). The mean distraction index, calculated from the presented data was 0.93 
months/cm and the mean external fixator index was 1.87 months/cm. 
 
Bone healing eventually occurred in 94% but complications were common, with an 
average of 3.5 complications per patient. These included, pin site infection (112%), 
cellulitis requiring antibiotic treatment (41%) and bone grafting (35%). 
 
Naggar et al (Naggar et al., 1993) reported 11 patients with a mean bone defect of 
6.7 cm following trauma. The average duration of treatment for this group was 
12.9-months, 50% had residual deformity exceeding 5o and 40% had a leg length 
discrepancy averaging 1.5 cm. Using the figures presented, the mean distraction 
index was 0.88 months/cm and the external fixator index was 1.93 months/cm. 
 
Prokuski et al (Prokuski and Marsh, 1994) reviewed the indications, techniques 
and results of segmental transport in acute trauma. Transport was considered 
appropriate for bone loss between 3 to 12 cm and early aggressive infection that 
required intercalary resection. 
 
Song et al (Song et al., 1998) reported the management of 27 tibial defects treated 
by internal transport using an Ilizarov fixator, followed for an average of 2.5-years. 
 
Satisfactory union occurred in all cases after an average time of 8-months in the 
fixator with a radiographic consolidation index of 1.3 months/cm. Complications 
were common and included tibial shortening (37%) ankle stiffness (33%) and 
malunion (19%) 
 
Paley et al (Paley and Maar, 2000) reported 19 patients with tibial defects treated 
by bone transport using an Ilizarov external fixator with a mean external fixator 
index of 1.6 months/cm. Debridement of bone ends and bone grafting at the end of 
transport was required in 53%. Union was achieved in all cases and was 
complicated with re-fracture at the docking site (5%), limb length discrepancy 
greater than 2.5cm (5%) and angular deformity greater than 5o (5%). 
 
Rogers et al (Rogers et al., 2007) used a stacked Taylor Spatial Frame (TSF) to 
achieve bone transport in 14 patients, 10 of which had bone loss secondary to 
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excision of an infected non-union. The mean external fixator time was 12.3-months 
with an external fixator index of 3 months/cm to reconstruct a mean defect of 49 
mm. Unplanned procedures were required in 15 and 8 required a docking 
procedure. Radiological and functional outcome were evaluated by the Association 
for the Study and Application of the Methods of Ilizarov (ASAMI) and SF 36 
protocols and were rated as excellent in 12 patients (86%). 
 
1.6.2 Bone Transport Following Benign Tumour Excision 
Lee et al (Lee et al., 2006) reported their experience of treating 16 children with 
osteofibrous dysplasia. Resection and segmental transport were used in 5 cases, 
2 of which had histological evidence of adamantinoma. One patient had a 
resolving equinus contracture; the remainder were without symptoms or 
recurrence. 
 
Hahn et al (Hahn et al., 2007) outlined the treatment 14 patients with osteofibrous 
dysplasia at mean age of 13.9-years (2-65). One patient aged 2-years was treated 
with a segmental excision and bone transport using an Ilizarov fixator. This 
resulted in recurrence 18-months later, which was treated with curettage and 
grafting and with no further evidence of disease at 11-years.  
 
1.6.3 Bone Transport Following Malignant Tumour Excision  
Segmental transport has previously been used after excision of malignant bone 
tumours; reports however, are usually single cases or small series.  
 
Lenoble et al (Lenoble et al., 1995) reported simultaneous bone and soft tissue 
transport to reconstruct tissue loss in the lower leg. The series considered 12 
patients, 2 of which had en bloc resection of bone, muscle and skin for malignant 
bone tumour. There are no details of the type of tumour or results in these 
individual cases. This paper does not allow any further sensible comment on the 
use of distraction osteogenesis in the management of bone tumours. 
 
Carter et al (Carter et al., 1999) reported the treatment of a low grade 
leiomyosarcoma in the mandible of a 7-year old girl. This was treated by incision 
biopsy and subsequent neck dissection with tumour excision and mandibular 
reconstruction using a dynamic reconstruction plate followed by a multi-
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dimensional distraction device. Bi-focal distraction osteogenesis was performed to 
bridge a 4 cm gap and this was subsequently augmented with an iliac crest graft. 
This patient did not receive chemotherapy as part of the tumour management. 
 
Iacobellis et al (Iacobellis and Olmeda, 2004) described the treatment of a 
mesenchymal chondrosarcoma and 2 cases of squamous skin carcinoma with 
tibial infiltration. The mesenchymal chondrosarcoma occurred in a male aged 14-
years who was treated with bone transport and tibio-talar arthrodesis. This patient 
underwent cyclical chemotherapy during the course of the distraction and had slow 
corticalisation of the regenerate with no evidence of recurrence at 10-years. The 
cases of squamous skin carcinoma were treated with bi-focal transport without 
chemotherapy, followed up for 2 and 3-years with no evidence of recurrence.  
 
1.6.4 Bone Transport in the Management of Ewing’s and Osteogenic 
Sarcoma with simultaneous Cytotoxic Chemotherapy  
Lammens et al (Lammens and Fabry, 1992) included one patient with osteogenic 
sarcoma of the ulna in a report of 6 cases. Resection resulted in a 10 cm defect, 
which was reconstructed with proximal corticotomy and bone transport.  The 
external fixator index was 24 days/cm, resulting in good function with no evidence 
of relapse.   There was however a fibrous non-union, which was pain free and did 
not cause any functional impairment. 
 
Naggar et al (Naggar et al., 1993) included one patient with an osteogenic 
sarcoma treated with an Ilizarov fixator in a series of 11 patients. The defect was 
18 cm with transport occurring over 5-months and consolidation over 11-months. 
There was no documentation of complications associated with this case. 
 
Canãdell et al (Canadell et al., 1994) used physeal distraction to expand the 
tumour free margin and preserve the epiphysis in 7 patients with Ewing’s and 13 
with osteogenic sarcoma. The paper includes details of the operative technique, 
which initially involved physeal distraction over 15 days to increase the tumour free 
margin by 2 cm. The tumour was resected en bloc and provided margins were 
clear, the defect was reconstructed with autograft from the contra-lateral tibia or 
allograft. There were no local recurrences in the epiphyseal region and one 
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diaphyseal recurrence at a mean follow-up of 54-months but 3 patients had died 
from pulmonary metastases.  
 
Said et al (Said and el Sherif, 1995) reported two cases in which limb 
reconstruction was accomplished by resection- shortening- distraction. Case 1 
involved a 14-year old male with Enneking Stage IIB osteogenic sarcoma. Pre-
operative chemotherapy was given for five weeks (Glasser and Lane, 1991) prior 
to en bloc excision including the knee, resulting in a 17 cm defect. This was closed 
using a Hoffman external fixator with eight cycles of post-operative chemotherapy. 
The external fixator was removed after bone union and initial management was 
with a 15 cm shoe raise.  A corticotomy was performed after completion of 
chemotherapy and 9 cm lengthening was achieved with a Wagner external fixator, 
complicated by a popliteal nerve palsy and severe equinus deformity. Case 2 
involved a 41-year old female with a malignant fibrous histiocytoma of the lower 
femur, which was resected en bloc with the knee leaving an 11 cm defect. The 
bone ends were brought together using an Ilizarov fixator and distraction 
osteogenesis was performed to a total of 9 cm. 
 
Tsuchiya et al (Tsuchiya et al., 1997) reported segmental transport, shortening 
distraction and distraction over an intramedullary nail to reconstruct defects 
produced after excision of malignant bone tumours. Segmental transport was used 
in 10 cases (5 osteogenic sarcomas, 5 giant cell tumours) using a monofocal 
osteotomy with iliac bone grafting at the docking site. The tumours were proximal 
tibial (8), midshaft tibial (1) and distal femoral (1). The average defect was 8.8 cm 
and 3 patients had chemotherapy during distraction. 
 
The mean external fixation index was 39.4 days/cm, with a total fixator time of 
251-days for the tibial transport group and 440-days for the femoral transport 
group. Significant complications were reported and included skin invagination (2), 
pes equnius (2), premature consolidation (1), fracture at the docking site (1), 
subluxation of the head of the fibula (1). 
 
Forty-three percent of patients who received chemotherapy during distraction 
osteogenesis were dead at a mean time of 29-months. This is significantly worse 
than would be expected with the contemporary management of osteogenic 
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sarcoma and suggests that the reconstruction technique modified the outcome. 
This may be due to compromising resection margins, activating the tumour with 
distraction osteogenesis or may be un-representative, given the small sample size. 
 
Canadell et al (Canadell et al., 1998) described a series of 61 cases of bone 
tumors managed with an external fixator. These were sub-divided into pathological 
fractures managed with external fixation and patients treated by external fixation at 
an interval after the primary oncological surgery to deal with bone lengthening, 
limb shortening, pseudarthrosis, infection and correction of angular deformities. A 
separate group is described in which an external fixator was used to maintain 
position of an autograft or to reconstruct a bone defect with physeal distraction or 
bone transport. 
 
Physeal distraction was carried out in 22 patients, 14 with osteogenic sarcoma and 
18 with Ewing’s sarcoma. In each case, the tumour was metaphyseal and proximal 
to the physeal cartilage, which was unaffected.  Distraction was performed using 
external fixator at the rate of 1 to 2 mm/day until a gap of approximately 2 cm was 
created. The fixator was left in situ for 10-20 days and the result was reported to 
be good in all patients.  It is not possible to assess the treatment within these 3 
groups from the data presented, as the patient demographics relate to the whole 
group. 
 
The details of bone transport in a 5-year-old girl with an osteogenic sarcoma of the 
distal femoral metaphysis is described separately.  Bone transport was effected 
using an Limb Reconstruction System (LRS) fixator, which was worn for 235-days. 
There is no information describing the chemotherapy regimen and insufficient 
clinical detail to allow any more sophisticated discussion of the role of bone 
transport in the situation. The recommendation was that bone transport should be 
conducted in very young patients with small diaphyseal and distal metaphyseal 
tumours of the femur.  
 
Ozaki et al (Ozaki et al., 1998) described the treatment of 5 patients with bone 
sarcomas (3 osteogenic sarcomas, one Ewing’s and one chondrosarcoma) 
managed by bi-focal bone transport. The mean skeletal defect after tumour 
resection was 17 cm (10-25). The mean duration of external fixation was 32-
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months (579-1340 days) and the mean treatment index was 95 days/cm. (53.5-
191). The average follow up period was 48-months (40-66). Satisfactory bone 
formation was only achieved in one case with significant functional impairment in 
all others. There were frequent complications, which included re-absorption of 
regenerate, skin necrosis, non-union, fixation failure, pin track infection and 
persistent equinus. In view of the poor experience the authors did not advise this 
as a method of reconstruction for bone sarcomas. 
 
Kapukaya et al (Kapukaya et al., 2000) reported 9 patients with femoral tumours, 
including one stage IIB Ewing’s and 3 stage IIB osteogenic sarcomas.  All 4 
received pre and post-operative chemotherapy although the regimen is not 
specified.  
 
The mean age of the osteogenic sarcoma group was 9.6-years (8-13) and the 
mean skeletal defect was 10.7 cm (10-12 cm). The mean distraction rate was 14.0 
days/cm (12-15.7) and the mean external fixation index was 33.4 days/cm (32.5-
34.5). The mean period of follow up was 33-months (20-30) and at the time of 
follow up one patient had died of their disease.  
 
The Ewing’s sarcoma was in a 7-year-old female with a skeletal defect of 13 cm 
with a distraction index of 12.7 days/cm and an external fixator index of 32.8 
days/cm. There was no evidence of recurrent disease or significant complication at 
20-months.   
 
There were 6 patients who did not receive chemotherapy and the authors noted 
that there was no difference in external fixator index between groups. They 
recognised that the numbers in this study were too small to allow a definitive 
opinion on this point. 
 
Millett et al (Millett et al., 2000) reported 2 cases aged 14 and 26-years, with a 
mean follow-up of 24-months. Reconstruction was with bone transport using a 
unilateral external fixator to bridge a bone defect of 15 and 18 cm. 
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The external fixator index was 30 and 38.5 months/cm and the distraction index 
was 11 and 15.7 months/cm. Both patients had a good function with no evidence 
of relapse and complications included premature consolidation and deep infection. 
 
Tsuchiya et al (Tsuchiya et al., 2002) reported the results of 11 patients with peri-
articular osteogenic sarcomas treated with intra-epiphyseal excision of the tumour 
and reconstruction by distraction osteogenesis. Eight of this group, with high-grade 
tumours received pre- and post-operative chemotherapy (5 cycles of intra-arterial 
cis-platinum, caffeine and adriamycin at intervals of 3-weeks).  
 
Evidence of good response consisted of sclerotic changes or good margination of 
the tumour on plain radiographs, marked shrinkage of any extension of the tumour 
into soft tissues on Magnetic Resonance Imaging (MRI) and disappearance of 
tumour vessels on angiography. Patients with at least 1cm of preserved epiphysis 
were considered for intra-epiphyseal excision with reconstruction using 
conventional bone transport, shortening distraction or bone transport after 
insertion of a diaphyseal bone cylinder. Distraction was started between 1 to 2-
weeks after surgery at a rate of 1mm/day. 
 
Chemotherapy was continued during the post-operative period for patients with 
high-grade tumours using 3 courses of intravenous cis-platinum, caffeine, 
adriamycin, vincristine, high dose methotrexate and citrovorum factor. Two 
patients had died at the time of follow-up, one from the sarcoma and one from 
hepatitis. The remainder had a continuous disease free interval average of 59-
months. This group had a mean lengthening of 9 cm with a mean distraction index 
of 14 days/cm and an external fixation index of 35 days/cm. Normal limb function 
was restored in 8 of the 9 surviving patients, 3 had initial shortening, 2 of whom 
required further lengthening and one required a shoe-lift. 
 
Laitien et al (Laitinen et al., 2005) reported their experience of 15 patients with 
primary malignant tumours of the distal tibia, 14 of which were treated with limb 
salvage surgery. Reconstruction was achieved by tibio-talar arthrodesis in 
combination with a variety of techniques, with 3 cases managed by bone transport. 
Patients received adjuvant or neo-adjuvant chemotherapy according to the Co-
operative Osteosarcoma Study (COSS) for osteogenic sarcoma and European-
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Ewing study for Ewing’s Sarcoma. Bone transport was not started until 
chemotherapy had been completed and a cement spacer was inserted into the 
resected area as an interim measure. The mean defect was 12.8 cm (12.5-13) and 
reconstruction was combined with an arthrodesis.  
 
Two female patients (14 and 16-years) had Enneking stage 11B osteogenic 
sarcoma with a Salzer-Kuntschik (Salzer-Kuntschik et al., 1983) grade 1 response 
to chemotherapy. At follow–up of 1.3 and 5.1-years, there had been wound 
healing problems that had been managed conservatively. There was no evidence 
of recurrent disease in either patient.   
 
A 37-year old male with Ewing’s sarcoma Grade 11B also had a grade 1 response 
to chemotherapy. There was no evidence of disease 9.1-years after initial 
presentation. Treatment was complicated by non-union of the bone transport and 
infection. The treatment was initially with a fibular transfer and subsequently an 
amputation.  
 
1.6.5 Distraction Osteogenesis to Manage Limb Length Discrepancy in 
Patients Previously Treated with Cytotoxic Chemotherapy 
Cara et al (Cara et al., 1993) reviewed their experience of surgical lengthening in 8 
patients who had previously undergone treatment for Ewing’s or osteogenic 
sarcoma. There is very little detail about the primary treatment and no information 
describing the prior use of chemotherapy. Lengthening was conducted with a 
mono-lateral (Wagner or Monotube LC) fixator at an unspecified time following 
primary treatment. The average discrepancy was 12.6 cm and equalisation was 
achieved in five patients. The authors state an interval of three years from 
completion of multi-disciplinary therapy should be allowed before limb lengthening 
is undertaken but there is no data in the text to validate this statement. 
 
Gonzalez-Herranz et al (Gonzalez-Herranz et al., 1995) presented 15 cases of 
lower limb length discrepancy greater than 5 cm in patients who had undergone 
treatment for Ewing’s or osteogenic sarcoma. The type and duration of 
chemotherapy and the interval between tumour treatment and limb lengthening is 
not specified. 
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Ten patients were managed by surgical lengthening, 3 with a second lengthening 
using an Orthofix fixator (11) and Ilizarov fixator (2). The average lengthening was 
8.1 cm with a healing index of 41 days/cm (31-56). The authors make the point 
that patients that have previously undergone field irradiation are unsuitable for 
surgical lengthening due to “irreversible lesions in the bone matrix”. 
 
Catagni et al (Catagni et al., 2003) used the Ilizarov method to correct limb length 
discrepancy in a 26-year old patient who underwent a hemi-pelvectomy for a 
Ewing’s sarcoma 15-years previously. Neo-adjuvant chemotherapy (Vincristine, 
Cyclophosphamide, Doxorubicin and Actinomycin D) had been completed 12-
years previously and there was no evidence of local recurrence. There was 6 cm 
residual shortening with tibio-femoral axis mal-alignment. 
Reconstruction was achieved with a 3 level hybrid Ilizarov fixator, allowing 
simultaneous femoral and tibial/fibular lengthening to a total of 6 cm.  
There was evidence of clinical and radiological consolidation 6-months after fixator 
application and a good functional outcome with unaided walking. 
 
Ilizarov et al (Ilizarov et al., 2007) described a patient who was initially treated for 
an osteosarcoma of the proximal humerus. Tumour resection was followed by 
shoulder hemi-arthroplasty, revised 10-months later to an arthrodesis with a 
vascularised fibular graft.  There was no detail of the chemotherapy associated 
with the initial tumour treatment. Nine-years after treatment a 9 cm discrepancy 
was corrected using a unilateral device with an external fixator index of 1.33 
cm/month. This was complicated with an oblique fracture in the central part of the 
regenerate, which was treated in a brace and subsequently with internal fixation. 
 
Oh et al (Oh et al., 2008) reported the use of sub-muscular plating after distraction 
osteogenesis to reconstruct segmental defects in children. Two required bone 
transport for a tibial and femoral defect. The external fixator index for the femoral 
transport was 14.2 days/cm, with a healing index of 46.5 days/cm.  The healing 
index for tibial transport was 39.6 days/cm, with a healing index of 66.4 days/cm. 
There are no details of tumour type or the use of cytotoxic drugs and it is therefore 
not possible to make any comments relating to the behaviour of regenerate in 
these patients. 
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Romanos et al (Romanos et al., 2008) reported a 13-year old female with a 
massive knee endoprosthesis after excision of a proximal tibial osteogenic 
sarcoma. There was a 9.5 cm limb length inequality, which was managed with 
attempted tibial lengthening with an Ilizarov fixator over the stem of the prosthesis. 
A 5cm lengthening was achieved with good quality regenerate. The procedure was 
however complicated by a severe infection, which did not respond to antibiotics 
and led to removal of the fixator, removal of the prosthesis with a 
methylmethacrylate spacer and an above knee cast. 
 
Erlap et al (Eralp et al., 2009) reported 8 patients with infection or deformity 
following surgery, 6 patients with shortening secondary to tumour surgery and 4 
patients with deformity and shortening secondary to multiple exostoses and 
Ollier’s disease.  
 
In the first group, there were 3 patients with Ewing’s and one with osteogenic 
sarcoma. All were treated for the complications of primary salvage surgery and at 
the time of external fixator surgery, were not currently or had not recently been 
treated with cytotoxic drugs.  
 
In the second group, there was one patient with a Ewing’s sarcoma and one with 
osteogenic sarcoma initially treated with a fibular graft resulting in non union and 
shortening. These patients were successfully treated with an external fixator 12 
and 144-months after primary treatment. This paper is therefore a technical report 
rather than a description of the management of the tumour, which it can be 
assumed, was cured by the primary treatment. 
 
Courvoisier et al (Courvoisier et al., 2009) described lengthening of vascularised 
free fibular grafts in 3 patients, 2 who had previously undergone resection for 
chondroblastic osteogenic sarcoma and Ewing’s sarcoma of the tibia, The 
histology of the patient with chondroblastic osteogenic sarcoma was subsequently 
reviewed and was judged to have been a chondromyxoid fibroma 
 
This series is therefore relevant only in that one patient who had Ewing’s sarcoma 
underwent distraction osteogenesis in a vascularised fibular graft at a point that 
they had effectively recovered for their primary tumour and initial treatment. 
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The authors highlighted major concerns associated with this type of approach and 
in particular, considered that whilst bone lengthening over a prosthesis stem is 
possible and may produce a good quality regenerate, it should be avoided due to 
the high risk of secondary bone infection. 
 
1.6.6 Overview of the Role of Distraction Osteogenesis in the Management 
of Malignant Bone Tumours 
Distraction osteogenesis in general and bone transport in particular has been 
reported in a number of previous publications discussing the management of 
malignant bone tumours. These contain small numbers and often include cases of 
malignant bone disease in a more broad description of technique. Other series 
describe strategies that use an external fixator in the tumour patient as an adjunct 
to alternative methods of reconstruction and in late reconstruction following the 
complications of primary treatment. 
 
It is clear from the previous literature that both traumatic and tumour cases are 
associated with significant complications with infection and mal-union being 
common. It is difficult to make direct comparisons due to the disparate nature and 
small numbers in each of the series considered. The series are non-standardised 
in terms of primary diagnosis, external fixator type and definition of each phase of 
treatment and it is not possible to draw robust conclusions. There is no previously 
published data that specifically considers the effect of cyclical cytotoxic 
chemotherapy on bone formation in human subjects. 
 
1.7 The Aim of This Thesis 
Thirty years ago, the outcome for patients with osteogenic sarcoma was bleak. 
The likelihood of survival beyond five years was of the order of 20 – 25%, with 
death predominantly being due to metastatic disease. The introduction of cytotoxic 
chemotherapy led to a rapid and significant improvement in survival.  An 
appreciation that survival was not influenced by the choice of treatment for local 
disease led to further important developments and in 1986, Simon et al (Simon et 
al., 1986) demonstrated equivalent survival for patients undergoing amputation or 
a limb sparing procedure. This stimulated advances in the surgical management of 
local disease with modification of conventional techniques. Biological or 
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endoprosthetic reconstruction techniques are prone to infection, lack of biological 
affinity or lack of durability.  
 
Distraction osteogenesis is widely used to manage intercalary defects following 
trauma and infection and could potentially provide a superior method of 
reconstruction. The concomitant use of chemotherapy in this situation however, 
adds an extra dimension to the complexity and although there are several reports, 
this technique is not in widespread use.  
 
The effect of cytotoxic drugs on regenerate bone is unknown and the efficacy of 
distraction osteogenesis in the management of malignant tumours is therefore 
uncertain. This thesis will attempt to address this specific deficiency in knowledge 
from two directions. 
 
The first pillar of this research is the development of a robust experimental model, 
which can be used to investigate the effects of cytotoxic chemotherapy on 
distraction osteogenesis.  
 
The second pillar uses this model to investigate the effect of cytotoxic drugs on the 
structural and material properties of the regenerate bone.  
 
1.7.1 General Hypothesis 
The general hypothesis is that it is possible to produce structurally competent 
bone by distraction osteogenesis in the presence of cyclical cytotoxic therapy. 
 
1.7.2 Deliverable Objectives 
Pillar 1 Development of an Animal Model  
An investigation was performed to develop a NZW rabbit model that used a 
combination of cis-platinum and adriamycin to consistently produce a clinically 
relevant cytotoxic effect without inducing renal or hepatic failure. 
 
Previous studies were concerned primarily with the pharmacokinetics and toxic 
effects of these drugs, using high doses with short periods of assessment. There 
was an absence of data indicating doses relevant to this investigation, the 
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optimum route of administration and the combined effect of cis-platinum and 
adriamycin on renal, cardiac and general metabolic function in this species.  
 
An appropriate chemotherapy schedule was identified that met the conflicting 
requirements of producing a measurable cytotoxic effect, without adversely 
affecting metabolic function.  A standard method of cytotoxic delivery was 
developed using an infusion pump to deliver drugs via the femoral vein.  
 
Pillar 2 Investigation of the Effect cis-Platinum and Adriamycin on the 
Structural and Material Properties of Bone Formed by Distraction Osteogenesis.  
Two cycles of either cis-platinum and adriamycin or normal saline were given to 
juvenile NZW rabbits that subsequently underwent limb lengthening using a mono-
lateral external fixator aged 12-weeks. 
 
The experiment model used either 2-cycles of drugs given 4 and 2-weeks before 
osteotomy and distraction (Neo-adjuvant Group) or one cycle 10-days before and 
4-days after osteotomy and distraction (Adjuvant Group). 
 
 
43 
The lengthened tibia was evaluated using plain radiography, DXA and 
compression testing to determine differences in the structural and material 
properties of the regenerate that could be reasonably attributed to the presence of 
cytotoxic drugs. The relationship between the timing of administration of the drugs 
and effect on the regenerate was also evaluated.  
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Section 2 Development and Validation of  the Animal Model   
The first pillar of the experiment involved the development of a NZW rabbit model 
in which a clinically relevant cytotoxic dose was infused whilst preserving normal 
renal and hepatic function. The compounding effect of deranged metabolic 
function would make interpretation of subsequent data impossible and 
preservation assumed primacy over the level of cytotoxic effect. The working 
compromise was to deliver maximum doses of cis-platinum and adriamycin 
compatible with normal renal and hepatic function, with a < 5% rate of infection. 
The dose at which this was achieved was the maximum that could be used in the 
next stage of the experiment. Reduction in percentage weight gain was taken as 
evidence of an adequate cytotoxic effect, similar to that which would be seen in a 
human patient and previously described in the NZW rabbit. (Wanless et al., 1987, 
Young et al., 1975) 
 
This chapter considers published studies that report the metabolic effects of cis-
platinum and adriamycin on this species and the effect of cytotoxic drugs on 
distraction osteogenesis. This resulted in the development of an experimental 
model, which satisfied the following criteria;   
 
1. Reproducible anaesthesia 
2. Reproducible infusion of cis-platinum and adriamycin 
3. Appropriate cytotoxic effect  
4. Normal renal function 
5. Normal hepatic function 
 
2.1 Studies using Adriamycin 
Young et al (Young et al., 1975) infused 8-week old NZW rabbits with adriamycin 
(0.7 mg/kg) 3 times per week for up to 4-months with a control group receiving 
equivalent volumes of saline. There was a significant mortality in the treated 
group, with 57% (8/14) dying of drug toxicity before the conclusion of the 
experiment. Post mortem analysis demonstrated severe cardiomyopathy and 
glomerulonephrosis. The remaining treated animals had evidence of myocardial 
damage and mild to moderate glomerulonephrosis. There was a significant 
increase in BUN, reduction in alkaline phosphatase levels and the rate of weight 
gain decreased in the treated group, with terminal weights 61% of control animals.  
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There were structural alterations in the skeleton of the treated group, with 
reduction of cortical thickness to 82% of controls. The distal femoral physis was 
radiologically indistinct, corresponding to histological differences including loss of 
the columnar arrangement in the zone of proliferation. The zone of provisional 
calcification was reduced in all treated bones and there was a paucity of 
vascularised connective tissue, osteoblasts and osteoclasts. There was a 
reduction in numbers of bony trabeculae in the primary and secondary spongoisa 
and trabeculae were frequently disorientated from the longitudinal axis of the 
bone. Cells surrounding the trabeculae were spindle to ovoid shaped and were 
considered to be populations of fibroblasts and resting stem cells. There was mild 
to moderate marrow hypoplasia with replacement fibrosis, which was particularly 
prominent in the metaphysis of animals treated for longer periods. The cortical 
bone from treated rabbits appeared histologically immature compared to age 
matched controls 
 
Jaenke et al (Jaenke, 1976) infused mixed sex NZW rabbits with adriamycin (2.25 
mg/kg/week in 3 divided doses) which were assessed after 23, 35, 43 and 75-days 
of continuous treatment. Adriamycin toxicity was assessed by total leukocyte 
count, haematocrit, creatine phosphokinase (CPK), lactate dehydrogenase (LDH) 
and weight gain. Myocardial lesions were described using qualitative and 
quantitative methods of microscopic assessment. Group B closely mimicked the 
experimental requirements of this study and received a total dose of 6.75 mg/kg 
during 23-days of treatment. In this group, there was an early rise in CPK and LDH 
levels, which continued throughout treatment, gradually normalising approximately 
10-weeks after cessation of adriamycin. There was no histological evidence of 
immediate or late (53-days) cardiac damage. 
 
Bertazzolli et al (Bertazzoli et al., 1976) investigated the cumulative effect on male 
NZW rabbits of an infusion of adriamycin (0.8mg/kg), 3 times per week for 7-
weeks compared to normal saline controls. There was histological evidence of 
myocardial degeneration in the treated group with decreased activity of succinate 
dehydrogenase CoQ10 indicating significant, cumulative cardiotoxicity.  
 
Arnolda et al (Arnolda et al., 1985) investigated the effect of chronic intravenous 
adriamycin (1mg/kg) administration twice weekly for 8-weeks in mixed strains 
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including NZW rabbits. This dose schedule was designed to produce minimal 
marrow toxicity and is a modification of the technique described by Jaenke et al. 
(Jaenke et al., 1980) All animals developed cardiac failure within 8-weeks with 
post mortem evidence of cardiac dilation, pleural and pericardial effusions, ascites 
and hepatic congestion. 
 
Wanless et al (Wanless et al., 1987) infused adult NZW rabbits with adriamycin 
(1mg/kg) via an ear vein, twice per week for 6, 8 or 10-weeks with control groups 
receiving no treatment. Assessment included simple clinical, haematological and 
biochemical investigations in addition to invasive cardiovascular monitoring. The 
treated group continued to increase in weight but at a slower rate than the control 
group. There was a significant reduction in haemoglobin and a non-significant 
decrease in white cell count, both these parameters returned to control levels in 
animals treated for 8-weeks with 2-weeks to recover. There was a variable, dose 
dependant effect on heart rate (HR), cardiac output (CO) and total peripheral 
resistance (TPR) with reduction of CO in all groups and a reduction of TPR in the 
8 and 10-week groups. 
 
Jones et al (Jones et al., 1990) infused NZW rabbits of unspecified age with 
adriamycin (1mg/kg) twice per week for 8-weeks with 2-weeks recovery. Outcome 
measures included enzymic analysis of cardiac myosites and measurement of 
contraction amplitude and velocity. After 8-weeks of adriamycin therapy, all 
animals had a cardiomyopathy similar to that occurring in human patients with 
adriamycin cardiotoxicity. There were post mortem signs of severe congestive 
cardiac failure with biventricular dilatation, pleural and pericardial effusions, ascites 
and hepatic congestion. There was histological evidence of widespread atrophy 
and lysis of the cardiac myocytes associated with interstitial fibrosis. 
Calderone et al (Calderone et al., 1991) identified a potential cellular mechanism 
of cumulative cardiotoxicity using juvenile NZW rabbits infused with adriamycin 
(0.75 mg/kg) 3 times per week for 11-weeks. This study demonstrated that 
adriamycin administration caused early dysfunction of the myocardial β- 
adrenergic system due to a decrease in adenyl cyclase activity. 
 
Cusack et al (Cusack et al., 1992) compared the effect of adriamycin on normally 
nourished and malnourished adult NZW rabbits weighing between 2.5 and 3.5 kg. 
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The normally nourished group is comparable to the experimental group in this 
thesis. Animals received 5 mg/kg adriamycin via an ear vein as a bolus over 2-
minutes. Plasma concentrations of adriamycin (doxorubicin) and the principle 
metabolite, doxorubicinol were obtained at intervals up to 52-hours after infusion. 
Malnourishment had a significant effect on the pharmacokinetics of both 
compounds but the duration of the experiment was short and did not include 
histological or haemodynamic assessment of renal or cardiac function. 
 
Bocherens-Gradient et al (Bocherens-Gadient et al., 1992) used male rabbits to 
investigate the effect of intravenous adriamycin (1mg/kg) twice per week for 9-
weeks. In this study, 11/15 animals did not survive to complete the experiment, 5 
due to the direct effects of adriamycin. All 4 survivors demonstrated signs of 
advanced cardiac failure but the severity of symptoms varied, indicating 
differences in the individual sensitivity of the animals to adriamycin.  
 
Cusack et al (Cusack et al., 1993) compared the pharmacokinetics of adriamycin 
(doxorubicin) and doxorubicinol in young male NZW rabbits infused with 5 mg/kg 
adriamycin by 2-minute bolus or 24-hour continuous infusion. Blood was sampled 
at intervals during infusion or following bolus administration. There was a 
significant increase in peak left ventricular tissue concentration following bolus 
administration but follow-up time was short and the study did not include 
histological or haemodynamic assessment of cardiac failure. 
 
Dodd et al (Dodd et al., 1993) infused adult NZW rabbits with adriamycin (1mg/kg) 
over 30-minutes via an ear vein twice weekly for a total of 12 to 18 doses and 
compared this to a saline infused control group. There was a significant increase 
in ventricular weight in the treated group and an increase in heart/body weight 
ratio. Microscopic changes in the ventricles included sarcotubular swelling without 
mitochondrial or myofibrillar loss and changes in papillary muscles consistent with 
adriamycin cardiomyopathy. The study identified a further potential mechanism of 
adriamycin cardiotoxicity that involved a decrease in calcium release channels in 
the sarcoplasmic reticulum. 
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2.2 Studies using cis-Platinum  
Schiffer et al (Schiffer et al., 1996) studied central nervous system toxicity in a 
NZW rabbit model by injecting a single 2 mg/kg dose of cis-platinum into the left 
carotid artery. There were no demonstrable clinical effects on the animals and no 
neurological abnormalities.  There was no demonstrable effect on brain 
histopathology following the administration of cis-platinum but neither renal 
function nor histology was evaluated. 
 
Frank et al (Frank et al., 1989) used gadolinium-DTPA enhanced dynamic MRI to 
monitor the nephrotoxic effects of cis-platinum in NZW rabbits. Animals were 
divided into 2 groups and given either 8 mg/kg (Group 1) over 1-hour or 3 mg/kg 
(Group 2) each day for 5 consecutive days. In group 1 there was MRI evidence of 
nephrotoxicity within 9-hours of administration and an increase in Blood Urea 
Nitrogen (BUN) and creatinine within 48-hours. The acute toxic effects of cis-
platinum led to severe anorexia and weakness and necessitated killing the animals 
by day-7. In group 2, the animals received a higher cumulative dose and 
demonstrated a marked deterioration in weight, but a less severe rise in BUN and 
creatinine.   
 
Histology of the kidneys from both groups demonstrated mild to moderate foci of 
necrosis of the PCT with proteinaceous material in the PCT extending to the loop 
of Henlé. Focal areas of cystic dilatation of the proximal tubules and areas of 
lymphocytic infiltration were also seen in the rabbits in group 2 and possibly 
represented the late effect of cis-platinum nephrotoxicity.  
 
Najjar et al (Najjar and Saad, 2001) used adult male NZW rabbits to investigate 
the effect of a single intravenous 5 mg/kg dose of cis-platinum. Normal rabbits 
were compared with streptozotocin induced diabetic rabbits 3-days after the 
induction of a diabetic state. Indices of nephrotoxicity (serum creatinine, BUN and 
serum albumin) were obtained at 0 and 7-days after cis-platinum administration for 
both groups. Comparisons between groups 7-days after cis-platinum treatment 
demonstrated highly significant elevations in serum creatinine and urea and a 
decrease in serum albumin levels in the non-diabetic group 
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2.3 Rabbit Models Assessing the Effect of Cytotoxic Drugs on Distraction 
Osteogenesis    
Prevot et al (Prevot et al., 1988) used an adult rabbit model to investigate the 
effect of methotrexate or methotrexate and adriamycin during tibial lengthening. 
Although consolidation was slightly delayed in the methotrexate group when 
compared to controls (average 9.5-weeks vs. 9.3-weeks), the difference was not 
statistically significant. The combination of methotrexate and adriamycin had a 
more pronounced negative effect on bone regenerate, although significant marrow 
and cardiac toxicity resulted in early death of numerous animals in the group. This 
study presented only qualitative histological and radiological analysis and did not 
specifically address the local or systemic complications that were encountered. 
 
Jarka et al (Jarka et al., 1998) investigated the effect of methotrexate in a NZW 
rabbit model of distraction osteogenesis using a ring fixator. The latent period was 
one-week, distraction continued at 0.5 mm twice daily for 3-weeks with sacrifice at 
28-days or 70-days. Haematological, biochemical and radiological evaluation was 
performed at intervals until sacrifice with post mortem histological examination of 
the lengthened tibia. Seventeen of 18 rabbits that received 130 mg/kg 
methotrexate gained weight, thrived and completed distraction. Radiographs were 
coded and evaluated blindly, with initial bone bridging observed at 4-weeks in all 
animals except one in the 28-day experimental group.  In the 70-day group, 
consolidation was observed at a mean of 6.4-weeks in the control group and 7.3-
weeks in the chemotherapy group and was not statistically significant. There was 
no difference in haemoglobin concentration or leukocyte count at day 20 or day 
70. The calcium and phosphorous concentration in bone regenerate of treated 
animals was slightly higher at 28-days and slightly lower at 70-days but neither of 
these findings was statistically significant. There was no quantitative or semi-
quantitative difference between the histological findings of the bone in the 
experimental or control group. 
 
2.4 Large Mammal Models Assessing the Effect of Cytotoxic Drugs on 
Distraction Osteogenesis    
Burchardt et al (Burchardt et al., 1983) investigated the effect of adriamycin and 
methotrexate on the healing of segmental defects in dogs. Adriamycin was given 
at doses of 30, 40 or 50 mg/m2 and compared with control and methotrexate 
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treated animals 6-months after repair of a segmental defect with a fibular 
autograft. There was evidence of decreased new bone formation and an increased 
rate of non-union which was not dependant on the dose of adriamycin.  Animals 
treated with 40 or 50 mg/m2 had disproportionate suppression of new bone 
formation at the periphery of the graft. The combination of new bone suppression 
and peripheral graft reabsorption resulted in a reduction in torque to failure with 
the higher doses. 
  
Ehrhart et al (Ehrhart et al., 2002) investigated the effect of cis-platinum on bone 
transport in a canine radius model. Five animals received 4 cycles of cis-platinum 
(70 mg/m2 i.v.) with 5 being given 0.9% saline control. DXA analysis was 
performed 24, 55 and 90-days after surgery, at which point the dogs were 
sacrificed. Histomorphometry was performed on non-decalcified sections of 
regenerate and the BMD and indices of newly formed bone were compared 
between groups. There was no difference in the BMD between groups but the cis-
platinum treated dogs had a decreased mineralised bone volume, decreased 
percentage of woven bone volume, decreased percentage of osteoblast covered 
bone, increased porosity and increased percentage of osteoblast covered surfaces 
compared with the controls. The lamellar bone volume and osteoid volume did not 
differ significantly between groups. This demonstrated that regenerate bone would 
form and remodel following the administration of cis-platinum. Histomorphometric 
analysis suggested an uncoupling of bone formation and reabsorption resulting in 
increased osteoclast activity or delayed secondary bone formation during 
remodelling. 
 
Gravel et al (Gravel et al., 2003b) investigated the effect of adriamycin in a goat 
model of tibial lengthening. Animals received an initial dose of 60 mg/m2 of 
adriamycin 6-weeks before surgery with the second dose 3-weeks later. Tibial 
lengthening was performed after a 5-day lag period with an Orthofix bone 
lengthener at a rate of 1mm per day for 20-days. The animals were sacrificed at 6, 
12 and 24-weeks and the lengthened tibiae underwent radiological, biomechanical 
and histological analysis. There was no significant difference in radiological 
histological and mechanical parameters between adriamycin treated and control 
groups. There was no evidence that chemotherapy affected the healing time or the 
torsional properties of the bone 
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2.5 Summary of Available Literature 
The published literature describing the use of adriamycin in the NZW rabbit 
involves either a short interval to sacrifice or omits histological or haemodynamic 
data. (Arnolda et al., 1985, Bertazzoli et al., 1976, Jaenke, 1976, Jaenke et al., 
1980, Young et al., 1975) These studies demonstrate that either cumulative low (1 
mg/kg) or bolus high (5 mg/kg) doses predictably induce cardiac failure. Most of 
these experiments involved a deliberate attempt to produce cardiac failure in a 
variety of circumstances, whereas preservation of cardiac function was required 
for the experimental component of this thesis. Jancke et al (Jaenke, 1976) 
demonstrated that intravenous infusion of adriamycin (2.25 mg/kg/week in 3 
divided doses) caused a transient rise in CPK and LDH but no histological 
evidence of myocardial damage at 53-days and provides a potentially safe 
schedule for adriamycin in isolation. 
 
Similar limitations relate to previous experiments using the NZW rabbit to evaluate 
cis-platinum and initial experiments involved high doses of cis-platinum. (Frank et 
al., 1989) Najjar et al (Najjar and Saad, 2001) demonstrated that doses of 5 mg/kg 
predictably produced renal failure but there is no good data to suggest a dose that 
will preserve renal function in this species. 
 
Previous studies have evaluated the use of single cytotoxic agents on bone 
healing (Burchardt et al., 1983) and bone transport (Ehrhart et al., 2002) in a 
canine model and limb lengthening in a goat model. (Gravel et al., 2003b) 
Methotrexate in isolation (Jarka et al., 1998) and in combination with cis-platinum 
(Prevot et al., 1988) has been evaluated to investigate the effect on  bone 
formation in the NZW rabbit. There is no previous experimental work that 
considers the combined effects of cis-platinum and adriamycin on bone formed by 
distraction osteogenesis.  
 
The initial experimental component of this thesis investigated the metabolic effect 
of variable doses of cis-platinum and adriamycin on the juvenile NZW Rabbit. The 
aim was to produce a model that fulfilled the conflicting requirements of a 
therapeutically relevant anti-neoplastic effect without significant side effects. 
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2.6 Experimental Considerations 
The cytotoxic dose restrictions associated with this experiment have been outlined 
in previous paragraphs. The working compromise was to deliver the maximum 
amount of cis-platinum and adriamycin compatible with normal hepatic and renal 
function, with a < 5% rate of infection. There were no previous studies that used 
this combination in the NZW rabbit and a study was undertaken to determine the 
dose that produced a 5% reduction in percentage weight gain. This was 
considered to be evidence of a relevant cytotoxic effect, which would imitate some 
of the effects that would be expected in a human patient.  
 
2.6.1 Breeding and Husbandry 
All animals were obtained from the Combined Universities Laboratory Animal 
Services (CULAS), Little Bay, New South Wales (NSW) 2036, Australia. The 
CULAS NZW Rabbit colony is an outbred Specific Pathogen Free (SPF) colony. 
The colony consisted of 4 bucks and 22 does, mated according to a minimal 
inbreeding scheme. The rabbits were free of all major rabbit pathogens and 
microbiological screening was conducted on a quarterly basis.  
Prior to delivery, the rabbits were housed in metal cages with an indirect paletted 
paper bedding system and trays were changed twice weekly.  
 
Animal feed was obtained from Tillside Rabbit Stud (Penrith NSW) and rabbits 
were fed daily on a diet of young stock feed rabbit pellets, Lucerne cubes and tap 
water ad libitum. Diet was initially unrestricted, but due to aspiration in 2 cases, 
intake was limited to water for 2-hours before surgery.  
 
Batches of five rabbits were transported to the Animal Care Facility at Westmead 
Hospital (Westmead NSW) and were between 8 and 10-weeks old on arrival 
depending on the experimental requirements. The animals were weighed on 
arrival and housed in individual steel cages (Batterie “P”, Imbros Pty, Hobart, 
Tasmania). The internal dimension of each cage was 482 mm (depth), 580 mm 
(width) and 365 mm (height) providing a floor area of 2 × 800 cm2. The cages were 
sited in an 8 foot (width) × 11 foot (length) × 9 foot (height) room, the temperature 
varied between 22oC and 24oC with 15 air changes per hour and a 12/12 light/dark 
cycle.  
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The general condition of the animals was assessed daily by an animal attendant. 
A veterinary surgeon was involved if there were any concerns and all interventions 
were documented.  
 
2.6.2 Ethical Approval 
Ethical approval was granted by the Animal Care & Ethics Committee, Western 
Sydney Area Health Service (Appendix 1). Experiments were conducted at the 
Animal Care Facility, Westmead Hospital and complied with the Australian code of 
practice for the care and use of animals for scientific purposes (National Health 
and Medical Research Council 1994).  The experiments were performed under the 
direct supervision of the veterinary officer, Dr Margaret Ferrara who performed all 
post mortem examinations.   
 
2.6.3 Laboratory Investigations 
Haematological analysis was performed using a Technicon H3 automated 
laboratory analyser (Bayer AG, Leverkusen, Germany) and produced a FBC with a 
differential. 
 
Biochemical analysis was performed using a Beckman Synchron CX5 auto 
analyser (Beckman Coulter Australia Pty., Ltd. Gladesville, NSW Australia). 
Analysis of sodium, potassium, chloride, bicarbonate and γGT was performed 
using standard Beckman reagents. Analysis of urea, protein, calcium, magnesium, 
phosphate and alkaline phosphate was performed using reagents from Trace 
Scientific (Nobel Park Victoria Australia).  
 
2.6.4 Anaesthesia  
Anaesthesia was conducted by FM with the assistance of an experienced animal 
attendant (TJ). To minimise discomfort, all animals were premedicated 30-minutes 
before surgery with intra-muscular Ketamine, 10 mg/kg, (Parnell Laboratories 
Australia Pty Ltd, Alexandria, NSW), Xylazine, 4 mg/kg, (Ilium Xylazil-20,Troy 
Laboratories Pty Ltd, Smithfield, NSW, Australia), and Buprenorphine, 0.05 mg/kg 
(Reckitt & Coleman Products Ltd, Hull, UK). 
 
General anaesthesia was induced via a face mask using an Enflurane (Abbott 
Australia Pyt. Ltd. Botany NSW Australia) and Nitrous-oxide / Oxygen mixture. The 
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anaesthetic was performed without endotracheal intubation and was 
uncomplicated in the majority of cases. The rabbit was placed on a heating pad 
and covered with a polyethylene drape to keep it warm but core temperature was 
not monitored. After each anaesthetic, the animal was observed until alert and 
drinking before being returned to its cage. 
 
2.6.5 Intravenous Access  
An incision was made in the right groin, the superficial femoral neurovascular 
bundle was identified and the femoral vein was isolated. (Figure iii). A 20 gauge 
intravenous cannula (Terumo Corporation, Tokyo, Japan) was inserted and 
secured between 2 silk sutures providing a watertight seal.  
 
The cannula was flushed to check for leaks and used to infuse either 50 ml 
adriamycin / cis-platinum (active) or 50 ml normal saline (control) over 2-hours 
using an IVAC® syringe pump. (ALARIS Medical Systems Australia, Pty. Ltd. 
Seven Hills NSW Australia)  After an interval of 2-weeks, an identical infusion was 
delivered via a left groin incision using an identical approach. 
 
In the dose response group, the animals were assessed on alternate days. In the 
main experimental group, the animals were assessed after each infusion, 
application of fixator and sacrifice. They were weighed and blood was obtained 
from an ear prick for full blood count (FBC), erythrocyte sedimentation rate (ESR), 
renal, hepatic and bone biochemistry.  
 
         Cranial 
 
 
 
  
               ________  
   1cm 
                   
            Caudal 
 
 
Figure iii Isolation of the Superficial Femoral Neurovascular Bundle 
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2.6.6 Chemotherapy Preparation and Delivery 
The animal was evaluated 24-hours before infusion with particular reference to 
general condition, hydration and weight. The cytotoxic drugs were prepared under 
sterile conditions in the pharmacy of the Children’s Hospital Westmead and 
delivered in pre-packed 50 ml syringes containing doses of cis-platinum and 
adriamycin in concentrations determined by the total body weight and phase of the 
experiment. These were stored overnight in a refrigerator and brought to room 
temperature 1-hour before infusion. Cytotoxic infusion was conducted over 2-
hours under general anaesthesia using techniques described in section 2.6.4. 
 
2.7 Dose Response Study 
Seven juvenile (8-week) male NZW rabbits were infused with cis-platinum and 
adriamycin using decreasing drug combinations. The initial, maximum dose was 
suggested by the available literature and this was decreased until the experimental 
requirements were satisfied.  
 
Each dose schedule was applied to a single rabbit to determine the dose which 
would be delivered to the active groups in the next phase of the experiment. This 
involved some risk, in that deterioration following the second infusion would 
require withdrawal of that group from further study, with a significant delay in 
completing the experiment. This risk was considered acceptable due to the time 
and budgetary constraints of the experiment and the estimations produced in the 
dose response study were robust and did not lead to withdrawal at any point.  
 
 
Rabbit A Cycle 1 6.5 mg/kg cis-platinum 6.5 mg/kg Adriamycin 
Cycle 2 6.5 mg/kg cis-platinum 6.5 mg/kg Adriamycin 
 
Rabbit B Cycle 1 4.5 mg/kg cis-platinum 4.5 mg/kg Adriamycin 
Cycle 2 4.5 mg/kg cis-platinum 4.5 mg/kg Adriamycin 
 
Rabbit C  Cycle 1 3.0 mg/kg cis-platinum 3.0 mg/kg Adriamycin 
Cycle 2 3.0 mg/kg cis-platinum 3.0 mg/kg Adriamycin 
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Rabbit D Cycle 1 2.0 mg/kg cis-platinum 2.0 mg/kg Adriamycin 
Cycle 2 2.0 mg/kg cis-platinum 2.0 mg/kg Adriamycin 
 
Rabbit E Cycle 1 1.0 mg/kg cis-platinum 1.0 mg/kg Adriamycin 
Cycle 2 1.0 mg/kg cis-platinum 1.0 mg/kg Adriamycin 
 
Rabbit F Cycle 1 1.0 mg/kg cis-platinum 2.0 mg/kg Adriamycin 
Cycle 2 1.0 mg/kg cis-platinum 4.0 mg/kg Adriamycin 
 
Clinical parameters including body weight and haematological and biochemical 
indices were measured at intervals of approximately 48-hours.  
 
The dose that produced a 5% reduction in percentage weight gain, without 
evidence of hepatic or renal failure was identified and used in the next component 
of the experiment to confirm that the model was robust 
 
The following section contains results from the dose response study presented as 
data from individual animals. Descriptive statistics from the main experimental 
groups are also presented to validate the animal model and demonstrate its 
suitability for use in the investigation of the characteristics of regenerate bone 
produced by distraction osteogenesis.  
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2.8 Dose Response Study Results 
 
2.8.1 Rabbit A 
Cycle 1  6.5 mg/kg cis-platinum 6.5 mg/kg adriamycin 
Cycle 2  6.5 mg/kg cis-platinum 6.5 mg/kg adriamycin 
 
On day 8, there was an obvious loss of appetite and a further deterioration leading 
to withdrawal of the animal and euthanasia on day 11.  
 
Post mortem examination demonstrated pericardial blood stained fluid with 
enlargement of both kidneys. The renal parenchyma was granular with an 
increase in peri-renal fat.   
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2.8.2 Rabbit B 
 
Cycle 1  4.5 mg/kg cis-platinum 4.5 mg/kg adriamycin 
Cycle 2  4.5 mg/kg cis-platinum 4.5 mg/kg adriamycin 
 
On day 17, the animal was not eating or drinking and required subcutaneous 
normal saline injections over a 4-day period. This produced a full recovery and the 
animal was in good condition at the time of sacrifice on day 28. 
 
Post mortem examination demonstrated a macroscopically normal heart and liver 
with minimally enlarged kidneys, which were morphologically normal.  
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2.8.3 Rabbit C 
 
Cycle 1  2.0 mg/kg cis-platinum 2.0 mg/kg adriamycin 
Cycle 2  2.0 mg/kg cis-platinum 2.0 mg/kg adriamycin 
 
A superficial wound dehiscence (3 mm) occurred on day 3. This did not require 
treatment and as the animal was in good condition, the experiment continued and 
healing was complete by day 14.  
The left inguinal cannulation and infusion were uncomplicated and the animal 
remained in a good clinical condition until the time of sacrifice on day-28. 
 
Post mortem examination demonstrated a macroscopically normal heart, liver and 
kidneys 
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2.8.4 Rabbit D 
 
Cycle 1  3.0 mg/kg cis-platinum 3.0 mg/kg adriamycin 
Cycle 2  3.0 mg/kg cis-platinum 3.0 mg/kg adriamycin 
 
Each cannulation and infusion was performed without incident. On day 19, there 
was a profound deterioration in general condition leading to death on day 21.   
 
Post mortem examination demonstrated macroscopically normal heart and liver. 
There was moderate enlargement of the kidneys with a granular parenchymal 
texture and increase in peri-renal fat.  
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2.8.5 Rabbit E 
 
Cycle 1 1.0 mg/kg cis-platinum 1.0 mg/kg adriamycin 
Cycle 2 1.0 mg/kg cis-platinum 1.0 mg/kg adriamycin 
 
The right inguinal cannulation and infusion were conducted without complication.  
The general condition was satisfactory following cannulation and the wound 
healed without incident.  
At the beginning of the second infusion, the animal sustained a fatal cardiac arrest.   
 
Post mortem examination demonstrated normal a heart, liver, kidneys. The lungs 
were normal with no evidence of aspiration and the presumed cause of death was 
an air embolism secondary to cannulation. 
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2.8.6 Rabbit F 
 
Cycle 1 1.0 mg/kg cis-platinum 2.0 mg/kg adriamycin 
Cycle 2 1.0 mg/kg cis-platinum 4.0 mg/kg adriamycin 
 
The initial groin exposure, cannulation and infusion were uncomplicated with rapid 
wound healing. The second groin exposure cannulation and infusion was also 
uncomplicated with rapid wound healing. The general condition remained 
satisfactory until the time of sacrifice at day 28. 
 
Post mortem examination demonstrated a macroscopically normal heart, liver and 
kidneys. The femoral and external iliac veins and inferior vena cava were patent 
without any complication related to cannulation.  
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2.9 Summary of Dose Response Study 
Doses of adriamycin and cis-platinum in excess of 3 mg/kg produced deterioration 
in general condition and renal function and at 6.5 mg/kg led to death 8-days after 
the initial infusion.  
 
A dose of 4.5mg/kg caused decline in renal function after each infusion, which 
initially recovered but deteriorated after the second infusion and had not recovered 
at the end of the period of observation.  
 
At 3 mg/kg there was deterioration in general condition leading to death at day 19, 
suggesting an idiosyncratic sensitivity to these drugs in some animals.  
 
A more modest increase in creatinine was observed following the first infusion of 2 
mg/kg but there was a permanent increase in creatinine after the second infusion 
suggesting a cumulative effect on renal function even at this low dose. This was 
considered to be due to the effect of cis-platinunum, which has been previously 
demonstrated to be nephrotoxic in this species (Frank et al., 1989) and suggested 
that the dose of cis-platinum should be limited to 1mg/kg.   
 
In the animal that received 1mg/kg cis-platinum and adriamycin there was a 
modest effect on body weight which recovered by day 6. This suggested that the 
cytotoxic effect was insufficient to produce a clinically relevant response, and 
would not mirror the effect that would be expected in a human patient receiving 
therapeutic doses of these agents. Death occurred as a result of experimental 
error but there was no biochemical evidence of renal impairment during the period 
of study. 
  
The dosage schedule in the distraction osteogenesis experiment used an initial 
infusion of 1mg/kg cis-platinum to protect renal function and 2mg/kg adriamycin. If 
the initial infusion demonstrated idiosyncratic sensitivity, the animal could be 
withdrawn with sufficient time to substitute and maintain experimental numbers. If 
the condition of the animal was satisfactory it would allow progression to a second 
dose of 4mg/kg and this was possible in all experimental animals. 
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The timing of drug administration was also investigated and the schedules were 
broadly defined as neo- adjuvant if drugs were given before surgery and neo-
adjuvant if drugs were given after surgery. Both strategies are used in the 
management of osteogenic sarcoma and the model attempted to mimic the COSS 
(Link et al., 1991, Link et al., 1986) and EOI (Bramwell et al., 1992, Souhami et al., 
1997)approach to this clinical problem. 
 
This formed the basis of the cytotoxic chemotherapy schedule for the distraction 
osteogenesis experiment. The drugs were given 4 and 2 weeks before osteotomy 
and distraction (Neo-adjuvant Group) or one cycle 10 days before and 4 days after 
osteotomy and distraction (Adjuvant Group). 
 
 
 
The next section reports the results that were used to validate the model and 
confirm that the prerequisites defined in previous paragraphs were satisfied. 
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2.10 Laboratory Parameters  
2.10.1 Neo-adjuvant Group Haemoglobin (g/dl) 
     Mean  σ 
Infusion 1 (Control)  11.69  1.16 
(Chemotherapy) 12.84  0.76 
 
Infusion 2 (Control)  12.25  0.98 
(Chemotherapy) 12.38  0.80 
 
Osteotomy (Control)  12.96  0.82 
(Chemotherapy) 11.28  0.71 
 
Sacrifice (Control)  12.79  1.23 
(Chemotherapy) 12.96  0.76 
 
Infusion 1 
p = < 0.01 
95% confidence interval for difference between means = -1.98 to -0.3 
Power (for 5% significance) = 97.22%Infusion 2 
 
Infusion 2 
p = 0.75 
95% confidence interval for difference between means = -0.92 to 0.67 
Power (for 5% significance) = 7.04% 
 
Osteotomy  
p = < 0.01 
95% confidence interval for difference between means = 0.94 to 2.41 
Power (for 5% significance) > 99.99% 
 
Sacrifice 
p = 0.76 
95% confidence interval for difference between means = -1.31 to 0.97 
Power (for 5% significance) = 7.18% 
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2.10.2 Adjuvant Group Haemoglobin (g/dl) 
     Mean   σ 
Infusion 1 (Control)  13.31   0.87 
(Chemotherapy) 13.03   0.88 
 
Osteotomy (Control)  13.08   0.84 
(Chemotherapy) 12.13  0.71 
 
Infusion 2  (Control)  13.40   0.26 
(Chemotherapy) 10.19  0.56 
 
Sacrifice (Control)   12.44  1.04 
(Chemotherapy) 11.79  0.78 
 
Infusion 1  
p = 0.44 
95% confidence interval for difference between means = -0.48 to 1.04 
Power (for 5% significance) = 17.52% 
 
Osteotomy  
p = 0.01 
95% confidence interval for difference between means = 0.21 to 1.67 
Power (for 5% significance) = 91.56% 
 
Infusion 2  
p < 0.01 
95% confidence interval for difference between means = 2.42 to 4.01 
Power (for 5% significance) > 99.99% 
 
Sacrifice 
p = 0.15 
95% confidence interval for difference between means = -0.26 to 1.56 
Power (for 5% significance) = 44.9% 
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2.10.3 Neo-adjuvant Group Haematocrit (L/L) 
     Mean  σ 
Infusion 1 (Control)  42.67  11.77 
(Chemotherapy) 42.62    2.16 
 
Infusion 2 (Control)  42.21    7.70 
(Chemotherapy) 40.50    2.91 
 
Osteotomy (Control)  43.42    7.78 
(Chemotherapy) 37.52    2.21 
 
Sacrifice (Control)  42.69    9.05 
(Chemotherapy) 44.40    5.53 
 
Infusion 1  
p = 0.99 (F test significant)  
95% confidence interval for difference between means = -7.11 to 7.21 
Power (for 5% significance) = 2.57% 
 
Infusion 2  
p = 0.52 (F test significant)  
95% confidence interval for difference between means = -3.66 to 7.08 
Power (for 5% significance) = 7.65% 
 
Osteotomy  
p = 0.06 (F test significant)  
95% confidence interval for difference between means = 0.23 to 11.57 
Power (for 5% significance) = 47.7% 
 
Sacrifice 
p = 0.67 
95% confidence interval for difference between means = -10.08 to 6.65 
Power (for 5% significance) = 9.24% 
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2.10.4 Adjuvant Group Haematocrit (L/L) 
Mean  σ 
Infusion 1 (Control)  41.27   2.62 
(Chemotherapy) 42.53  2.49 
 
Osteotomy (Control)  42.16  2.90 
(Chemotherapy) 39.01  2.00 
 
Infusion 2 (Control)  42.93  0.81 
(Chemotherapy 39.01  2.00 
 
Sacrifice (Control)  37.06  2.26 
(Chemotherapy) 39.89  2.17 
 
Infusion 1 
p = 0.25 
95% confidence interval for difference between means = -3.47 to 0.96 
Power (for 5% significance) = 34.01% 
 
Osteotomy 
p = >0.01 
95% confidence interval for difference between means = 0.86 to 5.45 
Power (for 5% significance) = 94.36% 
 
Infusion 
p = >0.01 
95% confidence interval for difference between means = 1.32 to 6.53 
Power (for 5% significance) = 92.53% 
 
Sacrifice  
p = 0.02 
95% confidence interval for difference between means = -5.09 to -0.58 
Power (for 5% significance) = 89.59% 
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2.10.5 Neo-adjuvant Group Leucocyte Count (x109) 
     Mean  σ 
Infusion 1 (Control)  4.53  1.73 
(Chemotherapy) 4.36  0.82 
 
Infusion 2 (Control)  5.15  1.71 
(Chemotherapy) 4.58  1.04 
 
Osteotomy (Control)  4.50  1.78 
(Chemotherapy) 3.09  1.89 
 
Sacrifice (Control)  8.36  3.96 
(Chemotherapy) 8.86  4.57 
 
Infusion 1  
p = 0.77 (F test significant)  
95% confidence interval for difference between means = -0.98 to 1.31 
Power (for 5% significance) = 4.38% 
 
Infusion 2  
p = 0.34 
95% confidence interval for difference between means = -0.66 to 1.81 
Power (for 5% significance) = 23.91% 
 
Osteotomy 
p = 0.11 
95% confidence interval for difference between means = -0.37 to 3.19 
Power (for 5% significance) = 58.16% 
 
Sacrifice  
p = 0.82 
95% confidence interval for difference between means = -5.08 to 4.07 
Power (for 5% significance) = 6.19% 
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2.10.6 Adjuvant Group Leucocyte Count (x109) 
     Mean  σ 
Infusion 1 (Control)  7.23  1.23 
(Chemotherapy) 6.24  2.02 
 
Osteotomy (Control)   5.95  2.00 
(Chemotherapy)  5.39   2.14 
 
Infusion 2 (Control)   7.93   3.84 
(Chemotherapy)  5.61   1.25 
 
Sacrifice (Control)   9.40  3.07 
 (Chemotherapy)  8.02   3.37 
 
Infusion 1  
p = 0.18 
95% confidence interval for difference between means = -0.48 to 2.45 
Power (for 5% significance) = 45.39% 
 
Osteotomy  
p = 0.58 
95% confidence interval for difference between means = -1.45 to 2.56 
Power (for 5% significance) = 10.97% 
 
Infusion 2 
p = 0.41 (F test significant)  
95% confidence interval for difference between means = -2.79 to 7.43 
Power (for 5% significance) = 4.39% 
 
Sacrifice 
p = 0.39 
95% confidence interval for difference between means = -1.96 to 4.72 
Power (for 5% significance) = 18.27% 
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2.10.7 Neo-adjuvant Group Urea (mmol/L) 
     Mean  σ 
Infusion 1 (Control)  6.35  0.95 
(Chemotherapy) 6.31  0.69 
 
Infusion 2 (Control)  6.32  0.85 
 (Chemotherapy) 7.43  0.74 
 
Osteotomy (Control)  7.23  0.78 
(Chemotherapy) 7.87  1.57 
 
Sacrifice (Control)  7.00  1.28 
(Chemotherapy) 6.97  1.46 
 
Infusion 1  
p = 0.90 
95% confidence interval for difference between means = -0.66 to 0.75 
Power (for 5% significance) = 5.31% 
 
Infusion 2  
p = > 0.01 
95% confidence interval for difference between means = -1.81 to -0.40 
Power (for 5% significance) = 98.71% 
 
Osteotomy 
p = 0.28 (F test significant)  
95% confidence interval for difference between means = -1.76 to 0.48 
Power (for 5% significance) = 18.33% 
 
Sacrifice  
p = 0.96 
95% confidence interval for difference between means = -1.46 to 1.52 
Power (for 5% significance) = 5.06% 
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2.10.8 Adjuvant Group Urea (mmol/L) 
Mean   σ 
Infusion 1 (Control)  4.62   0.71 
(Chemotherapy) 5.73  0.71 
 
Osteotomy (Control)   4.78   0.77 
(Chemotherapy) 6.49   2.04 
 
Infusion 2 (Control)   5.42  0.48 
(Chemotherapy)  6.62  1.18 
 
Sacrifice (Control)   5.38  0.59 
  (Chemotherapy) 6.31   1.83 
 
Infusion 1 
p = >0.01 
95% confidence interval for difference between means = -1.72 to -0.49 
Power (for 5% significance) = 99.84% 
 
Osteotomy  
p = 0.02 (F test significant)  
95% confidence interval for difference between means = -3.04 to -0.38 
Power (for 5% significance) = 70.56% 
 
Infusion 2 
p = < 0.05 
95% confidence interval for difference between means = -2.39 to -0.006 
Power (for 5% significance) = 68.62% 
 
Sacrifice 
p = 0.14 (F test significant)  
95% confidence interval for difference between means = -2.16 to 0.30 
Power (for 5% significance) = 28.51% 
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2.10.9 Neo-adjuvant Group Creatinine (µmol/L) 
     Mean  σ 
Infusion 1 (Control)  75.58  23.20 
(Chemotherapy) 68.25    8.47 
 
Infusion 2 (Control)  73.50  11.15 
(Chemotherapy) 76.33    8.44 
 
Osteotomy (Control)  81.10    9.39 
(Chemotherapy) 85.64  17.40 
 
Sacrifice (Control)  87.11  10.03 
(Chemotherapy) 88.33  13.16 
 
Infusion 1 
p = 0.32 (F test significant)  
95% confidence interval for difference between means = -7.45 to 22.12 
Power (for 5% significance) = 14.13% 
 
Infusion 2  
p = 0.51 
95% confidence interval for difference between means = -11.54 to 5.87 
Power (for 5% significance) = 14.01% 
 
Osteotomy  
p = 0.47 
95% confidence interval for difference between means = -17.51 to 8.43 
Power (for 5% significance) = 15.88% 
 
Sacrifice  
p = 0.84 
95% confidence interval for difference between means = -14.13 to 11.68 
Power (for 5% significance) = 5.96% 
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2.10.10  Adjuvant Group Creatinine (µmol/L) 
     Mean  σ 
Infusion 1 (Control)  67.82    4.09 
(Chemotherapy)  71.50     8.57 
 
Osteotomy (Control)   67.90     7.09 
(Chemotherapy)  87.50   21.32 
 
Infusion 2 (Control)   70.50     5.96 
Chemotherapy)  82.73   12.05 
 
Sacrifice (Control)   88.33  12.03 
(Chemotherapy)  91.36    8.74 
 
Infusion 1 
p = 0.20 (F test significant)  
95% confidence interval for difference between means = -9.43 to 2.07 
Power (for 5% significance) = 22.14% 
 
Osteotomy  
p = < 0.01 (F test significant)  
95% confidence interval for difference between means = -33.27 to -5.93 
Power (for 5% significance) = 79.36% 
 
Infusion 2 
p = 0.04 
95% confidence interval for difference between means = -23.50 to -0.95 
Power (for 5% significance) = 77.41% 
 
Sacrifice  
p = 0.52 
95% confidence interval for difference between means = -12.79 to 6.73 
Power (for 5% significance) = 13.12% 
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2.10.11  Neo-adjuvant Group Total Protein (g/L) 
     Mean  σ 
Infusion 1 (Control)  55.00  5.15 
(Chemotherapy) 56.25  3.60 
 
Infusion 2 (Control)  55.90  3.57 
(Chemotherapy) 54.42  3.68 
 
Osteotomy (Control)  58.40  4.22 
(Chemotherapy) 52.91  2.30 
 
Sacrifice  (Control)  59.80  7.18 
  (Chemotherapy)  56.17  3.92 
 
Infusion 1  
p = 0.5 
95% confidence interval for difference between means = -5.01 to 2.51 
Power (for 5% significance) = 15.23% 
 
Infusion 2  
p = 0.35 
95% confidence interval for difference between means = -1.74 to 4.71 
Power (for 5% significance) = 23.47% 
 
Osteotomy  
p = < 0.01 
95% confidence interval for difference between means = 2.43 to 8.56 
Power (for 5% significance) = 99.83% 
 
Sacrifice  
p = 0.28 
95% confidence interval for difference between means = -3.25 to 10.51 
Power (for 5% significance) = 38.91% 
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2.10.12  Adjuvant Group Total Protein (g/L) 
Mean  σ 
Infusion 1 (Control)  55.55  1.92 
(Chemotherapy) 55.92   3.12 
 
Osteotomy (Control)  57.00   4.74 
(Chemotherapy)  55.25  3.91 
 
Infusion 2 (Control)   55.00   0.71 
(Chemotherapy)  58.55  2.73 
 
Sacrifice (Control)   59.22   3.11 
(Chemotherapy)  58.27   3.80 
 
Infusion 1 
p = 0.74 
95% confidence interval for difference between means = -2.64 to 1.90 
Power (for 5% significance) = 7.3% 
 
Osteotomy  
p = 0.35 
95% confidence interval for difference between means = -2.09 to 5.59 
Power (for 5% significance) = 23.03% 
 
Infusion 2 
p = <0.01 (F test significant)  
95% confidence interval for difference between means = -5.44 to -1.65 
Power (for 5% significance) = 95.57% 
 
Sacrifice 
p = 0.55 
95% confidence interval for difference between means = -2.36 to 4.26 
Power (for 5% significance) = 11.87% 
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2.10.13  Neo-adjuvant Group ALT (U/L) 
     Mean  σ 
Infusion 1 (Control)  64.00  37.86 
(Chemotherapy) 41.09  12.10 
 
Infusion 2 (Control)  80.80  40.37 
(Chemotherapy) 59.00  33.19 
 
Osteotomy (Control)  121.70 80.71 
(Chemotherapy)   44.91   9.62 
 
Sacrifice (Control)  102.00 65.25 
(Chemotherapy)   58.67 18.68 
 
Infusion 1  
p = 0.08 (F test significant)  
95% confidence interval for difference between means = -2.09 to 47.91 
Power (for 5% significance) = 39.71% 
 
Infusion 2 
p = 0.18 
95% confidence interval for difference between means = -10.88 to 54.48 
Power (for 5% significance) = 43.32% 
 
Osteotomy  
p = 0.02 (F test significant)  
95% confidence interval for difference between means = 23.03 to 130.55 
Power (for 5% significance) = 76% 
 
Sacrifice  
p = 0.14 
95% confidence interval for difference between means = -13.48 to 100.15 
Power (for 5% significance) = 25.97% 
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2.10.14 Adjuvant Group ALT (U/L) 
Mean   σ 
Infusion 1 (Control)  68.64  18.93 
(Chemotherapy)  57.75  21.09 
 
Osteotomy (Control)  55.90   18.00 
(Chemotherapy)  40.27   10.11 
 
Infusion 2 (Control)  38.40    2.51 
(Chemotherapy)  38.64     5.20 
 
Sacrifice (Control)   47.44   13.59 
(Chemotherapy)  58.50   17.33 
 
Infusion 1 
p = 0.21 
95% confidence interval for difference between means = -6.55 to 28.33 
Power (for 5% significance) = 40.15% 
 
Osteotomy 
p = 0.02 
95% confidence interval for difference between means = 2.46 to 28.79 
Power (for 5% significance) = 90.31% 
 
Infusion 2 
p = 0.93 
95% confidence interval for difference between means = -5.55 to 5.08 
Power (for 5% significance) = 5.13% 
 
Sacrifice 
p = 0.14 
95% confidence interval for difference between means = -26.26 to 4.15 
Power (for 5% significance) = 51.25% 
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2.10.15  Neo-adjuvant Group γGT (U/L) 
     Mean  σ 
Infusion 1 (Control)    8.25  4.39 
(Chemotherapy)   6.73  2.37 
 
Infusion 2 (Control)    7.44  3.00 
(Chemotherapy)   6.08  4.32 
 
Osteotomy (Control)  11.30  6.34 
(Chemotherapy)   6.00  2.14 
 
Sacrifice (Control)  13.00  5.94 
(Chemotherapy) 10.29  2.56 
 
Infusion 1 
p = 0.32 
95% confidence interval for difference between means = -1.58 to 4.63 
Power (for 5% significance) = 28.72% 
 
Infusion 2 
p = 0.43 
95% confidence interval for difference between means = -2.16 to 4.89 
Power (for 5% significance) = 17.28% 
 
Osteotomy  
p = 0.03 (F test significant)  
95% confidence interval for difference between means = 0.89 to 9.71 
Power (for 5% significance) = 61.9% 
 
Sacrifice  
p = 0.29 
95% confidence interval for difference between means = -2.62 to 8.05 
Power (for 5% significance) = 29.71% 
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2.10.16 Adjuvant Group γGT (U/L) 
      Mean  σ  
Infusion 1 (Control)   11.64  5.03 
(Chemotherapy)  10.67  3.60 
 
Osteotomy (Control)     9.20  2.86 
(Chemotherapy)    9.17  1.59 
 
Infusion 2 (Control)     6.60  0.89  
(Chemotherapy)    8.27  1.10 
 
Sacrifice (Control)     6.11  1.76 
(Chemotherapy)    5.45  2.02 
 
Infusion 1  
p = 0.60 
95% confidence interval for difference between means = -2.80 to 4.74 
Power (for 5% significance) = 10.81% 
 
Osteotomy 
p = 0.97 
95% confidence interval for difference between means = -1.98 to 2.04 
Power (for 5% significance) = 5.02% 
 
Infusion 2 
p = <0.01 
95% confidence interval for difference between means = -2.885285 to -0.460169 
Power (for 5% significance) = 91.88% 
 
Sacrifice 
p = 0.45 
95% confidence interval for difference between means = -1.15 to 2.46 
Power (for 5% significance) = 16.29% 
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2.10.17  Neo-adjuvant Group Weight Gain (%) 
      Mean  σ 
Week 10  (Control)  24.07  10.07 
(Chemotherapy)   7.59  13.31 
 
Week 12   (Control)  37.19  12.02 
(Chemotherapy) 18.88    7.27 
 
Week16  (Control)  54.32    8.65 
(Chemotherapy) 28.42    9.02 
 
10 Weeks  
p = <0.01 
95% confidence interval for difference between means = -26.47 to -6.49 
Power (for 5% significance) = 99.58% 
 
12 Weeks 
p = <0.01 
95% confidence interval for difference between means = 9.90 to 26.72 
Power (for 5% significance) > 99.99% 
 
16 Weeks 
p < 0.01 
95% confidence interval for difference between means = -33.56 to -18.23 
Power (for 5% significance) > 99.99% 
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2.10.18  Adjuvant Group Weight Gain (%) 
     Mean   σ 
Week 12 (Control)     9.96     4.16 
(Chemotherapy)   5.22     6.56 
 
Week 16 (Control)  16.16     5.58 
(Chemotherapy) 10.06     6.65 
 
12 Weeks 
p = 0.03 
95% confidence interval for difference between means = 0.46 – 11.22 
Power (for 5% significance) = 84.67% 
 
16 Weeks 
p = 0.04 
95% confidence interval for difference between means = 0.24 – 11.95 
Power (for 5% significance) = 79.93% 
 
 
 
2.11 Overview of Dose Response Results   
 
2.11.1    Haematological Function  
The initial haemoglobin concentration was significantly lower in the control group 
of the neo-adjuvant arm.  This trend had reversed by week 12 indicating a relative 
decrease in haemoglobin concentration following chemotherapy.  This difference 
was no longer present at the conclusion of the experiment.   
 
In the adjuvant arm, there was no statistically significant difference in haemoglobin 
concentration at the commencement of the experiment.  There was a significant 
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reduction following both cytotoxic infusions, which had recovered at the conclusion 
of the experiment.  
 
The relative anaemia was associated with a statistically significant reduction in 
haematocrit in the neo-adjuvant group, only at the time of osteotomy and was not 
seen in the adjuvant group at any point.   
 
There were no statistically significant differences in total white cell count at any 
point in either arm of the experiment.  
 
2.11.2    Renal Function 
There was a statistically significant increase in serum urea concentration in the 
neo-adjuvant arm following the initial cytotoxic infusion, which had recovered at 
the conclusion of the experiment.  There were no differences in mean creatinine 
concentration between the active and control groups in the neo-adjuvant arm. 
 
There was a statistically significant increase in serum urea concentration in the 
cytotoxic group of the adjuvant arm at the commencement of the experiment, 
which persisted until the time of the osteotomy.  There was a statistically 
significant increase in serum creatinine concentration in the adjuvant arm at the 
time of osteotomy and second infusion.   
 
2.11.3    Hepatic Function  
A statistically significant reduction in total protein was observed in the neo-
adjuvant control group at the time of osteotomy and at the time of second infusion 
in the adjuvant chemotherapy group.  
 
There was a statistically significant increase in ALT at the time of the osteotomy in 
control groups in both neo-adjuvant and adjuvant arms of the experiment.   
 
There was a statistically significant increase in γGT in the control group of the neo-
adjuvant arm at the time of osteotomy with a reverse trend observed at the time of 
second infusion in the adjuvant group. 
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2.11.4    Weight Gain  
There was a statistically significant decrease in percentage weight gained in the 
chemotherapy group of the neo-adjuvant arm of the experiment. A significant but 
less marked trend was observed in the adjuvant group.  
 
2.11.5    Summary 
The dose response experiment demonstrated that an initial infusion of 1mg / kg 
cis-platinum and 2mg / kg adriamycin and a second infusion of 1 mg / kg cis-
platimum and 4 mg / kg adriamycin produced a statistically significant reduction in 
weight gain, irrespective of the timing of administration of the drugs. This 
combination did not produce biochemical evidence of renal or hepatic failure and 
surgery was possible without clinical evidence of infection. 
 
This schedule proved to be robust and satisfied the primary requirements of the 
experimental model  
 
1. Reproducible anaesthesia 
2. Reproducible infusion of cis-platinum and adriamycin 
3. Appropriate cytotoxic effect  
4. Normal renal function 
5. Normal hepatic function 
 
The model was used to investigate the structural and material properties of 
regenerate bone and the experimental considerations and results are presented in 
the next section. 
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Section 3 The Effect of Cytotoxic Drugs on Regenerate Bone 
The key surgical events in the management of osteogenic sarcoma are tumour 
excision and limb reconstruction. For the purpose of the animal model, osteotomy 
and distraction was used as a surrogate for surgical reconstruction and the effect 
and timing of cytotoxic drugs formed the subject of this component of the thesis. 
Two conditions were investigated with administration of 2 cycles of cis-platinum 
and adriamycin before osteotomy and lengthening or immediately before 
osteotomy and during the distraction period. 
 
This created experimental conditions that simulated neo-adjuvant and adjuvant 
prescriptions. The models were simplistic in terms of the components and total 
number of cycles but provided a useful tool to perform a preliminary investigation 
into this problem.  
 
3.1 Experimental Considerations 
The osteotomy was performed aged 12-weeks in both groups and the interval 
between chemotherapy infusions was constant at 2-weeks. The timing of infusion 
varied between groups to simulate a neo-adjuvant and adjuvant strategy. The 
experimental conditions were identical in the control group for each arm, with an 
identical volume of N saline infused under identical conditions. 
 
General health was assessed and markers of metabolic function were measured 
throughout the experiment. The lengthened tibiae were evaluated with plain 
radiographs, DXA and single cycle compression testing to failure. 
 
3.1.1 Application of External Fixator and Osteotomy 
Kaweblum et al (Kaweblum et al., 1994) investigated the timing of growth plate 
closure in juvenile NZW rabbits and demonstrated histological evidence of distal 
femoral physeal arrest at  20–23-weeks of age. Animals in both arms of the study 
were sacrificed at 16-weeks of age, representing approximately 75% completion of 
growth.  
 
The right leg was shaved and prepared with Chlorhexadine 0.5%/Alcohol 70% 
(Delta West Pyt. Ltd., Bentley, WA Australia) and the operative field was occluded 
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with sterile surgical towels. A medial longitudinal skin incision was used with sub-
periosteal exposure of the tibia along its length.  
 
Orthofix (Orthofix, Bussolengo, Italy) 3 mm external fixator pins were inserted 1.5 
cm proximal and distal to the mid tibial diaphysis. A standard jig and power drill 
draped in a sterile container was used and the positions of the remaining 2 pins 
were determined by the jig. The configuration of the external fixator required the 
paired pins to be accurately positioned along the length of the tibia to avoid 
rotational mal-alignment, which would cause cantilever bending when the pins 
were clamped. The juvenile NZW Rabbit tibia is brittle and a mid-diaphyseal 
osteotomy was performed initially with multiple drill holes and was completed with 
bone cutters. (Figure iv) 
 
An M100 mono-lateral fixator (Orthofix, Bussolengo, Italy) was attached 
approximately 1.5 cm from the skin, to accommodate for post-operative swelling 
and the wound was closed with interrupted sutures. (Figure v) 
The wound was dressed with Povidone Iodine ointment (Professional Disposables 
Inc. Orangeburg, New York) and the animal was observed until alert and drinking 
before being returned to its cage. 
 
 
 
Figure iv Tibial osteotomy and placement of paired parallel 3mm pins 
 
3.1.2 Distraction Phase 
A latent period of 5-days is standard practice in children and adolescents 
undergoing limb reconstruction by distraction histiogenesis. The bone healing time 
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in a juvenile rabbit however is significantly shorter, with consolidation of 
regenerate within 4-weeks. This indicates rapid bone metabolism in this age  
group with a risk of premature consolidation if an equivalent latent period were 
used in a rabbit model. A latent period of 24-hours was chosen to imitate the 
human situation and although previous studies (Kojimoto et al., 1988) have 
suggested that this may cause a retardation of callus formation, this complication 
was not encountered.  
 
 
 
Figure v Orthofix M 100 External fixator in situ following mid diaphyseal tibial 
osteotomy 
 
The fixator was distracted by one half turn every 12-hours which resulted in an 
incremental lengthening of 0.75 mm/day. This continued for 10-days, producing an 
overall lengthening of 7.5 mm. (Figure vi) 
 
Consolidation of the regenerate occurred over a period of 18-days following 
distraction, at this point all animals were sacrificed with an intravenous injection of 
pentobarbitone sodium (120 mg / kg)  (Valabarb Jurox Pty. Ltd., Silver Water, 
NSW, Australia). 
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Figure vi Incremental lengthening of 0.375 mm/12 hours after a 24-hour latent 
period. 
 
3.2 Outcome Measures 
3.2.1 Plain Radiography 
The right hind limb was disarticulated and transported fresh to the Radiology 
department at the New Children’s Hospital (Westmead NSW). The limb was 
aligned by an experienced radiographer (LC) to produce consistent cranio-caudal  
and medio-lateral images with a Siemens Multix H/UPH configuration using a 
Siemens digital luminous radiography cassette (18 x 24 cm) with a focus to film 
distance of 100 cm and a 50 kV (+/- 2mV) and 4 mA exposure. Hard copy images 
were produced with a Dry-View DVP Laser printer (Figure vii). 
 
The alignment in the antero-posterior and lateral planes was measured with a 
goniometer and the oblique plane deformity was calculated using the graphical 
method described by Paley et al. (Paley, 2002)  
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Figure vii A) Lateral and B) Antero-posterior radiographs following lengthening 
 
3.2.2 Dual Energy X-Ray Absorptiometry  
DXA is a non-invasive method used to measure the mineral content of bone. A 
collimated beam of photons generated by an X-ray tube passes through the bone. 
This beam contains two discrete energies, distinguishable on the basis of their 
attenuation by bone and soft tissue. One serves as a reference for soft tissue 
thickness, the second is predominately attenuated by bone and is used to 
measure the mineral content expressed as bone mineral content (BMC) and areal 
bone mineral density (BMD). Volumetric bone mineral density (vBMD) is derived 
from the BMD and the dimensions of the regenerate. 
 
DXA has been used widely to investigate the composition of small animal bones, 
including rodents (Mitlak et al., 1991) and dogs. (Markel and Chao, 1993, Markel 
et al., 1991) DXA has been used to evaluate the material properties of bone 
formed in a rabbit model of distraction of the mandible (Persing et al., 1991) and 
tibia, (Hamanishi et al., 1995) the effect of rhBMP-2 on bone formation in a rabbit 
femoral defect (Laffargue et al., 1999) and the contribution of periosteum and bone 
marrow to bone lengthening. (Guichet et al., 1998) 
 
An et al (An et al., 1994) investigated the relationship between the compressive 
strength of tricortical iliac crest grafts and BMD of the iliac crest and pelvis in 
humans using DXA. There was a high correlation between the ultimate load to 
A B 
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failure and compressive stress of the graft to the BMD of the intact pelvis and each 
graft. This suggested that the mechanical properties of bone are related to BMD, 
potentially providing a non-destructive method of assessment in clinical practice.  
 
Eyres et al (Eyres et al., 1993b) used DXA to measure BMC and BMD to evaluate 
the extent and rate of new bone formation over an 18-month period, before, during 
and after lengthening 10 leg segments in 6 patients. They identified a short delay 
in consolidation after maximal distraction with accelerated mineralisation in most 
cases over the initial 3-months, followed by slower bone formation in later stages 
of lengthening. 
 
This group (Eyres et al., 1993a) subsequently used DXA, ultrasonography and 
plain radiography to study the rate of formation of bone during lengthening of 17 
segments in 10 patients. New bone was identified by DXA and ultrasonography 
one to 2-weeks after osteotomy but not until 4 to 8-weeks by plain radiography. 
Limb alignment and distraction could be measured by DXA throughout the period 
of lengthening. Ultrasonography demonstrated the distraction gap as an 
echolucent window, with new bone appearing as echogenic islands, which 
became aligned longitudinally and progressively filled the window. 
Ultrasonography could only measure the gap difference during the early stages of 
distraction when the edges of the corticotomy were still well defined but was useful 
in defining cystic defects in the regenerate which were not recognised by DXA or 
plain radiography. 
 
Maffulli et al (Maffulli, 1997) studied the rate of regenerate BMC using DXA in 
callotasis lengthening of the lower limb in 11 children. From analysis of time 
graphs, a direct correlation emerged between early bone formation and 
subsequent bone mineral content accretion and 3 patient groups (slow, normal 
and fast) were identified. The pattern of accretion was not related to the fixator 
used, time or bone lengthened and appeared to be dependent on the underlying 
pathology. This suggests that the rate of mineral accretion is defined early in the 
lengthening process and administration of cytotoxic agents around the time of 
osteotomy may alter subsequent bone formation.  
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Reichel et al (Reichel et al., 1998) compared DXA and mechanical parameters in 
an ovine model of distraction osteogenesis using non-destructive axial 
compression testing and a torsional force to failure.  They did not demonstrate a 
significant correlation between axial compression and BMD, however there was a 
strong correlation between maximum torque and BMD.  
 
Chotel et al (Chotel et al., 2008) compared DXA measurements and 3-point 
bending assessment of bone stiffness in children undergoing lengthening by 
distraction osteogenesis.  There was a poor correlation for absolute DXA data but 
a linear correlation was identified between BMC measurements and stiffness, if 
BMC was expressed as a percentage of a symmetrical region of the contralateral 
side  
 
The literature discussed in previous paragraphs suggests that DXA is a valid 
method of evaluation of the material properties of the regenerate bone. It was 
readily available and inexpensive and provided a practical method of comparison 
between control and treated animals.  
 
3.2.2.1 DXA Measurements 
Bone density measurements were made by an experienced radiographer (JB) 
using a total body dual-energy X-ray densitometer (LUNAR DPX, LUNAR 
Radiation Crp., Madison, WI) with software designed for measuring small animals 
(LUNAR DPX, Small Animal Software version 1.0, LUNAR Radiation Crp., 
Madison, WI). This machine used a constant potential X-ray source (76 kV) and a 
K-edge filter (cerium) to produce stable dual-energy X-rays with effective energies 
of 38 and 70 keV.  
 
The disarticulated right hind limb was assessed with soft tissues intact and the 
scan length was determined by the length of the bone (the scan area was 
approximately 50 mm x 130 mm). Each leg was placed in a supine position on the 
scan table and an anterior-posterior scan was performed. The leg was then 
medially rotated through 90 degrees and a lateral scan was performed. BMD, 
BMC and bone area (BA) values were obtained with the “Manual Analysis” facility. 
The height of the boxes was determined by the length of the regenerate and all 
box widths were identical (15 mm).  
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The distance from the knee to the top of the regenerate was measured with a 
software ruler, and the length of the regenerate were measured and recorded. A 
“Region of Interest” (ROI) box was placed over the regenerate. The height of the 
ROI was such that the entire length of the regenerate was included. The boxes 
were positioned so that all the bone and some soft tissue were included in the 
region of interest. (Figure viii) 
 
                                        
 
Figure viii DXA Image with corresponding radiograph 
 
The software calculated BMC (g), BMD (g/cm²), average bone width (cm) and 
average bone area (cm²). vBMD was calculated assuming that the bone is an 
elliptical cylinder. 
 
The area of the cross-section of bone = 
 
π × (AP Bone Width) × (Lat Bone Width) 
2                    2 
 
The volume of the region V =  Cross-sectional Bone Area x ROI Height 
 
Volumetric BMD (g/cm3)     =  BMC 
   V 
 
Each scan produced the following data from the AP and Lat scans 
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Bone Width (cm)        (W)  
Bone Area (cm2)      (A)  
Bone Mineral Content (g)     (BMC)  
Bone Mineral Density (g/cm2)    (BMD)  
Volumetric Bone Mineral Density (g/m3)   (vBMD)  
 
From these data the following were calculated 
 
Mean BMC (g)  (Lat BMC + AP BMC)  
          2 
Mean BMD (g/cm2)  (Lat BMD + AP BMD)  
          2 
Mean vBMD (g/cm3) (Lat vBMD + AP vBMD) 
        2 
 
3.2.3 Mechanical Testing 
The mechanical testing of bone, whether intact or during fracture healing has been 
a subject of investigation for over a century. Wertheim (Wertheim, 1847) 
determined the maximum load in tension for small prepared specimens of human 
bone in 1847, whilst other investigators (Hulsen, 1896, Rauber, 1876) used static 
tensile and compressive tests but did not specify the origin of the bone and the 
experimental procedure used.  
 
In the middle of the 20th century, the interest in bone characterisation increased 
with particular emphasis on the measurement of the anisotropy of mechanical 
properties. (Evans and Lebow, 1951, Evans and Lebow, 1952)  
 
Sedlin et al (Sedlin and Hirsch, 1966) highlighted the effects of specimen 
preservation, temperature, geometry and age of donor on the mechanical 
properties of bone and Kraus (Kraus, 1968) documented the mechanical 
properties of machined specimens of excised cortical bone. The field of whole 
bone testing is less well documented and experimental values are more difficult to 
analyse, usually representing an average of an anisotropic property.  
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Burstein et al (Burstein and Frankel, 1971) described 5 criteria which they 
considered to be pre-requisites for a standard test of intact bones in experimental 
animals. 
1) The loading configuration should produce fractures similar to clinical 
fractures. 
2) The loading configuration should subject the bone to equally severe 
loading conditions at every section along its length, to be able to identify 
weak sections.  
3) The loading mode must not be critically dependent upon bone geometry, 
in particular bone length, in terms of the severity of its effect.   
4) The loading configuration must allow control of the rate of application of 
load, so that the time conditions produced in the test will be reproducible 
and preferably representative of those of normal trauma. 
5) The loading configuration should result in a test apparatus that is 
relatively inexpensive and may be operated by persons with only 
ordinary skills in handling such mechanical equipment.  
 
They considered that axial compression and tension did not meet criteria (1) and 
(5) and stated that whilst long bones were loaded in axial compression, they 
seldom failed because of this loading. This paper is often cited in clinical and 
experimental practice but it describes idealised conditions that are difficult to 
define and replicate in the clinical context. 
 
Previous studies have evaluated the biomechanics of intact bone, lengthened 
bone, excised bone segments and implanted bone. These have utilised a 
spectrum of testing configurations including tension, compression, torsion and 3-
point bending. There is no consensus of experimental design and the justification 
for a particular method of testing is seldom discussed.  
 
3.2.3.1 Tensile Testing 
Black et al (Black et al., 1984) evaluated the healing characteristics of a rabbit 
fibular osteotomy. Excised specimens were harvested at intervals and loaded in 
tension until failure. This demonstrated a rapid return of stiffness, which occurred 
within 16-days of osteotomy and correlated with the radiological appearance of the 
callus. This suggested that tensile testing minimised artefact and permitted direct 
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intrinsic determinations of tissue quality. The authors recognised that this method 
of testing was associated with severe limitations and in particular, there were 
significant technical difficulties associated with the bone-clamp interface. 
 
Walsh et al (Walsh et al., 1994) investigated the biomechanical properties of 
lengthened bone in a canine model of tibial lengthening. The tibiae were 
embedded in polymethylmethacrylate (PMMA) in aluminium moulds and the 
tensile mechanical properties were determined using a Model 810 Materials 
Testing Machine. Lengthened and control bones were tested at a rate of 50% 
working length/minute. The peak load to failure, energy to peak load and stiffness 
were measured at 3, 6, 9 and 12-weeks. Linear regression analysis demonstrated 
a strong correlation between peak load and stiffness with time after completion of 
lengthening. 
 
3.2.3.2 Torsional Testing 
Collier et al (Collier et al., 1976) used destructive torsional testing to determine 
whether porous-coated Vitallium intramedullary rods could be used to bridge 
segmental defects in a rabbit tibia. The model used a silastic spacer to bridge a 1 
cm defect in the mid shaft of the tibia with a rod inserted through the proximal tibial 
segment, through the spacer and into the distal bone segment. The animals were 
sacrificed 30-weeks postoperatively and the mechanical properties of the tibia 
from each rabbit were measured in a torsional testing machine. The load at failure 
of the tibia with the segmental defect averaged 90% of the contralateral control 
tibia, suggesting that bone ingrowth occurred under dynamic loading. The authors 
concluded that porous coated intra-medullary rods might provide a method of 
reconstruction of segmental bone loss. 
 
Paavolainen et al (Paavolainen, 1978) used torsional testing to demonstrate that 
the rabbit tibio-fibular complex exhibited right to left differences in energy 
absorption capacity, torsional rigidity, torque moment at fracture and angular 
deformation. In response to this observation and to remove asymmetry as a 
confounding variable, the right tibia was lengthened in the experimental 
component of this thesis.   
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Burchardt et al (Burchardt et al., 1983) used destructive torsional testing to 
evaluate the effect of adriamycin and methotrexate on the mechanical properties 
of fibular autograft reconstruction in a canine model. Thirty-two male mongrel dogs 
were used to compare the effect of adriamycin, methotrexate and an untreated 
group with a contralateral sham-operated limb. 
All grafts and sham segments were harvested at 6-months and tested with a rapid-
loading torsion machine to determine load to failure. This was analysed using 
actual values and the percentage difference between the graft and the sham 
segments of each dog in each group. 
 
Higher doses of adriamycin resulted in grafts that were mechanically weaker than 
normal. There was a reduction in the torque to failure, which was due to a 
combination of new bone suppression and peripheral graft reabsorption. The 
authors concluded that inhibition of new bone formation may prolong the interval 
required for osseous graft-host union, and there may be a greater incidence of 
graft-host non-union. 
 
Pilla et al (Pilla et al., 1990) investigated the effect of ultrasound on the healing of 
a NZW rabbit fibular osteotomy.  All bones were subjected to destructive torsional 
testing to produce a torque verses angular displacement curve. The maximum 
torque was represented by the peak of the curve immediately before failure. This 
study demonstrated that non-invasively applied ultrasound for 20-minutes daily, 
accelerated healing by a factor of approximately 1.7. The authors discussed the 
limitations of torsional analysis and in particular, the effect of increased surface 
area of the callus in osteotomised animals on the stiffness of the osteotomised 
specimens, which was greater than intact bone.    
 
Fyda et al (Fyda et al., 1995) used a rabbit femur to study the time-dependent 
mechanical and radiographic changes with various treatments of surgically created 
windows. Specimens were loaded to failure on a torsional testing apparatus at a 
constant rate of 30°/second to obtain values for ultimate torque, maximum angle of 
deformation, and energy capacity expressed as percent of paired control. The 
experiment demonstrated that replacement of a cortical window resulted in 
significantly greater whole bone strength, which was time dependent. 
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3.2.3.3 Bending Tests 
Bending tests (3-point, 4-point, or cantilever) are frequently used to assess the 
mechanical strength of bone as they are relatively straightforward and allow rapid 
analysis. Arguments in their favour usually emphasise that bending is the most 
common mode of deformation in vivo. This technique involves complex internal 
stress fields and produces results that are strongly dependent on testing skill and 
orientation of the test specimen. Furthermore, when applied to fractures or 
experimental osteotomies, there is a tendency to combine the properties of the 
bone with those of the developing callus in an unpredictable manner.  
 
Terjesen et al (Terjesen and Benum, 1983) used 3-point bending within the elastic 
range to study the in vitro stress-protecting effect of an external fixator on 
osteotomised rabbit tibiae. An Instron Testing machine (Type 1123) was used, 
with a constant rate of deformation of 5 mm/minute applied to the anterior edge of 
the bone. The osteotomy was performed with an oscillating saw at a standard 
anatomical site, allowing for precise positioning of the applied load. The BMC was 
measured by photon absorptiometry.  
The strength and stiffness were reduced to 87 and 88% of controls after 12-weeks. 
The mineral content in the bone segment, which had been stabilised by external 
fixation, was significantly reduced after 12-weeks. There was no significant change 
in BMC distal to the external fixation device.  
 
Hanafusa et al (Hanafusa et al., 1995) investigated the mechanical strength, bone 
mineral content and density in rabbit femoral osteotomies stabilised with either 
ultra high strength poly-L-lactic acid or stainless steel plates. The mechanical 
strengths of the paired femora were measured by 3-point bending using a 
Shimadzu Autograph SD-100 with load applied at the site of a transverse midshaft 
osteotomy. In the poly-L-lactic acid group, the mechanical strength of the 
specimen was identical to the untreated femur by 25-weeks. The stainless steel 
group showed significantly lower mechanical strength with osteopenia due to 
stress shielding after 25-weeks. 
 
An et al (An et al., 1996) investigated mechanical symmetry in NZW rabbit long 
bones with 3-point bending for diaphyseal bone and indentation for epiphyseal 
bone.  The loading point was defined as the mid shaft of the femur, junction of 
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middle and distal thirds of the tibia and the junction of the proximal 3/5 and distal 2/5 
the humerus. This demonstrated that the mean mechanical values for long bones 
were symmetrical and produced a normal comparable database for bending and 
indentation parameters of the rabbit femur, tibia, and humerus. 
 
Ayres et al (Ayers et al., 1996) investigated the relationship between the physical, 
structural and material  properties of  femora and tibiae of mice, rats, rabbits and 
cats. Physical parameters included total bone length, mid-diaphyseal cortical area, 
body mass and bone dry mass.  Three-point bending was performed with an 
Instron 1331 testing servo hydraulic testing system with a deflection rate of 
between 1 and 5 mm/minute depending on the species. Adjustable supports were 
positioned in a constant configuration at the proximal and distal diaphysis to 
measure structural (stiffness, elastic strength, maximum strength) and material 
properties (modulus of elasticity, elastic stress and elastic strain). Linear 
regression analysis was used to correlate the physical and mechanical properties 
and demonstrated that dry mass was a significant predictor of the structural 
properties of bone from these species.  
 
3.2.3.4 Compression Testing 
Ohyama et al (Ohyama et al., 1994) investigated the mechanical behaviour of 
regenerate in a Japanese White Rabbit model of femoral lengthening. Loading and 
unloading hysteresis and stress relaxation tests were used to investigate 
regenerate produced after continuous and discontinuous distraction. This 
demonstrated a time dependant effect, with viscoelastic behaviour in callus formed 
by continuous distraction and elastic behaviour in the discontinuous group, 
corresponding to the rest period. The authors correlated the mechanical behaviour 
with histological examination of retrieved specimens. In the continual distraction 
group, maintenance of viscoelastic properties was associated with central 
undifferentiated connective tissue. In the discontinuous group, the elastic 
properties were associated with central replacement of connective tissue with 
cartilage and bone.   
 
An et al (An et al., 1994) investigated the correlation between the mechanical and 
structural properties of tri-cortical bone grafts under compressive load and 
demonstrated a linear relationship between load to failure and compressive 
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strength.  The potential clinical application of this relationship was the use of DXA 
to predict the strength of iliac bone grafts in anterior interbody spinal fusion.   
 
3.2.3.5 Overview of Available Methods of Mechanical Testing 
The literature describing the optimum method of mechanical evaluation of bone is 
ambiguous. Tensile testing tests (Black et al., 1984, Walsh et al., 1994) depend on 
the original geometry of the bone, which is highly variable, even within a single 
species and age group. Analysis is also influenced by the integrity of the bone-
clamp interface and is a difficult technique to reproduce. 
 
Bending tests (An et al., 1996, Ayers et al., 1996, Hanafusa et al., 1995, Terjesen 
and Benum, 1983) involve complex internal stress fields and produce results that 
are influenced by the testing skill and orientation of the specimen. Bending tests 
also present technical difficulties associated with sample positioning which in the 
presence of non-uniform regenerate, would lead to unacceptable testing errors.  
 
Torsional testing has been used in previous studies (Collier et al., 1976, Fyda et 
al., 1995, Paavolainen, 1978, Pilla et al., 1990, Burchardt et al., 1983) and is a 
useful method of analysis for intact bone but was not appropriate for analysis of 
regenerate bone due to the mode of failure.  
 
Failure occurs on the compression side of an eccentrically loaded bone, leading to 
progressive bending of regenerate, which is observed in clinical practice. This 
mode of failure is simulated by axial compression, which was considered most 
representative of the in vivo mode of failure. Previous studies (An et al., 1994, 
Ohyama et al., 1994) have demonstrated a relationship between structural and 
mechanical properties of bone with this type of compression testing and a simple 
uni-axial loading test provided a reproducible method of analysis for this 
experiment.  
 
3.2.4 Mechanical Testing Used in this Experiment 
The logistical constraints of the experiment necessitated freezing the excised 
tibiae after DXA analysis.  Roe et al (Roe et al., 1988) demonstrated that freezing 
sterile canine cortical allografts at 20°c for 32-weeks did not alter the compressive 
load to failure. Griffon et al (Griffon et al., 1995) however, demonstrated  that 
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energy absorbed at failure and ultimate displacement in canine metacarpals, 
metatarsals and ribs frozen in  isotonic saline solution  were increased by 25 – 
30% and 18 – 24% respectively compared to bones that were dry frozen. Cortico-
cancellous grafts frozen in normal saline solution were less fragile and brittle than 
grafts stored in plastic without saline solution.  
 
To eliminate the potentially confounding effect of freezing on the mechanical 
properties of bone, all the harvested tibiae were processed in an identical manner. 
The soft tissues were excised from each of the lengthened (right) tibiae, the 
specimens were stored in saline and frozen at -20°c and thawed at room 
temperature for 6-hours before testing. 
 
Mechanical tests were performed in the Department of Mechanical and 
Mechatronic Engineering, University of Sydney by Mr J Wong Lee (JWL), 
Undergraduate Engineering Student in partial fulfilment of the requirements for the 
Degree of Bachelor of Engineering (University of Sydney 1996), supervised at all 
stages by FM. The experiment required reproducible longitudinal alignment of the 
bone during compression testing and this was achieved using a mounting block 
designed by JWL under the supervision of FM. The mounting block consisted of 
two cylinders with an adjustable connector to accommodate variable bone lengths 
(Figure ix, Appendix 2). 
 
 
Figure ix Tibial Mounting Block 
 
The tibiae were mounted in Permatex Autobody Filler (Permatex Inc, Hertford, 
Connecticut USA). Permatex is a 2 compound polyester resin, which was 
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analysed by compression testing, prior to its use in this experiment (Lee, 1996). 
Permatex resin was loaded in compression at 2 mm/min until failure and could be 
loaded to 5 kN without exceeding the elastic limit. The maximum load to failure for 
the rabbit tibia in all groups was 1.85 kN (Rabbit T) demonstrating that test bones 
failed at substantially lower loads than the polyester resin. 
 
3.2.4.1 Rate of Loading 
The material characteristics of mammalian bone are influenced by the loading 
environment and this has implications on the method of testing. 
 
McElhaney et al (McElhaney and Byars, 1965) investigated the response of cubes 
of bovine bone to compression loads at various strain rates and found that 
Young's modulus increased, ultimate stress increased, and strain to failure 
decreased with increasing strain rate. Wright et al (Wright and Hayes, 1976) 
demonstrated different mechanisms of bone failure that were dependent on the 
rate of applied load. At slow strain rates (5.0 x 10-4/sec) bone initially displays 
elastic deformation, followed by non-elastic deformation prior to failure. At higher 
strain rates (5.0 x 101/sec) bone exhibited elastic properties until the point of 
failure. 
 
Rubin et al (Rubin and Lanyon, 1982) concluded that physiological strain rates 
during walking and running for horses and dogs was in the range of 0.005–0.08 
s−1 and that this was also a realistic range also for humans. Lanyon et al (Lanyon 
et al., 1975) measured strain rates of 0.013 s−1 in humans during running and Burr 
et al (Burr et al., 1996) measured maximum strain rates of 0.050 s−1 during 
sprinting and downhill running. 
 
The experiment aimed to recreate loading characteristics of normal walking and a 
rate of loading of 2 mm/min was selected to reproduce a slow strain rate 
consistent with previous studies. This was validated by the consistent pattern of 
failure, which involved an initial elastic phase and non-elastic deformation prior to 
failure. (Figure xii) 
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3.2.4.2 Preparation and Mounting 
The ankle and knee were disarticulated and all soft tissues were removed, leaving 
the tibio-fibular complex. This was embedded in the mounting block described in 
section 3.2.3.1, placed in an Instron mechanical testing machine (Instron 
Corporation, Massachusetts USA) and loaded in compression to failure at a rate of 
2 mm/min using a 10 kN load cell (Figure x). The gauge length was determined by 
the position of the screw holes adjacent to the regenerate bone and measured 
approximately 3.5 – 4.0 cm. This configuration was chosen to standardise the 
mounting and to support the screw holes, which may have acted as a stress riser.  
Displacement (mm) for increasing load (Newtons) was measured until failure and 
data were saved in an Excel spreadsheet and exported to Easy Plot (Spiral 
Software Norwich, Vermont USA) and load displacement curves for each 
specimen were produced (Figure xi). 
 
 
Figure x Compression Testing 
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Figure xi  Load / Deformation Plot 
 
3.2.4.3 Stress/Strain Analysis 
The length of exposed bone (lo) was measured before compression testing. This 
was standardised during mounting, ensuring that the polyester resin covered the 
screw holes adjacent to the regenerate.  
 
 
 
 
 
 
 
 
 
 
  
(lo) 
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It was assumed that the regenerate was elliptical and the mean area was 
calculated from DXA measurements in the antero-posterior and medio-lateral 
planes using the following formula; 
 
 
 
 
 
The load/displacement data was transformed to produce stress/strain data using 
the following formula;  Stress     = Load/Area 
     Strain  Displacement/ lo 
The data were transferred to Easy Plot (Spiral Software) and Stress-Strain curves 
were produced for each specimen. (Figure xii)  
The Modulus of Elasticity is defined by the formula; 
  (σ 1 – σ 2 
  (ε 1 – ε 2) 
Where σn and εn are defined as equivalent co-ordinates within the elastic region, 
and illustrated in figure xii (- - -). 
 
 
Figure xii Stress / Strain Plot  
 
α 
β 
Area = παβ 
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The energy at yield and failure were represented as the area under the curve at 
each point and were calculated by integration.  
In some cases, there was an initial increase in strain without an associated change 
in load and it was assumed that this represented bedding down between the bone 
and jig. (Figure xiii) In this situation, the origin was recalibrated and the linear area 
was isolated using the data capture facility of the Easy Plot software.  
 
Figure xiii  Stress Strain Plot  Demonstrating Initial Increase in Strain Without 
Corresponding Increase in Stress 
 
The data between the yield point and failure point were isolated and a second 
gradient was produced (Figure xiv). This enabled confirmation of the yield point as 
evidenced by an obvious alteration in the gradient and therefore defined the extent 
of the elastic region.  The gradient of the linear region was calculated using the 
curve fitting function of the Easy Plot software. There was an identifiable linear 
region in all cases and the gradient of each plot was measured on 10 occasions. 
The mean gradient for each plot was calculated and represented the modulus of 
elasticity.  
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This was potentially subject to observer error and for this reason, each curve was 
assessed in sequence and the process repeated ten times (Figure xv). This 
prevented observer familiarity with an individual plot and was considered to be the 
most objective method of estimating the relevant points. The yield stress and 
strain, and failure stress and strain were also calculated in this manner. 
All data were entered into the Stats Direct Statistical Software programme and 
saved for individual specimens and as a cumulative data file. 
 
 
Figure xiv  Determination of Modulus of Elasticity 
 
 
Analysis was performed for all tibiae and individual measurements were combined 
to form a single data set for each of the four groups. 
Group 1 Chemotherapy  Group 1 Control 
Group 2 Chemotherapy  Group 2 Control 
 
This produced a range, mean, and standard deviation for the following parameters 
in each group: 
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Modulus of elasticity N/m2 
Energy to yield  J 
Yield stress   N/m2 
Yield strain   - 
Energy to failure  J 
Failure stress  N/m2 
Failure strain   - 
 
 
Fig xv 
3.2.5 Statistical Analysis  
Data from all sources were saved as an Excel spreadsheet. This interfaced with 
Stats Direct statistical software package, which was used for all statistical analysis. 
The statistical requirements for this project were discussed with Dr. Hazel Taylor 
(University of Bristol) and the following approach was recommended. 
 
It was initially assumed that the data was normally distributed and this was 
confirmed using a Shapiro Wilk test. In all cases, data was from a population with 
normal distribution. 
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Descriptive statistics are presented as Box and Whisker plots demonstrating the 
mean, standard deviation, minimum and maximum for each parameter.   
 
An unpaired t-test was used to compare groups and this was prefaced by an F-test 
to confirm equal variance. The two-sided statistic with a 95% confidence interval 
was used in each case 
 
Statistical significance was assumed at the p=0.05 level and power for this level of 
significance was also determined by post hoc analysis.  
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3.3 Regenerate Parameters  
 
3.3.1 Length / mm  
 
      Mean  σ   
 
Neo-adjuvant Control  0.74  0.15   
   Chemotherapy 0.73  0.11   
 
Adjuvant   Control  0.66  0.13   
Chemotherapy 0.72  0.08 
 
Neo-adjuvant 
p = 0.84 
95% confidence interval for difference between means = -0.11 to 0.13 
Power (for 5% significance) = 5.88% 
 
Adjuvant  
p = 0.31 
95% confidence interval for difference between means = -0.15 to 0.05 
Power (for 5% significance) = 28.06% 
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3.3.2 Area / cm2  
 
Mean  σ   
 
Neo-adjuvant  Control  0.77  0.29   
   Chemotherapy 0.57  0.06 
 
 
Adjuvant   Control  0.54  0.14    
   Chemotherapy 0.49  0.15 
 
Neo-adjuvant  
F test significant therefore assuming unequal variances 
p = 0.06 
95% confidence interval for difference between means = 5.4×10-3 to 0.4 
Power (for 5% significance) = 46.98% 
 
Adjuvant 
p = 0.53 
95% confidence interval for difference between means = -0.10 to 0.18 
Power (for 5% significance) = 13.38% 
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3.3.3 Volume/cm3     
 
Mean  σ   
 
Neo-adjuvant  Control  0.58  0.27   
Chemotherapy 0.42  0.07 
 
Adjuvant  Control  0.35  0.12   
Chemotherapy 0.35  0.09 
 
Neo-adjuvant 
F test significant therefore assuming unequal variances; 
p = 0.10 
95% confidence interval for difference between means = -0.03 to 0.35 
Power (for 5% significance) = 34.49% 
 
Adjuvant 
p = 0.97 
95% confidence interval for difference between means = -0.10 to 0.11 
Power (for 5% significance) = 5.03% 
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3.3.4 Oblique Plane Alignment (°)  
 
Mean  σ   
 
Neo-adjuvant  Control  3.62  3.73   
Chemotherapy 5.85  3.10 
 
Adjuvant  Control  5.73  1.66   
Chemotherapy 4.52  2.18 
 
Neo-adjuvant 
p = 0.22 
95% confidence interval for difference between means = -5.04 to 1.23 
Power (for 5% significance) = 41.17% 
 
Adjuvant 
p = 0.17 
95% confidence interval for difference between means = -0.57 to 2.99 
Power (for 5% significance) = 45.93% 
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3.4 DXA Parameters 
 
3.4.1 Bone Mineral Content  
      Mean  σ  
 
Neo-adjuvant Control  0.36  0.14 
   Chemotherapy 0.24  0.04 
 
Adjuvant  Control  0.22  0.08 
Chemotherapy 0.23  0.06 
 
Neo-adjuvant 
F test significant therefore assuming unequal variances; 
p = 0.02 
95% confidence interval for difference between means = 0.03 to 0.23 
Power (for 5% significance) = 68.41% 
 
Adjuvant 
p = 0.79 
95% confidence interval for difference between means = -0.07 to 0.06 
Power (for 5% significance) = 6.47% 
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3.4.2 Bone Mineral Density 
 
Mean  σ 
 
Neo-adjuvant Control  0.50  0.07 
   Chemotherapy 0.38  0.04 
 
Adjuvant  Control  0.40  0.06 
Chemotherapy 0.40  0.06 
 
Neo-adjuvant 
p = < 0.01 
95% confidence interval for difference between means = 0.06 to 0.17 
Power (for 5% significance) > 99.99% 
 
Adjuvant 
p = 0.97 
95% confidence interval for difference between means = -0.06 to 0.05 
Power (for 5% significance) = 5.03% 
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3.4.3 Volumetric Bone Mineral Density  
 
       Mean  σ 
 
Neo-adjuvant Control   0.65  0.09 
   Chemotherapy  0.57  0.06 
 
Adjuvant  Control   0.63  0.05 
Chemotherapy  0.67  0.09 
 
Neo-adjuvant 
p = 0.04 
95% confidence interval for difference between means = 0.006 to 0.15 
Power (for 5% significance) = 86.13% 
 
Adjuvant  
p = 0.34 
95% confidence interval for difference between means = -0.10 to 0.04 
Power (for 5% significance) = 24.86% 
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3.5 Mechanical Parameters 
 
3.5.1 Modulus of Elasticity 
       Mean  σ 
 
Neo-adjuvant Control   5.88 × 108 3.52 × 108  
   Chemotherapy  5.92 × 108 1.15 × 108 
 
Adjuvant  Control   4.62 × 108  1.41 × 108  
Chemotherapy  5.65 × 108  2.84 × 108 
 
Neo-adjuvant  
F test significant therefore assuming unequal variances; 
p = 0.97 
95% confidence interval for difference between means = -2.62 to 2.44 × 108 
Power (for 5% significance) = 2.63% 
 
Adjuvant 
p = 0.32 
95% confidence interval for difference between means = -3.1 to 1.1 × 108  
Power (for 5% significance) = 26.07% 
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3.5.2 Energy at Yield 
 
       Mean  σ 
 
Neo-adjuvant Control   3.14 × 107 1.74 × 107 
Chemotherapy  2.46 × 107 1.07 × 107 
 
Adjuvant  Control   3.93 × 107  6.26 × 107 
Chemotherapy  2.74 × 107  1.22 × 107 
 
Neo-adjuvant  
p = 0.31 
95% confidence interval for difference between means=-6.99×106 to 2.07× 107   
Power (for 5% significance) = 13.69% 
 
Adjuvant 
p = 0.01 
95% confidence interval for difference between means = 2.64 × 106 to 2.11 × 107 
Power (for 5% significance) = 94.13% 
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3.5.3 Yield Stress 
 
      Mean  σ 
 
Neo-adjuvant Control  1.63 × 106 5.40 × 106 
Chemotherapy 1.64 × 106 3.40 × 106 
 
Adjuvant  Control)  1.89 × 107 2.38 × 107  
   Chemotherapy 1.68 × 107  6.49 × 107 
 
Neo-adjuvant  
p = 0.94 
95% confidence interval for difference between means=-4.47 to 4.16×106   
Power (for 5% significance) = 5.11% 
 
Adjuvant 
F test significant therefore assuming unequal variances; 
p = 0.39 
95% confidence interval for difference between means = -2.8 to 6.9 × 106 
Power (for 5% significance) = 10.79% 
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3.5.4 Yield Strain 
 
      Mean  σ 
 
Neo-adjuvant  Control  3.68 × 10-2 1.49 × 10-2 
Chemotherapy 3.22 × 10-2 1.02 × 10-2 
 
Adjuvant  Control  5.20 × 10-2 1.35 × 10-2 
Chemotherapy 3.68 × 10-2 1.01 × 10-2 
 
Neo-adjuvant 
p = 0.44 
95% confidence interval for difference between means =-7.0×10-3 to 1.7×10-2 
Power (for 5% significance) = 19.04% 
 
Adjuvant 
p = 0.01 
95% confidence interval for difference between means = 2.7×10-2 to 3.5×10-2 
Power (for 5% significance) = 94.55% 
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3.5.5 Energy at Failure 
 
      Mean  σ 
 
Neo-adjuvant Control  5.48 × 107 2.33 × 107 
Chemotherapy 8.09 × 107 9.75 × 107 
 
Adjuvant  Control  6.41 × 107 2.28 × 107 
Chemotherapy 5.25 × 107 2.07 × 107 
 
Neo-adjuvant  
p = 0.59 
95% confidence interval for difference between means=-1.60×107 to 2.73×108  
Power (for 5% significance) = 6.76% 
 
Adjuvant  
p = 0.27 
95% confidence interval for difference between means = -9.5×106 to 3.36×107 
Power (for 5% significance) = 67.78% 
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3.5.6 Failure Stress 
 
      Mean  σ 
 
Neo-adjuvant Control)  1.87 × 107 5.52 × 107 
Chemotherapy)  1.95 × 107 3.52 × 107 
 
Adjuvant  Control  1.98 × 107 2.73 × 107 
Chemotherapy)  1.88 × 107 6.30 × 107 
 
Neo-adjuvant 
p = 0.71 
95% confidence interval for difference between means= -5.23 to 3.64×106   
Power (for 5% significance) = 4.86% 
 
Adjuvant  
F test significant therefore assuming unequal variances; 
p = 0.67 
95% confidence interval for difference between means = -3.8×106 to 5.8×106 
Power (for 5% significance) = 5.18% 
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3.5.7 Failure Strain 
 
      Mean  σ 
 
Neo-adjuvant Control)  5.36 × 10-2 1.88 × 10-2 
   Chemotherapy  4.74 × 10-2 1.33 × 10-2 
 
Adjuvant  Control  6.39 × 10-2 1.29 × 10-2 
Chemotherapy 5.24 × 10-2 1.71 × 10-2 
 
Neo-adjuvant 
p = 0.41 
95% confidence interval for difference between means=-1.0× to 2.2×10-2 
Power (for 5% significance) = 20.21% 
 
Adjuvant  
p = 0.11 
95% confidence interval for difference between means = -3.0×10-3 to 2.6×10-2 
Power (for 5% significance) = 58.1% 
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3.6 Significant Adverse Events 
3.6.1 Control Groups 
Rabbit 1 
On day 4, the animal was noted to be dragging the left hock but did not appear 
distressed.  The limb was inspected by the Veterinarian without anaesthesia and 
foot appeared to be flail, without external signs of injury and with normal perfusion.  
There was no imperative to explore the limb or terminate the experiment and 
normal limb function was observed by the time of the second infusion.  
 
Rabbit 3 
A significant (> 0.5 cm), non-infected medial wound dehiscence was identified on 
day 10 and was resutured under general anaesthesia. The wound was healing at 
the time of the second infusion on day 14 and did not require any further 
intervention.  
 
Rabbit 5 
A significant, non-infected medial wound dehiscence was identified on day 8 and 
was resutured under general anaesthesia.  The wound had healed by the time of 
the second infusion on day 14 and did not require any further intervention.  
 
Rabbit 7  
A significant, non-infected medial wound dehiscence was identified on day 15 and 
was resutured under general anaesthesia.  The wound did not require any further 
intervention and had healed by day 28.  
 
Rabbit 8 
A significant, non-infected wound dehiscence was identified on day 2 and was 
resutured under general anaesthesia. There was a further dehiscence on day 4 
requiring excision of infected, necrotic wound edges and resuturing. On day 14, 
there was a smooth induction of anaesthesia but prior to surgical exposure of the 
left groin, the animal became apnoeic. It was noted that there was copious turbid 
fluid in the mouth and the post mortem examination demonstrated that the lungs 
were congested with turbid fluid suggesting an aspiration pneumonitis. 
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Rabbit 9  
A minor (< 0.5cm), non-infected medial wound dehiscence was noted during pre-
anaesthetic assessment on day 14 but this did not require treatment. 
On day 16 there was a significant non-infected wound dehiscence that required 
resuturing under anaesthesia. This subsequently healed without further 
intervention.  
On day 17, a raw area was noted over the right knee, probably due to contact with 
the cage. This was inspected under general anaesthesia and the knee was 
padded with Betadine gauze and dressed with Elastoplast.  This was reinspected 
under anaesthesia at the time of osteotomy on Day 28, and was noted to have 
healed without infection.  
 
Rabbit 11 
The initial inguinal exposure, cannulation and infusion were uncomplicated. 
The animal became apnoeic during the second saline infusion.  
Post mortem examination demonstrated aspiration pneumonitis which was 
considered to be due to general anaesthesia without endotracheal intubation. . 
 
3.6.2 Chemotherapy Groups  
Rabbit F  
The animal developed a partial thickness abrasion to the right proximal medial 
thigh on Day 1 due to contact with the metal cage. This was inspected and 
irrigated with sterile saline without anaesthesia for 3-consecutive days.  The 
abrasion healed completely within seven days. 
 
Rabbit O 
A significant non-infected dehiscence was identified on day 3 and was resutured 
under general anaesthesia. The wound did not require any further intervention and 
had healed by day 14.  
 
3.7 Technical Failures  
3.7.1 Control Groups 
Rabbit 1 
The tibia was damaged during transit to the Department of Mechanical 
Engineering and was not suitable for testing. 
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Rabbit 2 
The disarticulated hock was lost in transit between the Animal Care Facility and 
the Department of Radiology and destroyed without further examination 
 
Rabbit 5 
The disarticulated hock was lost in transit between the Animal Care Facility and 
the Department of Radiology and destroyed without further examination 
 
3.7.2 Chemotherapy Groups 
Rabbit BB  
The tibia was incorrectly mounted with insufficient tibia between the resin 
mounting blocks. The bone was subjected to compression testing but this did not 
produce any meaningful data. 
 
Rabbit L 
The disarticulated hock was lost in transit between the Animal Care Facility and 
the Department of Radiology and destroyed without further examination 
 
Rabbit P 
The disarticulated hock was lost in transit between the Animal Care Facility and 
the Department of Radiology and destroyed without further examination 
 
Rabbit X 
The tibia was incorrectly mounted with insufficient tibia between the resin 
mounting blocks. The bone was subjected to compression testing but this did not 
produce any meaningful data. 
 
3.8 Summary of Results 
The raw experimental data is presented in table form. (Appendix 4) 
 
There were no statistically significant differences in regenerate length, area, 
volume and alignment between chemotherapy and control groups in either arm of 
the experiment.  
 
132 
There was a statistically significant reduction in BMC, BMD and vBMD in the 
chemotherapy group of the neo-adjuvant arm of the experiment. 
 
There were no statistically significant differences in the DXA parameters in the 
adjuvant arm of the experiment.   
 
There were no statistically significant differences in mechanical properties 
between groups in the neo-adjuvant arm. 
 
In the adjuvant arm, there was a statistically significant increase in energy at yield 
and yield strain in the control group. 
 
The relevance of these data and the implications for the clinical use of distraction 
osteogenesis are considered in the following section. 
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Section 4 Discussion, Clinical Relevance and Concluding Remarks 
The purpose of this work was to investigate the effect of cis-platinum and 
adriamycin on regenerate bone formation in a juvenile NZW rabbit model of 
distraction osteogenesis. The clinical basis was to explore the feasibility of limb 
salvage using bone transport following surgical excision of an osteogenic 
sarcoma, in the presence of neo-adjuvant or adjuvant cytotoxic drugs.  
 
A systematic review of the literature describing bone transport in the clinical 
context did not identify a consistent detrimental effect on bone formation. The 
relevant literature however, considered small patient numbers in uncontrolled 
series.  It was not possible to reach any robust conclusions and this study 
attempted to address the knowledge gap. Confirmation that the structural and 
material properties of the regenerate were unaffected by the cytotoxic agents 
would support the use of distraction osteogenesis for tumour reconstruction.  
 
The experiment consisted of two separate pillars of study. It was initially necessary 
to develop a reproducible animal model that simulated the metabolic effects of 
cyclical cytotoxic chemotherapy, without the confounding effects of renal and 
hepatic failure. This model was used to evaluate the effects of these agents on the 
material and structural properties of regenerate bone formed by distraction 
osteogenesis, which was used as a surrogate for bone transport. 
   
4.1 Development of the Animal Model 
This component of the experiment defined an appropriate cytotoxic regimen, which 
fulfilled the conflicting criteria of a clinically relevant response demonstrated by an 
appropriate effect on body weight, without biochemical evidence of renal or 
hepatic failure.  
 
The use of single animal data is a deficiency of this study and an increased 
number of animals in each dose group would enhance data interpretation. This 
data however, provided an indicator of an appropriate dose and it was a pragmatic 
approach, which was possible within the time constraints and resources available 
for the study. 
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The initial component of this study investigated the effects of 2 cycles of cis-
platinum and adriamycin, infused with an IVAC pump over 2-hours, at an interval 
of 14-days using various dose combinations. The infusion technique involved 
insertion of a peripheral cannula into the femoral vein and this technique was 
refined in the initial experimental group.  
 
It was possible to predictably identify the vascular anatomy and isolate the femoral 
vein using sling sutures. It was necessary to produce watertight cannulation of the 
vein with a single attempt to prevent contamination of the adjacent soft tissues, 
which would introduce a significant risk of soft tissue necrosis. In all cases, it was 
possible to identify and cannulate the femoral vein, with uncomplicated delivery of 
drugs. 
 
A pre-requisite of the model was the production of an adequate cytotoxic effect 
and the initial component of the experiment involved the development of a model 
that predictably produced a reduction in percentage weight gain, whilst preserving 
normal renal and hepatic function, assessed by analysis of peripheral blood 
samples. Renal or hepatic failure following cytotoxic infusion would introduce a 
confounding variable and any subsequent effect on bone formation could not be 
confidently attributed to the cytotoxic drugs. 
 
Infusion with 6.5 mg/kg cis-platinum and 6.5 mg/kg adriamycin led to failure to gain 
weight with a rapid deterioration in renal function and general condition 8-days 
after infusion, with death on day 11. Frank et al (Frank et al., 1989) investigated 
the effect of 8 mg/kg cis-platinum and demonstrated MRI evidence of 
nephrotoxicity within 9-hours with significant deterioration of renal function (BUN, 
creatinine). Histology from this series demonstrated mild to moderate focal 
necrosis of the proximal convoluted tubule. Histological analysis was not available 
for this experiment, but the macroscopic post mortem findings included 
enlargement of both kidneys, granular renal parenchyma and an increase in peri-
renal fat. This suggested that although the dose of cis-platinum was lower, 
combination with an equivalent dose of adriamycin produced a rapidly fatal 
deterioration in general condition and renal function. 
Infusion with 4.5 mg/kg cis-platinum and 4.5 mg/kg adriamycin led to an initial 
reduction in the rate of weight gain and the pre-infusion weight did not recover until 
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26-days after the initial dose. This would have been ideal in terms of the cytotoxic 
effect but there was a rapid increase in urea and creatinine, peaking approximately 
2-4-days after each infusion. At the conclusion, there was persistent elevation of 
serum creatinine (164 µ mol/L) and serum urea (13.4 mmol/L).  
 
The pattern of renal failure mirrors that described by Najjar et al (Najjar and Saad, 
2001) after an  infusion of 5 mg/kg with a highly significant increase in serum 
creatinine and urea within 7-days of infusion.  
Persistent abnormalities in renal function would potentially influence bone 
mineralisation due to the effect on calcium and phosphate homeostasis, 
parathyroid hormone and vitamin D metabolism.  This would introduce an 
important confounding variable and make subsequent data interpretation difficult. 
A fundamental requirement of the experimental model was therefore preservation 
of renal function. 
 
Reduction to 3 mg/kg cis-platinum and 3 mg/kg adriamycin resulted in an initial 
11% and subsequent 13% loss of percentage body weight but led to an increase 
in urea and creatinine within 3-days of the initial infusion. This approximates the 
lower dose group described by Frank et al (Frank et al., 1989) and although the 
total dose received was greater, the individual doses are identical. There was a 
catastrophic deterioration in renal function leading to death at day-21 suggesting 
that the combined effect of the 2 cytotoxic agents produced an amplified 
nephrotoxic effect although this was not validated by histological examination. 
 
Further reduction to 2 mg/kg cis-platinum and 2 mg/kg adriamycin produced a 
more modest reduction in weight gain, returning to the pre-infusion weight 8-days 
after initial infusion, with a gradual increase in weight and a small decline after the 
second infusion. There was an initial increase in serum creatinine and urea, which 
was also maximum 2-4 days after initial infusion, suggesting renal tubular damage 
and recovery. After the second infusion there was a profound increase in serum 
creatinine with a modest increase in serum urea, which persisted until the 
conclusion of the experiment. The haematocrit during this period was unrelated to 
urea and creatinine levels. This suggested acute tubular damage following infusion 
with a cumulative effect of both agents on the degree of tubular damage and rate 
of recovery. 
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Two cycles of 1 mg/kg cis-platinum and 1 mg/kg adriamycin over 2-hours did not 
adversely affect renal function. The percentage weight loss however was small 
and was regained by day 6 with an increase in percentage body weight thereafter. 
This would potentially lead to the conclusion that any lack of observed alteration in 
the properties of the regenerate would be due to sub-therapeutic doses of the 
agents used.  
 
The compromise was an initial infusion of 1 mg/kg cis-platinum and 2mg/kg 
adriamycin, increasing to 4 mg/kg and this was used for the main component of 
the experiment. The aim was to prevent the deterioration in renal function 
associated with doses of cis-platinum greater than 1 mg/kg, minimise the risk    of 
the amplified deterioration associated with these drugs in combination and 
produce a clinically relevant cytotoxic effect. This schedule acknowledged 
concerns relating idiosyncratic sensitivity to adriamycin. (Bocherens-Gadient et al., 
1992) It was necessary to promptly identify animals that were particularly sensitive 
and replace early in the experiment and before application of external fixator and 
osteotomy.  
 
The timing of drug administration was also investigated and the schedules were 
broadly defined as neo-adjuvant if drugs were given before surgery and adjuvant if 
additional drugs were given after surgery. Both strategies are used in the 
management of osteogenic sarcoma and the model attempted to mimic the COSS 
(Link et al., 1991, Link et al., 1986) and EOI (Bramwell et al., 1992, Souhami et al., 
1997) approach to this clinical problem. 
 
This formed the basis of the cytotoxic chemotherapy schedule for the distraction 
osteogenesis experiment. The drugs were given 4 and 2-weeks before osteotomy 
and distraction (Neo-adjuvant Group) or 10-days before and 4-days after 
osteotomy and distraction (Adjuvant Group).  
 
4.2 Validation of the Animal Model 
Anaesthesia and surgical procedures were well tolerated in the majority of cases. 
The animals recovered rapidly, did not appear distressed and were observed until 
alert and drinking before being returned to their cage. An animal care assistant 
monitored the animals on a daily basis and significant adverse events were 
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documented, discussed with the Veterinarian and a decision made on continuing 
with the experiment or sacrificing the animal. 
In the early part of the experiment, general anaesthesia was complicated by fatal 
aspiration pneumonitis during induction of anaesthesia in 2 cases. Diet was 
therefore restricted for 2-hours before infusion with clear fluids continued ad 
libitum and this complication was eradicated.  
 
Consideration was given to pooling the control data for the neo-adjuvant and 
adjuvant groups to produce a single control group. This would potentially simplify 
the presentation of results and allow direct comparison of active groups. 
Preliminary statistical analysis demonstrated significant differences between the 
control data for several parameters and invalidated this approach. This 
observation confirmed the need for a properly controlled environment and 
individual data is presented for each group.  
 
4.3 Neo-adjuvant Chemotherapy Group  
The active group received 1.0 mg/kg cis-platinum and 2.0 mg/kg adriamycin at 8-
weeks and 1.0 mg/kg cis-platinum and 4.0 mg/kg adriamycin at 10-weeks. The 
tibial osteotomy was performed when the animals were 12-weeks old. 
 
Rabbits that had been infused with cis-platinum and adriamycin demonstrated a 
statistically significant reduction in relative weight gain at 10, 12 and 16-weeks of 
age.  Decrease in weight has been identified in previous animal studies as an 
indicator of cytotoxic effect. (Wanless et al., 1987) This effect is also seen in 
human clinical practice and is due to several factors, including anorexia and a 
catabolic response to cytotoxic drugs. The difference demonstrated in each 
experimental group suggests that the animals received clinically relevant amounts 
of cis-platinum and adriamycin. It was not possible to quantify the mechanism 
leading to this observation, as food and water were given ad libitum.  
 
There were significant differences in the serum haemoglobin between groups at 
the start of the experiment, this trend had reversed at the time of the tibial 
osteotomy and there was no observable difference in haemoglobin concentration 
at the conclusion of the experiment.  
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There is no obvious explanation for the initial difference. These animals were of 
equivalent age, reared in identical conditions and there was no evidence of 
concomitant disease. The specimens were provided and selected without any 
known bias. The animals were not randomised but there was no consistently 
observed difference in the clinical condition, weight or other features.  
 
The reversal in trend at the time of tibial osteotomy suggests that haematopoiesis 
was affected by the cytotoxic infusion, which has been demonstrated in previous 
studies using adriamycin in this species. (Wanless et al., 1987) The relative 
anaemia following chemotherapy is similar to the effect of therapeutic doses of 
cytotoxic agents in human patients. This is due in part to marrow suppression and 
whilst it suggests that the animal model was clinically relevant, it has not been 
directly demonstrated. Future work should include marrow biopsy to investigate 
whether the alteration in haemoglobin concentration occurs as a result of marrow 
suppression 
 
There was no effect on the leucocyte count at any of the points of measurement. 
The pattern of leucopenia seen in the dose response group indicated that the 
decline in leucocyte count was most obvious between 2 and 4-days after infusion 
and the lack of observed effect may have been due to the timing of the samples. It 
could also indicate a lack of therapeutic effect, but in the presence of decline in 
haemoglobin and weight gain in the chemotherapy groups, this was considered 
less likely. Future work should assess leucocyte count at intervals of 24-48 hours 
to determine whether there is a transient reduction following cytotoxic infusion. 
This should be correlated with an alteration in marrow composition to confirm that 
the model was a reasonable surrogate.     
 
There was a reduction of total protein concentration at 12-weeks (osteotomy) in 
the chemotherapy group, but the difference in means was small (58.4 g/L vs. 52.9 
g/L) with a minimum in each group of 49.0 g/L. This difference was not considered 
clinically significant and was not present at the conclusion of the experiment. The 
stable total protein indicates that hepatic production and renal excretion are 
unaffected, consistent with normal laboratory tests of hepatic and renal function 
(vide infra). It also implies that the observed weight loss was not due to anorexia 
and associated malnutrition although there is no direct evidence. The duration of 
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the experiment was short and conclusions relating to malnutrition would be more 
accurately addressed by measuring dietary intake. 
   
The combination of decreased weigh gain and reduction in haemoglobin indicates 
that the chemotherapy regimen adversely affected the general condition of the 
animals. It demonstrates that the model has merit and produces effects in the 
rabbit that would be expected in a human patient. 
 
There was a statistically significant increase in serum urea following the initial 
cytotoxic infusion (10 weeks), which had recovered at the conclusion of the 
experiment. The difference in means was small (6.32 mmol/L vs. 6.31 mmol/L) 
and was not considered to be clinically significant.   
There was no correlation between urea, creatinine and haematocrit, excluding 
dehydration as a cause for this observation. There was no statistically significant 
difference in serum creatinine between groups at any point in the experiment.  
 
A statistically significant increase in ALT was noted at the time of the osteotomy in 
the control group, with a large difference in means (121.21 U/L vs. 44 U/L). This 
observation is difficult to explain, as the reverse would be expected given the 
hepatotoxic properties of adriamycin.  
 
There was statistically significant increase in γGT in the control group but the 
difference in means was small (11.30 U/L vs. 6.00 U/L) and all measurements 
were within the normal limits defined by the initial levels. There was no difference 
in ALT or γGT at the conclusion suggesting that there was no prolonged effect on 
hepatic function.  
 
4.4 Adjuvant Chemotherapy Group 
This group received 1.0 mg/kg cis-platinum and 2.0 mg/kg adriamycin at 10-
weeks. The tibial osteotomy was performed when the animals were 12-weeks old 
and 1.0 mg/kg cis-platinum and 4.0 mg/kg adriamycin was infused 4-days later. 
The interval between infusions was therefore constant at 2-weeks. 
 
Rabbits in the active group demonstrated reduced weight gain at 12 (5.85%) and 
16-weeks (6.1%). Each of these differences was statistically significant at the p = 
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0.05 level with a power of 85 and 80% suggesting that, as in the initial group, this 
was a robust observation.  
 
The haemoglobin levels where initially equal, with a statistically significant 
reduction in means at the time of osteotomy (p = 0.01, power 92%) and second 
infusion (p = 0.01, power >99%) in the animals that received chemotherapy. The 
reduction in haemoglobin was mirrored by a reduction in haematocrit, which was 
statistically significant but represented a difference in means of 4 L/L, which was 
not considered to be clinically important. The trend in weight gain and 
haemoglobin was identical for the adjuvant and neo-adjuvant groups and is further 
evidence that the chemotherapy schedule had adversely affected the general 
condition of the experimental animals. 
 
 There was no statistically detectable difference in white count at any point in this 
group. It was not possible to comment on whether an effect had been missed due 
to the infrequent sampling and the lack of marrow aspirate prevented evaluation of 
the effect on the stem cell populations.   
There was a statistically significant reduction in total protein at the time of the 
second infusion with a small difference in means of 55.0 g/L vs. 58.4 g/L at the 
time of the second infusion (p <0.01, power 96%) and this had normalised at the 
completion of the experiment.  
 
There was statistically significant difference in mean urea levels at the time of the 
each infusion and osteotomy in the chemotherapy group.  This was not considered 
to be of clinical significance as the difference in means was small (Initial Infusion; 
4.62 mmol/L vs. 5.73 mmol/L, Osteotomy; 4.78 mmol/L vs. 6.5 mmol/L; Second 
Infusion 5.42 mol/L vs. 6.62 mol/L) and all except Rabbit W (Osteotomy; 11.1 
mmol/L) were within the normal range, based on the presenting urea in both 
groups. There was a statistically significant increase in serum creatinine 
concentration at the time of osteotomy and second infusion.  The difference in 
means was small on each occasion (osteotomy; 67.9 µmol/L vs. 87.5 µmol/L, 
second Infusion 70.5 µmol/L vs. 82.73 µmol/L) and no individual reading exceeded 
the upper limit of normal based on the presenting creatinine concentration for both 
groups. These differences were therefore not considered to be of clinical 
significance. 
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There was a statistically significant increase (p = <0.01. power 96%) in the mean 
ALT level at the time of second infusion (124 weeks) in the control group. The 
difference in means was 10.9 (55.9 U/L vs. 40.27 U/L) and this was therefore 
unlikely to be clinically relevant. There was a statistically significant increase in 
γGT in the chemotherapy group at the time of the second infusion. The difference 
in means was also small (6.66 U/L vs. 8.27 U/L) and all readings were within the 
normal limits defined by initial readings suggesting that these differences were 
unlikely to represent a clinically significant deterioration in hepatic function. In 
addition, compared to the presenting serum levels, ALT and γGT were not raised 
at the conclusion of the experiment demonstrating that any effect on hepatic 
function was transient.  
 
4.5 Summary 
4.5.1 Animal Model 
The final model was based on results from a small series of individual rabbits, 
which were used to estimate the appropriate dose of adriamycin and cis-platinum. 
This strategy was born out of financial and time constraints and carried an inherent 
risk of failure. 
 
The prescription however, satisfied the requirements of the experiment and 
produced a statistically significant reduction in percentage weight gain whilst 
preserving hepatic and renal function. The technical aspects of the model 
including anaesthesia and cannulation were conducted without difficulty. It was 
necessary to restrict diet prior to surgery, but no other modifications were 
necessary and the model provided the basis for investigation of the second pillar 
of this thesis. 
 
A more comprehensive investigation involving larger numbers and more 
sophisticated drug combinations may lead to improvements in the model and 
should be considered as a precursor to further work on this subject. 
A standard surgical technique was developed and used throughout the experiment 
and involved a mid-diaphyseal osteotomy, with lengthening produced by a mono-
lateral external fixator. The rabbit tibia is brittle at this age but it was possible to 
predictably insert 4 external fixator pins using a standard jig. The osteotomy was 
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performed with a bone cutter after pre-drilling and this produced a predicable 
osteotomy, without propagation into the adjacent pins. 
 
Particular care was taken to maintain a sterile surgical field at all times. The wound 
was irrigated with sterile saline throughout the procedure and was dressed with 
povidone Iodine following attachment of the fixator.  
For the purpose of this experiment, major wound dehiscence was defined as a 
breakdown greater than 0.5 cm requiring re-suturing under general anaesthetic. 
The incision was approximately 2 cm in the first part of the experiment and this 
was considered to contribute to a 30% rate of major dehiscence. As the 
experiment continued and the vascular anatomy could be identified with more 
confidence, the surgical wound was reduced to approximately 1cm.  This led to a 
reduction in the number of wound complications, which fell to 2.5% for the 
subsequent three groups. 
 
The tibial osteotomy was performed at 12-weeks of age in an attempt to reproduce 
the stage of skeletal development equivalent to a human adolescent. This was 
based on the age of physeal closure as previously reported by Kawblum. 
(Kaweblum et al., 1994) It was possible to lengthen the right tibia an average of 
7.1 mm, which is approximately 10% of the inter-physeal length in an animal of 
this age. This is the equivalent of a 2.5 cm regenerate in a 10-year old human.   
 
2.5.2 Methods of Evaluation 
Plain radiographs were used to assess the morphology of the regenerate and 
determine the alignment of the lengthened bone in 2 orthogonal (antero-posterior 
and medio-lateral) planes. It was important to lengthen without mal-alignment in 
either plane. This would influence the results produced with compressive testing 
adding a further confounding variable. The radiological appearances were uniform, 
with a fusiform regenerate and abundant new bone formation. There was no 
significant difference in the quality of the regenerate or the alignment seen on plain 
radiographs in the main experimental groups.  
 
DXA was an available and accessible technology and using small animal software, 
provided a simple and reproducible method of analysis. Alternative methods of 
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assessment include pQCT (peripheral Quantified Computerised Tomography) in 
vivo and micro-CT post mortem . 
 
Markel et al (Markel and Chao, 1993, Markel et al., 1991) developed a canine 
model to compare pQCT, SPECT (Single Photon Emission Computed 
Tomography) and DXA as a method of assessment of the torsional properties of 
healing tibial osteotomies. SPECT had the strongest association with maximum 
torque and torsional stiffness and pQCT and SPECT with indentation stiffness but 
these were not significantly different from DXA. 
 
The principal advantage of pQCT and micro-CT over DXA relates to the resolution 
and accuracy of assessment of the three dimensional structure of bone. 
(Hudelmaier et al., 2004) pQCT has a field view of 5-15cm with a resolution of 
100-1000 µm and allows assessment of peripheral sites in intact experimental 
animals and determination of BMD with assessment of trabecular architecture 
parameters. Micro-CT has a field of view between 1-5cm with a resolution of 10-
100 µm  and allows assessment of complete trabecular architecture in small ex-
planted samples or small animal peripheral sites in vivo. DXA does not account for 
the spatial distribution and inherent material properties of the tissues and pQCT 
would have offered a potentially superior method of assessment and should be 
considered as a method of assessment in future work.  
 
DXA measurement was confined to a single assessment for each tibia and was 
performed by an experienced radiographer (JB) who was blinded to the treatment 
group. Inter and intra-rater reproducibility was not assessed and this introduced a 
potential bias, which could have influenced the results and their interpretation.   
 
The lack of structural definition produced by DXA was overcome in part, by 
estimating the volumetric bone mineral density of the regenerate. It was not 
possible to make any assumptions about the degree of cortication of the 
regenerate, which would have added a potentially useful clinical dimension to this 
work. The lunar DPX software allowed an estimation of the spatial distribution of 
bone mineralisation by modelling the region of interest. This assumed that the 
regenerate was cylindrical and that mineralisation was homogenous.  
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There is no consistently reported method of mechanical evaluation of intact bone 
in general and the rabbit tibia following osteotomy and lengthening in particular. 
Tensile testing tests depend on the original geometry of the bone, which is highly 
variable, even within a single species and age group, analysis is also influenced 
by the integrity of the bone-clamp interface. The advantage of such tests however, 
is the absence of specimen machining, which is difficult to control and duplicate.  
 
Bending tests involve complex internal stress fields and produce results that are 
influenced by the testing skill and orientation of the specimen and 3 and 4-point 
bending tests present technical difficulties associated with sample positioning. The 
location and size of the regenerate in this study varied between specimens and 
the differences in relative positions were likely to produce large and unquantifiable 
errors. Testing would therefore be difficult to standardise and the results difficult to 
interpret. Furthermore, this type of testing, when applied to fractures or 
experimental osteotomies, have a tendency to combine the properties of the bone 
with those of the developing callus in an unpredictable manner also making 
analysis of the regenerate bone difficult. 
 
Torsional testing is a useful method of analysis for intact bone but was not 
appropriate for analysis of regenerate bone due to the mode of failure. Progressive 
bending of regenerate under load is a common mode of failure observed in clinical 
practice. This is simulated by axial compression, which was considered most 
representative of the in vivo mode of failure. Previous studies (An et al., 1994, 
Ohyama et al., 1994) have demonstrated a relationship between structural and 
mechanical properties of bone with this type of compression testing and a simple 
uni-axial loading test provided a reproducible method of analysis for this 
experiment.  
 
The experiment aimed to recreate loading characteristics of normal walking and a 
rate of loading of 2 mm/min was selected to reproduce a slow strain rate 
consistent with previous studies(Burr et al., 1996, Lanyon et al., 1975, Rubin and 
Lanyon, 1982).  
 
The dimensions of each lengthened bone were measured and used to produce a 
stress/strain curve for each sample after simple uni-axial compression loading to 
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failure. In the majority, there was a standard pattern of failure with an initial linear 
area, definable yield point and definable end point. A more physiological approach 
would involve non destructive cyclical loading as described in previous sections 
(Ohyama et al., 1994) and this is relevant to future work. 
 
Data derived from DXA and uni-axial compression testing was evaluated to 
determine the effect of cis-platinum and adriamycin on the structural and material 
properties of regenerate bone. Consideration was also given to pooling the control 
data for the neo-adjuvant and adjuvant groups to produce a single control group to 
simplify the presentation of results and allow direct comparison of active groups. 
As with the laboratory data discussed in previous paragraphs, preliminary 
statistical analysis demonstrated significant differences between the control data 
for DXA and mechanical parameters. This suggests that the temporal relationship 
between anaesthesia, infusion and surgery have an independent influence on the 
properties of the regenerate and confirmed that a meticulously conducted and 
properly controlled experiment was necessary. Individual data pairs were therefore 
considered for each parameter.  
 
4.5.3 The Effect of Neo-adjuvant Chemotherapy  
The regenerate produced was of equivalent length, which would be expected 
given that this was determined by the external fixator.  There was a reduction in 
the area of the regenerate of 0.2 cm2 which did not reach statistical significance (p 
= 0.06). The power of this observation was 47% and 35 pairs would be required to 
identify a significant difference with 80% probability. 
There was no obvious difference in the volume of regenerate but this should be 
interpreted cautiously as the power of this observation was 34% and 46 pairs 
would be required to give this observation appropriate power.  
 
There were significant differences noted in bone mineral content, bone mineral 
density and volumetric bone mineral density with reduction in the chemotherapy 
group. The observations were appropriately powerful (BMC 78%, BMD 99.9%, 
vBMD 92%) and the observation was likely to be a real effect. This contradicts 
previous work (Ehrhart et al., 2002) that did not demonstrate an alteration in DXA 
parameters following cis-platinum infusion. A possible explanation is that the 
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addition of adriamycin has produced a more profound effect on regenerate 
mineralisation, but more detailed comment is not possible from the data produced. 
 
The alteration in bone mineralisation was not associated with any alteration in the 
mechanical properties of the regenerate in this group with no significant 
differences in the means of any of the parameters that were tested. There was a 
minor reduction in the modulus of elasticity from 5.47 to 5.15 x 107, which would 
be expected, as modulus/stiffness is dependant on the degree of mineralisation. 
The power of this observation was 4.7%, indicating that 1900 pairs would be 
required to give this observation a power of 80%. This is not a practical 
undertaking and suggests that the effect of chemotherapy is small and would be 
insignificant in clinical terms.  
The lack of effect on the structural properties of regenerate is in agreement with 
Gravel et al,(Gravel et al., 2003a) even with the addition of cis-platinum. 
 
The mechanism in which adriamycin and cis-platinum affect regenerate 
mineralisation is not clear. The formation of regenerate bone involves a sequence 
of events including neo-angiogenesis (Rowe et al., 1999), chondrocyte 
differentiation with expression of bone matrix proteins (Sato et al., 1998), and 
collagen I formation (Yasui et al., 1997).  
 
Adriamycin causes structural alterations in normal bone with reduction in cortical 
thickness and histological changes within the physeal plate and marrow 
hypoplasia (Young et al., 1975). In addition, it specifically inhibits prolyl 
hydroxylation leading to loss of stability of procollagen. (Sasaki et al., 1987)  
 
cis-Platinum causes histomorphometric changes in bone including decreased 
volume of mineralised bone volume and decreased proportion of osteoblast 
covered bone (Ehrhart et al., 2002). 
 
It was not possible to comment on the exact mechanism of action that led to these 
differences and future work will require histological analysis of regenerate at 
intervals following osteotomy. 
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4.5.4 The Effect of Adjuvant Chemotherapy  
There was no statistically significant difference in the regenerate length, which was 
expected, given that this was under the control of the fixator. There was no 
statistically significant difference in the mean regenerate area or volume.  
 
There was no observed difference in the bone mineral concentration, bone mineral 
density or volumetric bone mineral density. Power analysis in each instance 
indicated that 500 pairs would be required to identify a significant difference with 
80% probability. 
 
There were statistically significant reductions in energy at yield (p = 0.01, power 
94%) and yield strain (p = 0.01, power 95%) in the chemotherapy group. There 
was no significant difference in modulus of elasticity, yield stress, energy at failure, 
failure stress or failure strain. This contradicts previous work (Gravel et al., 2003a) 
but this involved adriamycin in isolation, and the effect of cis-platinum is likely to 
have an additional effect. 
 
It is not possible to comment on the lack of the observed differences in the DXA 
assessment on the basis of the data produced. The power of these observations 
was low and post hoc analysis indicated that large sample sizes would be required 
suggests that even if there is a real effect, this is negligible and unlikely to be of 
clinical significance The differences in mechanical parameters is unlikely to 
represent a Type I error even with the relatively small sample size. The lack of 
correlation between the structural and mechanical properties may simply be a 
function of the relative insensitivity of the methods of assessment used.   
 
Future work will require more sophisticated assessment using pQCT or micro CT 
to investigate changes in mineral distribution, tetracycline labelling to investigate 
the effect on the kinetics of bone turnover and histological assessment of the 
ultrastructural changes. Biochemical analysis of collagen and collagen metabolites 
should also be included in future experiments to investigate whether abnormalities 
in synthesis are a factor that may explain some of the observed differences in 
mineralisation. In addition the group sizes proved to be barely adequate to allow 
robust statistical analysis of the mechanical parameters and future work should 
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focus on a single specific area with larger number of animal pairs to allow 
improved statistical analysis. 
 
4.6 Clinical Relevance 
The purpose of this work was to explore the null hypothesis that cyclical cytotoxic 
chemotherapy has a no effect on the structural and mechanical properties of 
regenerate bone in a small mammal model of limb lengthening.  The clinical 
relevance was to investigate the feasibility of reconstruction of segmental defects 
following malignant bone tumour excision by distraction osteogenesis in the 
presence of cytotoxic chemotherapy. The main issue is whether observed 
differences matter and are of sufficient concern to prevent reconstruction by this 
method.  
 
The experimental model demonstrated that it is possible to perform distraction 
osteogenesis in this species without significant complications. The initial difficulties 
with wound healing were overcome by modifying the surgical technique and were 
not seen in the chemotherapy arm of the experiment. Pin site infection, which 
would be expected in this circumstance, was not seen in any case.  There was a 
significant reduction in percentage weight gain and haemoglobin in animals that 
received chemotherapy but there was no effect on the peripheral leucocyte count.  
 
Patients receiving cytotoxic drugs for malignant bone tumours frequently 
experience profound leucopenia and the absence of this effect may be due to the 
superficial nature of the animal model and an inadequate total dose of adriamycin 
and cis-platinum. The dose response experiment demonstrated that an increase in 
dose of either agent led to renal failure, which would have invalidated the model. 
Future work should therefore involve an increased number of cycles of 
chemotherapy with an increase in the total dose of these agents.    
 
In group 1 there were statistically significant differences in DXA parameters with a 
difference in means of 33% (BMC), 23.3% (BMD) and 10.8% (vBMD), suggesting 
that neo-adjuvant chemotherapy has a detrimental effect on mineralisation.  
 
In group 2 there was no observed difference in bone mineralisation which concurs 
with previous work by Erhart et al. (Ehrhart et al., 2002) The power of these 
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observations was however low and this may represent a Type II error. The high 
power of the equivalent observations in the neo-adjuvant group is suggestive of a 
real effect and the lack of difference between groups may be spurious. 
 
There were significant differences in energy at yield and yield strain with difference 
in means of 30.3% (energy at yield) and 28.8% (yield strain) and appropriate 
statistical power. This is suggestive of a real effect and may have clinical 
implications, particularly as regenerate failure following fixator removal is an 
important consideration in human practice. The reduction in energy at yield 
following cytotoxic chemotherapy may be clinically important and if translated into 
human practice may represent an increased risk of regenerate failure following 
limb reconstruction.  
 
4.7 Conclusions 
It has been possible to develop an animal model that fulfilled the primary 
requirements of this experiment. The animals were suitable for sequential 
cannulation and prolonged cytotoxic infusion. There was a significant reduction in 
weight gain in the treated group with no evidence of clinically significant hepatic or 
renal failure. This model is suitable for future experiments investigating the effect 
of cyclical cytotoxic chemotherapy in the juvenile New Zealand White Rabbit. 
 
It has been possible to develop a reproducible model of limb lengthening in this 
species. The risk of wound and pin site infection is low, bone is consistently 
formed in the distraction gap and the overall alignment is satisfactory in all 
lengthened limbs 
This model is suitable for future experiments investigating limb lengthening in the 
juvenile New Zealand White rabbit. 
 
There was a significant reduction in bone mineral content, bone mineral density 
and volumetric bone mineral density in the regenerate formed after 2 cycles of 
neo-adjuvant chemotherapy. This difference was not observed when adjuvant 
chemotherapy was given prior to and 4-days following osteotomy. It not possible to 
explain this effect from the data produced in this experiment and factors including 
the effect on neo-angiogenesis, chondrocyte differentiation, expression of bone 
matrix proteins and collagen I formation should be considered in future studies. 
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There were significant reductions in the energy at yield and yield strain after 2 
cycles of neoadjuvant chemotherapy. This may have implications for the use of 
distraction osteogenesis in reconstruction following tumour excision. This may 
require either prolonged fixator wear or external support following fixator removal.  
It is not possible to make any more robust conclusions from the data produced by 
this thesis.  
 
4.8 Future Work  
The surgical model of limb lengthening using a juvenile NZW Rabbit is 
reproducible and has proved suitable for use in subsequent experiments. (Little et 
al., 2001a, Little et al., 2001b, Little et al., 2003, Uglow et al., 2003, Williams et al., 
2001) The lack of a demonstrable effect following cytotoxic chemotherapy may be 
due to the simple fact that insufficient quantities of drugs were administered. 
Efficacy was assessed on the basis of reduction in percentage weight gain, with 
no other corroboration.  It is not possible to increase the concentrations of the 
drugs, as this led to unacceptable complications, particularly acute renal failure. 
The obvious modification would be to increase the number of cycles and broaden 
the cytotoxic prescription. Histological analysis of retrieved organs, particularly 
kidney, liver, heart and growth plate should also be performed to confirm that the 
cytotoxic model is not associated with irreversible visceral damage, which would 
have an independent effect on the regenerate bone. 
 
Future work should also assess leucocyte count at intervals of 24 to 48-hours to 
determine whether there is a transient reduction following cytotoxic infusion. This 
should be conducted in association with marrow biopsy to assess the effect of the 
cytotoxic drugs on stem cell numbers and function.   Future work should also 
investigate the effect of the drugs on growth in a more sophisticated manner, with 
tetracycline double labelling to assess bone turnover. 
 
This work has demonstrated that regenerate bone will form in the presence of cis-
platinum and adriamycin. It has not however provided evidence at a level that 
allows direct translation to clinical practice. The group sizes proved to be 
inadequate to allow robust statistical analysis of the mechanical parameters and 
future work should focus on a single specific area with larger number of animal 
pairs to allow improved statistical power.  
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Assessment of the material properties of the regenerate was unsophisticated and 
DXA does not account for the spatial distribution and inherent material properties 
of the tissues. pQCT would have offered a potentially superior method of 
assessment and should be considered as a method of assessment in future work.  
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Appendix 3 
Abbreviations  
AP   Antero-posterior 
ASAMI  Association for the Study and Application of the Methods of 
Ilizarov 
BA     Bone area  
BMC   Bone mineral content  
BMD   Bone mineral density  
vBMD   Volumetric Bone Mineral Density  
BUN   Blood Urea Nitrogen 
COSS   Cooperative Osteosarcoma Study 
CO    Cardiac output  
CPK    Creatinine phosphokinase  
CULAS  Combined Universities Laboratory Animal Services 
DXA   Dual Energy X-Ray Absorptiometry 
DNA  Deoxyribonucleic Acid 
E Modulus of elasticity    
Energy F  Energy to failure    
Energy Y  Energy to yield    
ESR    Erythrocyte Sedimentation Rate 
EOI    European Osteosarcoma Intergroup 
FDA    American Food and Drug Administration 
FM    Fergal Monsell 
F Strain  Failure strain     
F Stress  Failure stress 
FBC   Full Blood Count     
γGT    Gamma-Glutamyl Transpeptidase 
G-CSF  Granulocyte Colony Stimulating Factor 
HR    Heart rate 
JWL    Jay Wong Lee    
Lat    Lateral 
LC    Lyndal Cohen 
LDH    Lactate Dehydrogenase  
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LRS    Limb Reconstruction System  
MIOS   Multi-Institutional Osteosarcoma Study 
MTSS   Musculoskeletal Tumour Society Score 
MRI    Magnetic Resonance Imaging 
NSW   New South Wales 
NZW   New Zealand White 
PCT     Proximal convoluted tubule  
PMMA  Poly Methyl Methacrylate 
p-QCT  Peripheral Quantified Computerised Tomography 
RNA    Ribonucleic Acid 
RNOH  Royal National Orthopaedic Hospital  
ROI    Region of Interest 
SF 36   Short Form 36 
SPECT   Single Photon Emission Computed Tomography 
SPF    Specific Pathogen Free   
TJ    Troy James  
TPR    Total peripheral resistance    
TSF    Taylor Spatial Frame  
Y Strain  Yield strain     
Y Stress   Yield stress 
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Appendix 4 
 
Neo-adjuvant Group Regenerate Data 
 
Rabbit 1 3 4 6 7 9 10 12 13 14 
Length 0.84 0.6 0.72 0.84 0.84 0.96 0.72 0.48 0.84 0.6 
Area 0.67 0.9 0.51 1.19 1.32 0.5 0.84 0.66 0.49 0.62 
Volume 0.56 0.54 0.37 1.00 1.11 0.48 0.6 0.31 0.41 0.37 
Obliq  Oblique Plane Alignment  6.00 0.00 5.66 0.00 2.00 11.66 2.83 2.00 0.00 6.00 
 
Rabbit DD G H I J K M N O Q 
Length 0.84 0.72 0.84 0.84 0.84 0.60 0.6 0.60 0.72 0.72 
Area  0.48 0.55 0.62 0.62 0.48 0.53 0.56 0.65 0.56 0.62 
Volume 0.41 0.40 0.52 0.52 0.41 0.32 0.33 0.39 0.40 0.45 
Oblique Plane Alignment  8.49 11.66 4.47 7.21 4.47 6.00 7.21 0.00 4.47 4.47 
 
Adjuvant Group Regenerate Data 
 
Rabbit 15 16 17 18 20 21 22 23 24 25 
Length 0.60 0.72 0.72 0.60 0.48 0.60 0.84 0.84 0.72 0.48 
Area 0.47 0.61 0.71 0.43 0.33 0.43 0.61 0.77 0.57 0.46 
Volume 0.29 0.4 0.54 0.24 0.18 0.24 0.34 0.55 0.36 0.33 
Oblique Plane Alignment 2.94 4.47 6.43 6.32 6.32 4.47 6.32 8.94 6.49 4.55 
 
Rabbit AA BB CC R T U V W X Y Z 
Length 0.72 0.72 0.72 0.72 0.72 0.72 0.60 0.60 0.84 0.72 0.84 
Area 0.55 0.41 0.45 0.51 0.64 0.63 0.64 0.62 0.15 0.37 0.45 
Volume 0.40 0.30 0.33 0.37 0.46 0.45 0.38 0.37 0.12 0.27 0.38 
Oblique Plane Alignment 2.00 2.00 4.47 4.47 4.47 8.94 4.47 2.00 5.66 4.00 7.21 
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Neo-adjuvant Group DXA Data 
 
Rabbit 1 3 4 6 7 9 10 12 13 14 
LAT BMD 5.11E-01 4.84E-01 3.54E-01 6.77E-01 6.39E-01 5.18E-01 4.87E-01 5.43E-01 5.04E-01 5.70E-01 
LAT BMC 4.42E-01 2.93E-01 2.09E-01 5.32E-01 6.54E-01 3.61E-01 3.82E-01 2.07E-01 3.08E-01 2.67E-01 
LAT Area 8.64E-01 6.05E-01 5.90E-01 7.87E-01 1.02E+00 6.98E-01 7.85E-01 3.82E-01 6.12E-01 4.68E-01 
LAT Width 1.03E+00 1.01E+00 8.19E-01 1.09E+00 1.22E+00 7.27E-01 1.09E+00 7.95E-01 7.29E-01 7.80E-01 
AP BMD 6.06E-01 4.14E-01 3.81E-01 4.55E-01 5.53E-01 4.30E-01 5.87E-01 3.81E-01 4.18E-01 4.35E-01 
AP BMC 4.23E-01 2.83E-01 2.17E-01 5.31E-01 6.41E-01 3.63E-01 4.14E-01 1.92E-01 3.00E-01 2.66E-01 
AP Area 6.98E-01 6.84E-01 5.69E-01 1.17E+00 1.16E+00 8.43E-01 7.05E-01 5.04E-01 7.18E-01 6.12E-01 
AP Width 8.31E-01 1.14E+00 7.90E-01 1.39E+00 1.38E+00 8.78E-01 9.79E-01 1.05E+00 8.55E-01 1.02E+00 
AREA 6.72E-01 9.03E-01 5.08E-01 1.19E+00 1.32E+00 5.01E-01 8.38E-01 6.56E-01 4.90E-01 6.25E-01 
VOL 5.64E-01 5.42E-01 3.66E-01 1.00E+00 1.11E+00 4.81E-01 6.03E-01 3.15E-01 4.11E-01 3.75E-01 
LAT VBMD 7.83E-01 5.41E-01 5.71E-01 5.31E-01 5.90E-01 7.50E-01 6.33E-01 6.58E-01 7.49E-01 7.12E-01 
AP VBMD 7.50E-01 5.23E-01 5.93E-01 5.30E-01 5.79E-01 7.54E-01 6.86E-01 6.10E-01 7.30E-01 7.09E-01 
           
Rabbit G H I J K M N O Q DD 
LAT BMD 4.34E-01 3.49E-01 3.88E-01 3.28E-01 3.35E-01 3.96E-01 3.42E-01 4.10E-01 4.68E-01 3.33E-01 
LAT BMC 2.47E-01 2.69E-01 2.93E-01 2.26E-01 1.64E-01 2.01E-01 1.80E-01 2.57E-01 2.80E-01 2.30E-01 
LAT Area 5.69E-01 7.70E-01 7.56E-01 6.89E-01 4.90E-01 5.08E-01 5.26E-01 6.27E-01 5.98E-01 6.91E-01 
LAT Width 7.90E-01 9.17E-01 9.00E-01 8.20E-01 8.16E-01 8.47E-01 8.76E-01 8.72E-01 8.30E-01 8.23E-01 
AP BMD 3.74E-01 3.53E-01 4.08E-01 3.57E-01 3.37E-01 4.13E-01 3.38E-01 4.59E-01 4.28E-01 3.77E-01 
AP BMC 2.40E-01 2.54E-01 3.02E-01 2.26E-01 1.68E-01 2.08E-01 1.92E-01 2.71E-01 2.94E-01 2.36E-01 
AP Area 6.41E-01 7.18E-01 7.42E-01 6.33E-01 4.97E-01 5.03E-01 5.69E-01 5.90E-01 6.87E-01 6.26E-01 
AP Width 8.90E-01 8.55E-01 8.83E-01 7.53E-01 8.29E-01 8.38E-01 9.48E-01 8.20E-01 9.54E-01 7.46E-01 
AREA 5.52E-01 6.16E-01 6.24E-01 4.85E-01 5.31E-01 5.57E-01 6.52E-01 5.62E-01 6.22E-01 4.82E-01 
VOL 3.98E-01 5.17E-01 5.24E-01 4.07E-01 3.19E-01 3.34E-01 3.91E-01 4.04E-01 4.48E-01 4.05E-01 
LAT VBMD 6.21E-01 5.20E-01 5.59E-01 5.55E-01 5.14E-01 6.01E-01 4.60E-01 6.36E-01 6.25E-01 5.68E-01 
AP VBMD 6.04E-01 4.91E-01 5.76E-01 5.55E-01 5.27E-01 6.22E-01 4.91E-01 6.70E-01 6.57E-01 5.83E-01 
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Adjuvant Group DXA Data 
 
Rabbit 15 16 17 18 20 21 22 23 24 25 
LAT BMD 3.90E-01 4.14E-01 4.61E-01 3.84E-01 3.51E-01 3.78E-01 4.16E-01 4.39E-01 3.09E-01 6.14E-01 
LAT BMC 1.74E-01 2.62E-01 3.35E-01 1.71E-01 1.16E-01 1.60E-01 2.55E-01 3.48E-01 1.85E-01 2.30E-01 
LAT Area 4.46E-01 6.34E-01 7.27E-01 4.46E-01 3.31E-01 4.25E-01 6.12E-01 7.92E-01 5.98E-01 3.74E-01 
LAT Width 7.44E-01 8.80E-01 1.01E+00 7.44E-01 6.90E-01 7.08E-01 7.29E-01 9.43E-01 8.30E-01 7.80E-01 
AP BMD 3.28E-01 4.22E-01 5.05E-01 3.67E-01 3.30E-01 3.17E-01 4.23E-01 4.45E-01 3.60E-01 3.99E-01 
AP BMC 1.60E-01 2.46E-01 3.45E-01 1.53E-01 1.07E-01 1.35E-01 2.53E-01 3.30E-01 1.97E-01 2.15E-01 
AP Area 4.90E-01 5.83E-01 6.84E-01 4.18E-01 3.24E-01 4.25E-01 5.98E-01 7.42E-01 5.47E-01 5.40E-01 
AP Width 8.16E-01 8.10E-01 9.50E-01 6.96E-01 6.75E-01 7.08E-01 7.11E-01 8.83E-01 7.60E-01 1.13E+00 
AREA 4.77E-01 5.60E-01 7.54E-01 4.07E-01 3.66E-01 3.94E-01 4.07E-01 6.54E-01 4.95E-01 6.89E-01 
VOL 2.86E-01 4.03E-01 5.43E-01 2.44E-01 1.76E-01 2.36E-01 3.42E-01 5.49E-01 3.57E-01 3.31E-01 
LAT VBMD 6.08E-01 6.50E-01 6.17E-01 7.01E-01 6.61E-01 6.77E-01 7.46E-01 6.33E-01 5.19E-01 6.95E-01 
AP VBMD 5.59E-01 6.10E-01 6.36E-01 6.27E-01 6.09E-01 5.72E-01 7.40E-01 6.01E-01 5.52E-01 6.50E-01 
 
Rabbit AA BB CC R T U V W X Y Z 
LAT BMD 4.28E-01 4.98E-01 3.67E-01 3.85E-01 5.10E-01 4.30E-01 3.62E-01 4.11E-01 2.98E-01 4.07E-01 4.76E-01 
LAT BMC 2.59E-01 2.15E-01 1.80E-01 2.38E-01 3.23E-01 3.07E-01 2.16E-01 2.16E-01 1.05E-01 1.93E-01 2.92E-01 
LAT Area 6.05E-01 4.33E-01 4.91E-01 6.19E-01 6.34E-01 7.13E-01 5.98E-01 5.26E-01 3.53E-01 4.75E-01 6.12E-01 
LAT Width 8.40E-01 6.01E-01 6.81E-01 8.60E-01 8.80E-01 9.90E-01 9.96E-01 8.76E-01 4.20E-01 6.60E-01 7.29E-01 
AP BMD 4.20E-01 3.30E-01 2.79E-01 4.16E-01 4.65E-01 5.11E-01 4.57E-01 3.84E-01 2.76E-01 3.38E-01 4.33E-01 
AP BMC 2.54E-01 2.06E-01 1.69E-01 2.28E-01 3.10E-01 2.98E-01 2.24E-01 2.07E-01 1.03E-01 1.73E-01 2.84E-01 
AP Area 6.05E-01 6.26E-01 6.07E-01 5.48E-01 6.66E-01 5.83E-01 4.90E-01 5.40E-01 3.74E-01 5.12E-01 6.55E-01 
AP Width 8.40E-01 8.70E-01 8.43E-01 7.61E-01 9.25E-01 8.10E-01 8.16E-01 9.00E-01 4.46E-01 7.11E-01 7.80E-01 
AREA 5.54E-01 4.11E-01 4.51E-01 5.14E-01 6.39E-01 6.30E-01 6.38E-01 6.19E-01 1.47E-01 3.69E-01 4.47E-01 
VOL 3.99E-01 2.96E-01 3.25E-01 3.70E-01 4.60E-01 4.53E-01 3.83E-01 3.72E-01 1.24E-01 2.65E-01 3.75E-01 
LAT VBMD 6.49E-01 7.27E-01 5.54E-01 6.43E-01 7.02E-01 6.77E-01 5.64E-01 5.81E-01 8.50E-01 7.27E-01 7.78E-01 
AP VBMD 6.37E-01 6.97E-01 5.21E-01 6.16E-01 6.73E-01 6.57E-01 5.85E-01 5.57E-01 8.33E-01 6.52E-01 7.57E-01 
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Neo-adjuvant Group Mechanical Data 
 
Rabbit 3 4 6 7 9 10 12 13 14 
Mean E 4.50E+08 5.63E+08 3.17E+08 1.94E+08 1.44E+09 6.07E+08 5.70E+08 6.66E+08 4.83E+08 
Mean eY 5.56E+07 5.19E+07 6.26E+06 3.08E+07 9.67E+06 2.17E+07 4.08E+07 2.50E+07 4.10E+07 
Y Stress 1.41E+07 2.32E+07 5.64E+06 1.09E+07 1.66E+07 1.68E+07 2.05E+07 1.95E+07 1.94E+07 
Y Strain 3.10E-02 4.17E-02 1.99E-02 5.83E-02 1.10E-02 4.14E-02 3.70E-02 3.75E-02 5.37E-02 
Mean eF 5.03E+07 6.97E+07 3.69E+07 3.82E+07 1.75E+07 4.68E+07 6.18E+07 8.07E+07 9.14E+07 
F Stress 1.66E+07 2.43E+07 8.67E+06 1.14E+07 1.95E+07 1.95E+07 2.12E+07 2.45E+07 2.23E+07 
F Strain 4.75E-02 4.83E-02 6.07E-02 6.48E-02 1.50E-02 5.27E-02 4.64E-02 6.21E-02 8.48E-02 
Post Yield e -5.30E+06 1.78E+07 3.06E+07 7.40E+06 7.83E+06 2.51E+07 2.10E+07 5.57E+07 5.04E+07 
 
Rabbit G H I J K M N O Q DD 
Mean E 7.13E+08 5.20E+08 3.52E+08 6.85E+08 5.61E+08 5.55E+08 5.41E+08 7.55E+08 6.20E+08 6.13E+08 
mean eY 2.23E+07 3.42E+07 3.07E+07 9.50E+06 2.47E+07 3.72E+07 3.57E+07 2.24E+07 5.07E+06 2.40E+07 
Y Stress 1.94E+07 1.84E+07 1.39E+07 1.23E+07 1.63E+07 1.94E+07 1.94E+07 1.79E+07 9.65E+06 1.78E+07 
Y Strain 2.80E-02 4.15E-02 4.11E-02 1.66E-02 3.05E-02 4.65E-02 3.67E-02 2.53E-02 1.82E-02 3.77E-02 
Mean eF 6.78E+07 3.42E+07 3.52E+08 2.20E+07 4.00E+07 8.31E+07 6.14E+07 3.44E+07 7.76E+07 3.64E+07 
F Stress 2.75E+07 1.84E+07 1.81E+07 1.47E+07 1.71E+07 2.10E+07 2.17E+07 2.03E+07 1.67E+07 1.91E+07 
F Strain 4.69E-02 4.15E-02 6.00E-02 2.64E-02 4.23E-02 6.20E-02 4.89E-02 3.27E-02 6.97E-02 4.40E-02 
Post Yield e 4.55E+07 0.00E-01 3.21E+08 1.25E+07 1.53E+07 4.59E+07 2.57E+07 1.20E+07 7.25E+07 1.24E+07 
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Adjuvant Group Mechanical Data  
 
 
Rabbit 15 16 17 18 20 21 22 23 24 25 
mean E 3.50E+08 5.38E+08 2.52E+08 4.85E+08 5.15E+08 5.72E+08 7.17E+08 3.96E+08 5.05E+08 2.89E+08 
mean eY 4.19E+07 3.19E+07 5.08E+07 4.00E+07 2.85E+07 3.69E+07 3.91E+07 4.06E+07 3.78E+07 4.50E+07 
Y stress 1.90E+07 1.89E+07 1.66E+07 1.82E+07 1.79E+07 2.16E+07 2.41E+07 1.68E+07 1.89E+07 1.66E+07 
Y strain 5.73E-02 4.05E-02 8.36E-02 4.46E-02 4.31E-02 4.47E-02 4.13E-02 5.68E-02 4.48E-02 6.28E-02 
mean eF 4.19E+07 6.54E+07 6.20E+07 8.50E+07 8.62E+07 5.19E+07 1.07E+08 4.06E+07 3.78E+07 6.27E+07 
F stress 1.90E+07 2.09E+07 1.72E+07 1.90E+07 2.13E+07 2.27E+07 2.53E+07 1.68E+07 1.89E+07 1.71E+07 
F strain 5.73E-02 5.83E-02 9.10E-02 6.90E-02 6.85E-02 5.23E-02 6.77E-02 5.68E-02 4.48E-02 7.32E-02 
Post Yield e 0.00E-01 3.35E+07 1.12E+07 4.50E+07 5.77E+07 1.50E+07 6.79E+07 0.00E-01 0.00E-01 1.77E+07 
 
 
Rabbit AA CC R T U V W Y Z 
mean E 6.15E+08 4.68E+08 2.70E+08 1.05E+09 3.81E+08 4.55E+08 2.17E+08 7.13E+08 9.17E+08 
mean eY 1.72E+07 1.11E+07 1.63E+07 2.24E+07 3.62E+07 4.41E+07 2.13E+07 3.69E+07 4.10E+07 
Y stress 1.46E+07 1.03E+07 9.84E+06 2.23E+07 1.61E+07 1.89E+07 9.06E+06 2.23E+07 2.76E+07 
Y strain 2.60E-02 2.96E-02 3.62E-02 2.74E-02 4.75E-02 5.19E-02 4.93E-02 3.24E-02 3.08E-02 
mean eF 4.94E+07 2.12E+07 9.37E+07 5.92E+07 6.54E+07 5.55E+07 3.18E+07 4.28E+07 5.36E+07 
F stress 1.73E+07 1.20E+07 1.49E+07 2.71E+07 1.73E+07 1.96E+07 1.02E+07 2.28E+07 2.84E+07 
F strain 4.72E-02 3.83E-02 8.77E-02 4.15E-02 6.36E-02 5.88E-02 6.13E-02 3.71E-02 3.57E-02 
Post Yield e 3.22E+07 1.01E+07 7.74E+07 3.68E+07 2.92E+07 1.14E+07 1.05E+07 5.90E+06 1.26E+07 
 
